,ticker,content
0,BAX,friday baxter international bax get positive adjustment relative strength rs rating re research best stock buy watch be sure pay attention relative price strength proprietary rating identify technical performance used worst best score identify stock price performance last week stack other stock database year market history show best perform stock tend have better rs rating early stage move see baxter international continue show renew price strength clear threshold look best stock buy watch start herebaxter international be try complete flat base buy point see clear price heavy trading baxter international show earning growth last quarter revenue increase baxter international hold rank peer medical product industry group abiom abmd align technology algn edward lifescience ew be top highly rate stock group get newsletter deliver inbox more info product service privacy policy term also stock be show rise relative strength use ibd relative strength rating relative strength line help judge stock
1,BAX,motivated goal create meaning work edward lifescience ew ceo mike mussallem push boundary follow passion help person live best life process mussallem team have transform edward global leader patient focuse innovation structural heart disease well critical care surgical monitoring mussallem believe key leader success be find meaning work talk folk be develop leader strongly encourage person find meaning work allow be best even surprise term much impact have mussallem tell ibd mussallem meaning work be impact individual patient life change lifesave technology such think have be drive force edward patient first culture innovation strategy lead edward introduction lifesave life sustain therapy such transcatheter aortic valve replacement tavr rapid deployment surgical heart valve replacement noninvasive hemodynamic monitoring take mussallem soul search identify true call early work try pull help pay education work steel mill say time younger year be probably more focuse big paycheck be good benefit be probably wasn joined health care start think do something really matter person life mussallem leadership role edward trace back career baxter international bax start work hold number post include group vice president cardiovascular division mussallem be part group baxter propose cardiovascular division innovate faster better serve patient spun independent company happened april edward lifescience be establish begin life public company mussallem be first only chairman ceo edward have have stand alone company thank ongoing innovation guide mussallem passion help improve save patient life edward position medical technology industry have sky-rocket edward be leader surgical transcatheter heart valf say glenn novarro analyst manage director rbc capital market reason have best technology invest most med tech company heart valf novarro tell ibd re always first market edward team have propel impressive financial growth gain attention investor last year edward top line have grow more stock price have go split adjust ipo april april gain learn lot year do say more more find have great culture be first foremost underpin success company especially culture drife real purpose company feel driver lot success give great comfort be align edward culture be ground patient focus say mussallem edward have opportunity be close patient heart valf have unique serial number edward trace back person handmade inspect valve edward often have reunion patient team make individual valf imagine do team say reinforce importance person work add novarro be passion put everything company be great leader most successful ceo be passionate mike take level not just edward be passion edward do patient also be passion mussallem say company doesn try solve health care problem stay very focuse structural heart disease critical care medicine feel patient be better serve be today be big opportunity apply technology improve care focus bold innovation literally breakthrough technology be exist care get right add lot value patient edward big groundbreaker have be pioneer effort bring transcatheter aortic valve replacement market turn have lead major transformation company abundantly clear year edward have be public company mike not only have thoughtfully reshape company post spinoff portfolio divest acquire also have clearly demonstrated visionary insight innovate brilliantly complex medical device space company tavr structural heart initiative rick wise senior medical technology analyst manage director stifel tell ibd mussallem see big opportunity tavr fact cannibalize company exist lead product be continue be leader surgical heart valf tavr be such radical idea most customer discourage say mussallem rationale be someone be go disrupt core business feel be be have be one else pursue radical idea work very hard develop therapy be not simple linear persist promise patient be so powerful be first time career have chance experience significant way call triple improve mortality improve quality life patient improve economic health care system edward sapien family transcatheter aortic heart valf delivery system be used treat heart valve disease used catheter base approach certain patient traditional open heart surgery isn optimal company say deliver heart be beating valf enable patient have better quality life sooner receive traditional surgical therapy motivate guide employee mussallem team have develop secret sauce principle eye always patient need mussallem encourage team dream big not be afraid failure learn mistake mussallem develop leadership management principle many source baxter mussallem gain confidence skill lesson learn be not be afraid difficult job say often job be not high profile involve take underperform business function isn see glamorous be opportunity someone get significant responsibility demonstrate own ability add value lesson help mussallem support decision spin independent company cardiovascular division baxter mussallem be responsible time cardiovascular business be poorest performer baxter portfolio say have low growth rate low profitability uncertain future have lot hard work do early year say team stay optimistic time be able sharpen strategy seriously invest new innovation be able completely change profile company element strategy have be priority be leadership feel try be best do add proud edward sell be global position mussallem be born grow gary ind earn bachelor degree chemical engineering rise hulman institute technology graduation work union carbide chemical engineer make prestone antifreeze time realize be do something more fulfill change person life then go health care develop many personal value passion innovation younger year ve never be be afraid take challenge say be fortunate have loving parent other live life give child better life always feel responsibility do best believe company have many same idea transform edward global leader innovator structural heart diseaseovercame risky business decision spin edward baxter develop complex therapy lesson find meaning work allow be best even surprise term much impact have
2,BAX,stock index keep recent sideway trend thursday utility outperformed fifth session row nasdaq end just flat dow jone industrial average fall respectively index close high day range be bullish dow jone
3,BAX,do novartis nvs amgen amgn merck mrk pfizer pfe celgene celg gilead science gild baxter international bax eli lilly lly have common have licensing other business relationship ligand pharmaceutical lgnd ligand be recently add ibd list top growth stock be lead biotech stock
4,BAX,important metric look stock be higher relative strength rating baxter international bax now clear threshold jump wednesday proprietary rating measure market leadership used worst best score identify stock price performance trail week match rest market history reveal best stock tend have rs rating begin biggest price move look best stock buy watch start herenow be not ideal time jump isn proper buy zone see stock go form chart pattern break earning share growth decline last quarter sale grow previous report next quarterly number be expect feb baxter international hold rank peer medical product industry group align technology algn abiom abmd inogen ingn be top highly rate stock group related stock rise relative strength ratingswhy use ibd relative strength rating relative strength line help judge stock
5,BAX,medical supplier stock collectively topple month low intraday tuesday becton dickinson bdx biggest loser report emerge amazon com amzn be plan sell supply hospital analyst largely doubt amazon put pressure manufacturer higher tech product include implantable device insulate company medtronic mdt stryker syk cantel medical cmd conm cnmd teleflex tfx needham analyst mike matson write note client other industry amazon have typically disrupt middleman more manufacturer say view amazon model work lower tech product be unlikely work higher tech product matson say lower tech product list lower price single use item don require service be typically used sale representative present higher tech item be often implantable need service require sale rep present use perhaps not surprisingly lower tech product be already typically sell distributor such owen minor omi higher tech product be typically sell directly manufacturer say view amazon simply represent distribution channel lower tech product ibd take stock market remain high market still thro correction important keep tab key action visit big picture evercore analyst vijay kumar say amazon be formidable player basic medical supply category include plastic glove drape simple catheter company cover group be becton baxter bax becton baxter be likely happy supply amazon well other distributor say report client close bell stock market today becton sank finish earlier fall much collectively medical supplier stock topple much low last see april group end day baxter trade medical product group dip medical product stock broadly fall much be marginally close related payer win balk price tag vertex new drugis teva pharma restructure plan actually more reasonable regeneron benefit lackluster datum present rival
6,BAX,baxter international bax have relative strength rs rating upgrade thursday ibd unique rating track market leadership worst best score score show stock price performance trail week compare other stock database history show best stock typically have better rs rating launch biggest climb look best stock buy watch start herebaxter international be buy zone breaking past entry flat base once stock move higher original entry consider proper buy area earning growth drop most recent quarter revenue gain moved higher company hold rank peer medical product industry group align technology algn abiom abmd teleflex tfx be top highly rate stock group related stock be show rise relative strength use ibd relative strength rating relative strength line help judge stock
7,BAX,baxter international gap bolt day move average friday
8,BAX,move come news baxter international bax subsidiary baxter healthcare commercialize rockwell medical rmti hemodialysis concentrate product line select foreign market
9,BAX,be much need shot arm baxter break flat base july then rolled undercut base stock have see considerable institutional selling recent week evidence weak accumulation distribution rating
10,BAX,rockwell be also sharply friday
11,BAX,medical product industry group have be average performer recovery rank group ibd track group have fade hit time high march slightly less year date
12,BAX,baxter develop drug device treat hemophilia immune disorder infectious kidney disease
13,BAX,baxter earning growth be strictly single digit affair reliably so year earning stability factor be scale low number correspond steady earning growth
14,BAX,latest quarter baxter ep rise revenue be analyst forecast earning next report schedule oct market open rise share baxter year annualize earning growth rate be analyst forecast increase earning year increase next year
15,BAX,baxter return equity be impressive double benchmark investor seek yet long term debt equity ratio year be steep pretax margin be
16,BAX,wednesday baxter paid quarterly dividend cent work annualize yield company have year annualize dividend growth rate baxter international gap bolt day move average friday move come news baxter international bax subsidiary baxter healthcare commercialize rockwell medical rmti hemodialysis concentrate product line select foreign market be much need shot arm baxter break flat base july then rolled undercut base stock have see considerable institutional selling recent week evidence weak accumulation distribution rating rockwell be also sharply friday medical product industry group have be average performer recovery rank group ibd track group have fade hit time high march slightly less year date baxter develop drug device treat hemophilia immune disorder infectious kidney disease baxter earning growth be strictly single digit affair reliably so year earning stability factor be scale low number correspond steady earning growth latest quarter baxter ep rise revenue be analyst forecast earning next report schedule oct market open rise share baxter year annualize earning growth rate be analyst forecast increase earning year increase next year baxter return equity be impressive double benchmark investor seek yet long term debt equity ratio year be steep pretax margin be wednesday baxter paid quarterly dividend cent work annualize yield company have year annualize dividend growth rate
17,BAX,medical product giant baxter international bax beat earning estimate lift organic sale growth guidance thursday lower ep outlook due divestiture stock initially drop early afternoon be fraction stock market today
18,BAX,baxter sale rise year earlier quarter line analyst consensus earning climb share beating estimate cent
19,BAX,baxter lift organic sale guidance percentage point range now however knock cent ep range be now reflect sale vaccine business pfizer pfe
20,BAX,leerink analyst danielle antalffy note baxter hemophilia franchise grow double digit new long act rival biogen idec biib be launch earlier year
21,BAX,represent potential early signal bax advate fact hold share better expect competitive long act product come market antalffy write flash note thursday morning give stock lackluster performance year date expect share outperform today
22,BAX,stock have indeed be slide several month hit month low wednesday
23,BAX,baxter be plan split mid biopharma business spin name baxalta original baxter continue sell medical equipment rbc capital market analyst glenn novarro note side business perform solidly quarter biotherapeutic industry underperform compare international counterpart
24,BAX,follow amy reeve twitter ibd_areeve medical product giant baxter international bax beat earning estimate lift organic sale growth guidance thursday lower ep outlook due divestiture stock initially drop early afternoon be fraction stock market today baxter sale rise year earlier quarter line analyst consensus earning climb share beating estimate cent baxter lift organic sale guidance percentage point range now however knock cent ep range be now reflect sale vaccine business pfizer pfe leerink analyst danielle antalffy note baxter hemophilia franchise grow double digit new long act rival biogen idec biib be launch earlier year represent potential early signal bax advate fact hold share better expect competitive long act product come market antalffy write flash note thursday morning give stock lackluster performance year date expect share outperform today stock have indeed be slide several month hit month low wednesday baxter be plan split mid biopharma business spin name baxalta original baxter continue sell medical equipment rbc capital market analyst glenn novarro note side business perform solidly quarter biotherapeutic industry underperform compare international counterpart follow amy reeve twitter ibd_areeve
25,BAX,sale growth be pick medical device pharmaceutical giant baxter international deerfield ill base baxter bax have put double digit revenue gain latest quarters straight period flat single digit growth revenue grow fourth quarter first quarter earning be flat strong demand baxter hemophilia drug last year buyout sweden gambro ab specialize dialysis product be help lift growth baxter sale come hemophilia treatment include flagship drug advate well recombinate rixubis company recently win regulatory clearance advate russia turkey advate be now available country gambro baxter buy nearly contribute sale fourth quarter first quarter late march baxter say plan split company middle next year firm focus drug other other medical product baxter result be due june profit be expect rise share revenue be slate grow many company baxter slash shareholder dividend financial crisis company have be bring back baxter raise quarterly payout cent share quarterly dividend have more double new rate baxter annualize dividend yield work have highest yield ibd medical product industry group baxter share have be steady trend year be work flat base buy point
26,BAX,medical sector have be lot selling pressure recent month biotechs particular have be hard hit certain subgroup be hold just fine include ibd medical product group
27,BAX,high quality defensive name group be baxter international bax large cap firm market capitalization just north make renal device other medical equipment treatment
28,BAX,share soar late march baxter announce plan spin unit independent company unit do sale more half sale come hemophilia treatment hemophilia be chronic bleed disorder
29,BAX,lot baxter international fundamental standpoint year earning stability factor point steady record profit growth smr rating be top notch
30,BAX,april company report profit share year sale rise medical product sale rise come acquisition gambro baxter acquire swedish medical equipment maker late
31,BAX,annual return equity be stellar pretax profit margin also deliver
32,BAX,earlier month baxter announce dividend cent share give current yield dividend be payable july shareholder record june baxter have consistent record dividend increase evidence annualize dividend growth rate
33,BAX,come recent price volume trend baxter much well surge nearly week end march stock settle flat base current buy point be baxter recently try break volume never come stock trading just buy point medical sector have be lot selling pressure recent month biotechs particular have be hard hit certain subgroup be hold just fine include ibd medical product group high quality defensive name group be baxter international bax large cap firm market capitalization just north make renal device other medical equipment treatment share soar late march baxter announce plan spin unit independent company unit do sale more half sale come hemophilia treatment hemophilia be chronic bleed disorder lot baxter international fundamental standpoint year earning stability factor point steady record profit growth smr rating be top notch april company report profit share year sale rise medical product sale rise come acquisition gambro baxter acquire swedish medical equipment maker late annual return equity be stellar pretax profit margin also deliver earlier month baxter announce dividend cent share give current yield dividend be payable july shareholder record june baxter have consistent record dividend increase evidence annualize dividend growth rate come recent price volume trend baxter much well surge nearly week end march stock settle flat base current buy point be baxter recently try break volume never come stock trading just buy point
34,BAX,major index be nearly flat afternoon trading wednesday small cap lead amazon com amzn share crossed key hurdle xamazon rise day move average key steppingstone stock try form new base so far most pattern have be bury line make base weaker also late stage pattern loop capital initiate coverage amazon buy rating price target nasdaq composite dow jone industrial average make fractional change session trendless trading russell add small cap benchmark lead market second consecutive day volume be higher nasdaq lower nyse compare same time tuesday more dozen stock top buy point today trading be semiconductor sector xilinx xlnx top buy point cup handle base volume be only average undermine integrate device technology idti surge past buy point cup handle base volume be nearly time average entegris entg have milder move still rise buy point lopsided cup handle volume be well average barron quote keybanc capital market analyst report integrate device benefit wireless charge apple aapl new smartphone broadcom provide wireless charge integrate device stand benefit chinese handset maker also move adopt wireless charge company have design deal manufacturer performance food group pfgc break past buy point base heavy trading remain buy range food service distributor tuesday hold investor day backed outlook fiscal end next june growth adjust ep health care sector group continue produce breakout novocure nvcr crossed entry consolidation active turnover be latest series breakout occur medical product industry group neogen neog icu medical icui boston scientific bsx baxter international bax have break past couple week related google buck amazon demand voice search growslate debut iphone disappoint apple investor
35,BAX,alexion pharmaceutical alxn stock plummet nearly year low tuesday announce executive be leave only month chief executive ludwig hantson joined alexion baxalta close stock market today alexion stock be earlier fall much low last see october position be vacated only have be filled brian goff succeed chief commercial officer carsten thiel be leave pursue new opportunity june goff background include time baxalta neurovance baxter international bax novartis nvs johnson johnson jnj chief financial officer dave anderson resign end august martin mackay executive vice president head research development retire end clare carmichael executive vice president chief human resource officer leave june seek new opportunity leerink analyst geoffrey porge note leadership change completely management team build alexion soliris franchise preside value destroy acquisition synageva soliris be approve rare disorder ibd take alexion stock have ibd composite rating meaning have outperformed stock key metric past month biotech group be lead therapeutic have cr best possible head ibd stock checkup top rate biotechs change be not complete surprise give signal have be come new ceo alarm many investor give concern be other shoe drop term disclosure additional underlie issue core business operation say past hantson have comment doesn have much excitement anything alexion pipeline alxn treatment patient paroxysmal nocturnal hemoglobinurium immune disorder result destruction patient red blood cell still departure anderson be surprising give position be permanent be expect remain place least year transition many goal strengthen financial report system improve operate margin be still underway porge say many initiative continue be implement company commitment margin improvement goal seem now be question write note client importantly alexion didn see turnover midlevel management sale force porge note hantson believe morale commitment patient dedication be still write be commit absorb widespread change company say porge maintain outperform rating alexion stock related amgen gilead biogen win lead biotech boom so alexion beat first quarter sale profit top cent
36,BAX,baxter bax stock fall monday worry related department justice investigation potential price fix intravenous fluid allegation analyst deem extraordinary stock market today baxter stock fall justice department send grand jury subpoena baxter employee subpoena be receive friday relate criminal investigation justice department antitrust arm ask document testimony related manufacturing pricing selling shortage intravenous solution baxter communication rival evercore analyst vijay kumar note price fix allegation isn new stem year old investigation begin new york ongoing class action suit northern district illinois related supply shortage shortage be trigger flu season benefit manufacturer hospira third quarter see growth unit produce intravenous fluid kumar say hospira be acquire pfizer pfe class action lawsuit allege manufacturer intravenous fluid falsely create shortage justify spiking price baxter have file motion dismiss suit call allegation extraordinary idea public company voluntarily create supply shortage hope competitor similarly restrict output order raise price seem stretch kumar tell client note ibd take baxter stock trade ibd company medical product industry group be lead medtronic mdt stryker syk boston scientific bsx term market cap medtronic boston edward lifescience ew compete heart valve replacement market check edition sector leader see stack fda regulator regularly inspect manufacturing facility note class action lawsuit seem imply baxter other intravenous fluid manufacturer be able hoodwink inspector post shortage notice say baxter say incur cost comply increase fda regulatory requirement meet supply constraint meanwhile price increase only contribute growth kumar say intravenous fluid solution contribute third segment growth imply pricing be average kumar say assume bag intravenous fluid cost equate increase cent bag apart price collusion prosecutor have argue baxter earning increase intravenous fluid price be reasonable kumar estimate hike price intravenous fluid baxter have margin earning interest taxe related boston scientific make acquisition battle medtronic edward best stock own analyst
37,BAX,load player here investing action plan need know investor come day apple aapl be expect report third straight quarter year year earning revenue decline tuesday general motor gm fiat chrysler automobile fcau lockheed martin lmt merck mrk edward lifescience ew also be tap
38,BAX,specialty drugmaker shire shpg close buyout baxalta early friday get price target increase analyst see deal boost shire long term growth rate shire month sale total say combine company bring come rare disease treatment baxalta dominant position treat rare disease hemophilia inherited be spun baxter international bax last july be chief attraction shire be however face increase competition hemophilia arm biogen biib be process be spun potentially experimental gene therapy biomarin pharmaceutical bmrn spark therapeutic once shire be now global leader rare disease number rare disease platform base revenue pipeline program shire ceo flem ornskov say statement jeffery analyst david steinberg raise price target shire stock writing addition baxalta lift annual ep growth rate estimate revenue growth rate add be few potential upside well such cost saving greater shire project higher sale shire other product thank newly expand global presence further acquisition shire stock rise stock market today high trading volume ibd relative strength rating have be improve still score only
39,BAX,big biotech biogen biib say tuesday spin hemophilia business independent company move much anticipate wall street biogen focus mainly neurological disease get hemophilia launch long act infusion treatment eloctate alprolix hemophilia respectively carved market share leader baxter international bax mid april press report relay rumor biogen be think selling spin business baxter have already make similar move spun hemophilia focuse biopharma arm baxalta bxlt last july baxalta be quickly snap shire shpg deal baxalta biogen infusion therapy be potential threat new gene therapy be able cure disease time treatment least manage far fewer treatment biomarin pharmaceutical bmrn early stage trial result hemophilia gene therapy report last month support method potential biogen press release mentioned investment research be rationale spinoff new company be name later date focus discovery development therapy treatment hemophilia say release new company plan bring longer act therapy utilize xten technology clinical development first half accelerate development bispecific antibody hemophilia related gene therapy program add spinoff also enable remain portion biogen focus core multiple sclerosis business have be struggle lately show biogen earning last month still rbc capital market analyst michael yee find decision bit puzzling biogen want remove grow profitable long ip duration biologic business diversify biogen dilute ep remove ask research note addition biogen be not selling business bring cash approximate valuation prior today question be do cash buy aren get cash deal so seem odd perhaps imply valuation be not street perceive buyer be not willing pay biogen stock be fraction early trading stock market today stock have find support day line
40,BAX,stock struggle bit moved lower yesterday remain range point yesterday note late morning test level find support rally close bell trading be light investor trader appear unwilling commit market ahead onslaught earning today think apple aapl facebook fb procter gamble pg exxon mobil xom baxter bax mmm freeport mcmoran fcx corning glw lockheed martin lmt eli lilly lly revenue beat ep miss ct whirlpool whr miss top line revenue miss bottom line report vs exp be announce today ahead tomorrow fomc announcement remember today begin day fed meeting be lot anticipation paralysis say tomorrow again mkt do not expect change rate do expect clarification terminology concern june next expect hike recall last hike december send mkts tailspin cause fed become bit more dovish search reason calm mkts time cite unstable global mkts culprit then mkts have come roar back now dow look disastrous year result strength expect janet intimate return path higher rate not necessarily faster just bit higher expect word be parsed sentence be deconstructed everyone look next clue now low volume well be number reason really never mind current regulatory environment abuse suffer so many manager yesterday be news right eco report significant earning speech big international event nothing so do anything mkt hold tight give reason deviate plan so only one really play yesterday be hft guy asset manager be tweak core position tweak do not mean change investment strategy just mean tweak now oil do come bit pressure yesterday fall end day tell be recent run oil be bit premature give current glut lack deal opec nation etc so oil trade current band good break surge higher just yet morning see oil small dollar appear bit weaker think rate hike remember get weekly api american petroleum institute report afternoon now yesterday do get broad measure housing mkt again stat be longer mkt move event be change see yesterday be new home sale typically be good barometer state broader economy guess disappointment new home sale fall vs exp rise be bit concern well be time year new home sale be strong so be disappointment just barometer weaken economic picture be really mind boggle be be now decade housing collapse decade be yr incomplete recovery pocket single family housing continue stall new home sale total unit basis come unit significantly yr average more unit greenspan era subprime loan mortgage propel sale new home stratosphere send high unit yr begin crash crash create adjustable rate mortgage manage destroy so many person trigger wave foreclosure then ignited great financial crisis say crisis be still ongoing ll leave future be pt early trading mkt get ready react slew earning report note whirlpool note miss number be quote buck pre mkt trading quote not trading just yet so let see investor trader think today be also big economic day lot macro datum consider durable good exp ex tran cap good order cap good ship markit pmi richmond fed survey earning be happen prior open macro datum begin go be create lot noise early trading once settle be then expect discussion revolve fed once analyst consider implication today macro datum reveal again expect broader mkt hold tight range tomorrow think fed paralysis individual name today get reward punish depend report say future day work take good care
41,BAX,kpfollow kenny polcari twitter kenny polcari comkenny polcari be vice president director nyse floor operation behalf neil security inc sister company investor business daily market commentary be opinion author be base decade industry market experience however guarantee be make imply respect opinion commentary be not be intend be rely authoritative take substitution exercise judgment comment note herein not be construe offer sell solicitation offer buy sell financial product official statement endorsement neil security incorporate affiliate
42,BAX,big biotech gilead science gild beat analyst estimate tuesday guidance be soft send stock more hour trading day several large drugmaker report gilead earning rise year earlier quarter share top analyst ep consensus cent accord thomson reuter revenue increase vs analyst expectation full year ep rise revenue gain gilead guide product sale cover nearly revenue analyst have expect product sale total revenue gilead do not provide total revenue ep guidance do provide guidance expense be slightly expectation sale general administrative line evercore isi analyst mark schoenebaum calculate imply ep guidance be miss consensus hepatitis drug sovaldi harvoni beat estimate entirely due sale outside analyst have less visibility next year expect revenue decline be due anticipate decline hcv market have enormous lift drug be approve have flattened ever larger number patient have be cure disease conference call analyst commercial operation chief paul carter say expect hcv market behave similarly do second half essentially flat grow foreign market be still be launch say see growth payer seem be loosen restriction drug initially strained finance due high price enormous volume patient however acknowledge revenue patient be likely fall less sick patient come require shorter treatment carter also sound confident gilead ability fend competition get new entrant last week merck mrk zepatier be approve last week price well gilead abbvie abbv hcv drug re confident label be very strong re very much support real world datum ve see launch harvoni carter say earlier day big pharma pfizer pfe say revenue rise year earlier quarter beating analyst consensus earning exclude time item slip cent share beating estimate penny year ep decline sale slide however pfizer profit guidance miss wall street expectation share analyst schoenebaum blame foreign exchange headwind exclude roughly negative top line top line fx impact due venezuela currency impact alone bottom line impact due fx top bottom line guidance have bracket street schoenebaum write email speak pfizer believe street underestimated fx impact capital iq analyst jeffrey loo raise rating pfizer buy hold say valuation have become attractive almost other drug stock have sell recent month view growth global innovative product unit positively drive prevnar ibrance loo write research note expect pending acquisition allergan agn be complete second half pfizer stock close mallinckrodt mnk rise close specialty drugmaker report fiscal first quarter earning share year earlier quarter top consensus cent sale climb street average estimate mallinckrodt raise full year ep guidance baxter international bax leader dialysis product also beat expectation most recent quarter pull sharp increase earning decline sale fourth quarter profit continue operation jump cent share cent past wall street consensus revenue drop baxter stock rise tuesday close baxter say expect ep year beating consensus forecast current quarter be street however cent
43,BAX,medical stock pfizer pfe mallinckrodt mnk baxter international bax be move tuesday early quarterly report guidance pfizer say revenue rise year earlier quarter beating analyst consensus accord thomson reuter earning exclude time item slip cent share beating estimate penny year ep decline sale slide however pfizer profit guidance miss wall street expectation share evercore isi analyst mark schoenebaum blame foreign exchange headwind exclude roughly negative top line top line fx impact due venezuela currency impact alone bottom line impact due fx top bottom line guidance have bracket street schoenebaum write email speak pfizer believe street underestimated fx impact pfizer stock be afternoon trading stock market today pfizer also say have end midstage trial experimental alzheimer disease drug october independent datum monitoring committee say be futile continue drug pf target brain receptor call ht similar drug rvt currently late stage testing axovant science axon rvt be only drug axovant pipeline axovant stock be intraday hit month low mallinckrodt meanwhile be tuesday afternoon specialty drugmaker report fiscal first quarter earning share year earlier quarter top consensus cent sale climb street average estimate mallinckrodt raise full year ep guidance leerink analyst jason gerberry write beat look high quality give reason say selling general administrative sg expense be less expect biggest driver be low sg spend sale vs street assumption spend range gerberry write research note be partially offset higher spend quarter follow sale mix drive higher gross margin quarter vs top line beat drive specialty brand baxter also beat expectation most recent quarter pull sharp increase earning decline sale profit continue operation jump cent share cent past wall street consensus revenue drop baxter say expect ep year beating consensus forecast current quarter be street however cent baxter comparison be somewhat complicate fact july spun biopharma arm baxalta bxlt leave business comprise mostly dialysis hospital product account previous company leerink analyst danielle antalffy write path independent company be become clearer now post split baxter be margin expansion story company work synergy implement broader cost control execute new product launch antalffy write research note quarterly datum point now hand seem clear baxter be track exceed margin expansion trajectory company layer analyst meeting adjust operate margin expansion immediately post split ramp baxter stock be afternoon trading
44,BAX,so january come end not fast enough many fall hard january set be sure be turbulent year investor stock manage hold friday gain yesterday even oil fall barrel factory order shrank straight month come
45,BAX,petm express pet break saucer handle base buy point friday show solid volume day upward run stock rise move come prior earning be announce monday market open analyst be look cent share increase year earlier online dog cat
46,BAX,month so talk big pharmas shire baxalta early monday announce merger value say create company drug treat rare disease
47,BAX,ireland base shire shpg pay baxalta bxlt shareholder cash shire ad american depositary share share own say come baxalta share base friday close price
48,BAX,shire stock fall monday be july peak baxalta stock fall monday baxalta stock hit time high thursday gain last week expectation takeover be market worst first week trading ever shire stock fall last week
49,BAX,company expect deal close midyear pending regulatory shareholder approval say transaction value bannockburn ill base baxalta premium stock price aug have disclose aug negotiation have be ongoing least july shire make unsolicited offer baxalta baxalta share
50,BAX,baxter international bax spun baxalta july bid unlock shareholder value biopharma operation hold medical product business baxalta retain franchise bloodderive treatment disease such hemophilia primary
51,BAX,shire ceo flem ornskov statement monday say deal allow realize vision build lead biotechnology company focuse rare disease
52,BAX,together have leadership position multiple high value franchise become clear partner choice rare disease expand portfolio presence more country drive growth anticipate annual revenue
53,BAX,baxalta ceo ludwig hantson statement say baxalta shareholder receive substantial immediate value well ongoing stake combine global leader rare disease strong growth prospect
54,BAX,company say combination emerge rare disease platform revenue pipeline depth product especially hematology immunology neuroscience lysosomal storage disease endocrine treatment hereditary angioedema
55,BAX,shire say merger create operate cost synergy gaap earning be accretive month so talk big pharmas shire baxalta early monday announce merger value say create company drug treat rare disease ireland base shire shpg pay baxalta bxlt shareholder cash shire ad american depositary share share own say come baxalta share base friday close price shire stock fall monday be july peak baxalta stock fall monday baxalta stock hit time high thursday gain last week expectation takeover be market worst first week trading ever shire stock fall last week company expect deal close midyear pending regulatory shareholder approval say transaction value bannockburn ill base baxalta premium stock price aug have disclose aug negotiation have be ongoing least july shire make unsolicited offer baxalta baxalta share baxter international bax spun baxalta july bid unlock shareholder value biopharma operation hold medical product business baxalta retain franchise bloodderive treatment disease such hemophilia primary shire ceo flem ornskov statement monday say deal allow realize vision build lead biotechnology company focuse rare disease together have leadership position multiple high value franchise become clear partner choice rare disease expand portfolio presence more country drive growth anticipate annual revenue baxalta ceo ludwig hantson statement say baxalta shareholder receive substantial immediate value well ongoing stake combine global leader rare disease strong growth prospect company say combination emerge rare disease platform revenue pipeline depth product especially hematology immunology neuroscience lysosomal storage disease endocrine treatment hereditary angioedema shire say merger create operate cost synergy gaap earning be accretive
56,BAX,drugmaker baxalta bxlt be trading monday tide broad stock market decline inked immuno oncology deal be rumore be close sale shire shpg baxalta say have agree pay privately hold symphogen upfront option right therapy symphogen be develop target checkpoint
57,BAX,rest stock market crumble pharmaceutical company make new high heavy volume monday baxalta bxlt rise buy point cup handle base volume average stock close day course take extraordinary development bring buyer baxalta announce
58,BAX,stock future monday dive hard loss first trading session confused day china appear rattle global market dow future drop more point fair market value start bell nasdaq future dive point future swoon point russell future tumble point tough day china appear ripple international market shanghai stock fall reportedly weak december manufacturing datum fuel concern yet downshift economic output chinese investor be already edge regard next week expiration selling moratorium certain stock put place last summer market correction new rule have automatically halter trading twice market remain close second shut global market be already edge weekend protest iran saudi arabia execution shiite cleric cause saudis close embassy cut diplomatic ty iran combination send hong kong loss tokyo nikkei drop europe market drop hard frankfurt dax more cac paris london ftse trading nearly lower midday bond dollar slip commodity be map oil rise brent crude almost barrel natural gas fall gold rise copper platinum fall economic calendar get roll et stock market today researcher markit release final manufacturing purchasing manager index tally december institute supply management deliver december manufacturing index commerce department report november construction spending datum premarket action show most dow stock trading lower lead jpmorgan jpm american express axp more apiece few gainer baxalta bxlt shot news be partner symphogen develop therapy design help immune system fight cancer deal include initial payment baxalta symphogen give exclusive right target treatment baxalta spun baxter international bax last july stock end thursday cup handle base buy point weak end fmc fmc wynn resort wynn netflix nflx red hat rht be stock post deeper decline tesla motor tsla drop announce sunday delivery hit low end company reduce guidance leader china base stock be take serious beating start bell ibd list noah noah drop alibaba baba tumble noah end thursday test support day move average drop line complicate current base build effort alibaba have be trading fairly neat flat base buy point end thursday just few penny day move average red hat also ibd stock have be struggle clear buy point flat base briefly clear mark twice mid december retreat back buy marker early gain ibd list be less
59,BAX,be year distinct part drug stock first month continue bull run last year sudden resurface drug pricing debate lead rocky month overall group come ahead top perform big cap show solid story make political worry eye investor incyte incy be wednesday close year steady gain lone market product jakafi well pipeline potential blockbuster march jakafi win eu approval blood cancer polycythemia vera be already approve blood cancer myelofibrosis disease be rare incyte be shooting much bigger market late stage candidate baricitinib epacadostat baricitinib incyte be develop partnership eli lilly lly test successfully phase trial rheumatoid arthritis placebo methotrexate current market leader abbvie abbv humira nov initiation report incyte goldman sachs analyst richter estimate peak annual sale more expect launch richter add more important future driver share likely be incyte entry bud field immuno oncology incyte have be testing lead candidate field epacadostat combination merck mrk keytruda variety cancer early november incyte stock fall small study combo patient advanced cancer disappoint wall street richter write likely bring more clarity more result come incyte have be operate loss due research spending analyst expect turn first annual profit next year stock current ibd composite rating be danish diabetes giant nordisk nvo be end year flat base follow early gain march stock rise sharply say refile approval long act insulin analogue tresiba shorter act sister drug ryzodeg drug suffer surprise rejection fda seek more datum possible risk heart time agency be convince approve also boost stock early year be february release positive clinical trial datum latest glucagon peptide glp receptor agonist og have be selling earlier glp agonist victoza market have get more competitive last couple year new glp launch sanofi sny glaxosmithkline gsk eli lilly drug be injectable however new candidate be oral announce further positive result drug july september financial result currency suffer foreign exchange headwind hit global drugmaker year still manage solid ibd ep rank relative strength rating regeneron pharmaceutical regn continue multiyear run stock market hit lifetime high aug get catch larger biotech sell still year regeneron flagship eye drug eylea continue perform well aid new approval diabetic retinopathy march draw more attention be launch cholesterol drug praluent july praluent be not only first new class cholesterol drug be follow shortly market amgen amgn repatha also first number novel monoclonal antibody regeneron have be develop partnership sanofi next entry dupilumab be late stage testing asthma eczema be also expect attain multibillion dollar annual sale regeneron be also highest rate stock list highest possible composite rating eli lilly be top perform traditional big pharma year gain sale growth have be flat due age drug well currency headwind company have improve profit margin cost control get lot investor excited pipeline note partnership incyte have bear fruit baricitinib trial lilly doesn have much presence rheumatoid arthritis other immunology disease lilly be plan change not only baricitinib ixekizumab psoriasis treatment plan launch next year be expect sell billion eventually lilly already launch diabetes drug jardiance yielded pharma biggest upside surprise year giant study effect cardiovascular health show reduce death heart failure drive stock year high september turn cup handle base stock hold cr baxalta bxlt be start trading july spin baxter international bax seek unlock shareholder value biopharma arm just day later company receive unsolicited buyout offer british drugmaker shire shpg see baxalta hemophilia franchise ideal addition rare disease portfolio baxalta reject offer situation remain unresolved last week rumor be buzz shire bid hasn yet baxalta financial have be slow steady lead ep rank acquisition hope have lift stock rs rating
60,BAX,stock future hold steady gain move monday open market head november final trading session dow future stand point fair market value nasdaq future be point future fly straight level point small cap flex premarket muscle russell future rise stronger usual point
61,BAX,stock market today set november sharp slowdown october bounce nasdaq show gain month vs leap october small cap look bit better russell bound ahead month ibd have also outpaced market so far
62,BAX,week euro be likely be center attention european central bank be widely expect amp monetary stimulus effort meeting thursday dollar rise tracking biggest month gain vs euro march
63,BAX,side note china yuan also see unusual attention today international monetary fund expect vote include currency special draw right basket currency hoisting china currency play field dollar euro pound yen
64,BAX,oil stir buzz week organization petroleum export country set meet friday oil trade bit less early monday kingsbury international be deck report chicago purchasing manager index november et october pending home sale number be expect national association realtor
65,BAX,stock action monday show merck mrk microsoft msft lead dow more
66,BAX,stock be generally quiet premarket mood baxter international bax kimco realty kim top group gain
67,BAX,beaten stock fitbit fit horizon pharma hznp jump apiece remain deep correction far possible buy point
68,BAX,leader grupo financiero galicia ggal pop nearly lead ibd list argentina base bank drop last week sharp pullback argentina related stock follow country nov presidential election share end week cup base buy point
69,BAX,other gain ibd stock hold less alaska airline alk post worst pre open slip ibd stock bit more stock future hold steady gain move monday open market head november final trading session dow future stand point fair market value nasdaq future be point future fly straight level point small cap flex premarket muscle russell future rise stronger usual point stock market today set november sharp slowdown october bounce nasdaq show gain month vs leap october small cap look bit better russell bound ahead month ibd have also outpaced market so far week euro be likely be center attention european central bank be widely expect amp monetary stimulus effort meeting thursday dollar rise tracking biggest month gain vs euro march side note china yuan also see unusual attention today international monetary fund expect vote include currency special draw right basket currency hoisting china currency play field dollar euro pound yen oil stir buzz week organization petroleum export country set meet friday oil trade bit less early monday kingsbury international be deck report chicago purchasing manager index november et october pending home sale number be expect national association realtor stock action monday show merck mrk microsoft msft lead dow more stock be generally quiet premarket mood baxter international bax kimco realty kim top group gain beaten stock fitbit fit horizon pharma hznp jump apiece remain deep correction far possible buy point leader grupo financiero galicia ggal pop nearly lead ibd list argentina base bank drop last week sharp pullback argentina related stock follow country nov presidential election share end week cup base buy point other gain ibd stock hold less alaska airline alk post worst pre open slip ibd stock bit more
70,BAX,british drugmaker shire agree pay cash orphan drug specialist dyax monday shire shpg pay share dyax dyax premium nearly dyax friday close price deal include contingent value right cvr share total dyax drug candidate dx be
71,BAX,biotechs still be generally favor group have be firm recent week hold own ibd industry group ranking even large cap name biogen biib celgene celg unite therapeutic uthr have come selling pressure be still plenty top rate name group show relative strength amgen amgn
72,BAX,so be number surprise last week first ecb leave rate alone hint more stimulus come december then overnight thur friday china announce further loosen monetary policy bid boost slow economy then bell thursday big tech stalwart surprised market much better
73,BAX,last couple week market have be punish formerly highflying drug device stock common side effect lower valuation be more buyout fan fair bit wall street chatter speculation week here be get most attention most likely be true friday afternoon bloomberg
74,BAX,barely hatch independent company drugmaker baxalta bxlt get unsolicited buyout proposal shire shpg send stock sharply early trading tuesday shire say july propose stock transaction exchange shire adr share baxalta imply value share base
75,BAX,medical product maker baxter international bax beat analyst expectation thursday conservative guidance underwhelm street share drop early re-cover be flat midday trading stock market today baxter earning rise year earlier quarter share top analyst consensus cent sale rise beating analyst
76,BAX,baxter international bax have be tear go third straight week solid advance good volume news finally split company announce year spin bioscience division board director approve move only june june
77,BAX,handful lead stock clear buy point en route new high tuesday propel better expect earning report share buyback takeover offer cdw cdw provider information technology hardware software jump much clear buy point cup base pare gain stock end
78,BAX,stock remain lower early afternoon trading tuesday analyst warning new apple iphone hurt share company supplier nasdaq be dow jone industrial average be volume be tracking lower nyse higher nasdaq decline stock have small edge advancer nyse loser lead nasdaq solar energy automaker staffing dairy product company be poorest performer stock market today tesla tsla skid more sink deeper day day move average metal retail utility real estate investment trust industry group be best tuesday supplier apple aapl iphone be lower credit suisse warn company be cut back component order iphone model apple share gap loss average volume cirrus logic crus slide busy trading fall day move average skywork solution swks gap day move average shed heavy trading side ruth hospitality ruth better know ruth chris steak house clear buy point double bottom base active trading company beat earning expectation couple week ep jump restaurant industry group have be trend lower ibd group ranking
79,BAX,best lead influence first be clear be stand suggestion come harry kraemer author become best former ceo baxter international bax multibillion dollar medical product firm now executive madison dearborn partner private equity firm tip become best self take stock kraemer believe self reflection be crucial best do end day suggest ask do act self reflective manner do get catch emotion urgency day do do say be go do not not do fall short expectation do treat person lead person follow person have day live again do differently note more self reflective be better equip be become best self day pursue balance see side gain better perspective improve decision don just rely think know purposefully seek broader perspective engage other kraemer tell ibd add leader recognize have moral responsibility develop person team fullest potential feedback team member be not give once year hr form continuous feedback open honest conversation so person understand strength area need be develop lock objective pick time suggest joel fotino publisher author life contract say have too many objective time mean spend only small amount time strive consistency re haphazard effort probably win see much movement major objective daily positive action create more positive result fotino say compare go gym regularly ll not only see result more quickly see result propel further exercise modesty help believe everyone deserve respect matter title be now genuine humility also remind come kraemer say often ask senior leader recall be junior person cubicle back then be person reach make feel part organization have experience vow ever become boss leader act same way now often realize haven fulfilled promise forget come say remember cube be mantra genuine humility add shift focus other help see lend hand remind always put spotlight team contribution act stop wait permission sometimes boss parent spouse someone else give indication time move forward fotino say waste lot time wait external permission really move forward time so not now
80,BAX,halozyme therapeutic halo stock rise new high wednesday biotech announce collaboration abbvie abbv be worth more
81,BAX,abbvie agree pay upfront milestone payment target plan work used halozyme
82,BAX,enhanze platform design aid dispersion absorption injectable drug abbvie also pay unspecified tiered royalty sale product go market enhanze be already be used collaboration roche rhhby pfizer pfe johnson johnson jnj baxter international bax
83,BAX,halo rise stock market today late afternoon trading
84,BAX,halozyme stock have have strong achieve ibd relative strength rating help clinical trial datum lead drug candidate pegph sunday company interim analysis midstage study pegph metastatic pancreatic cancer push stock new high monday exceed wednesday
85,BAX,halozyme only product market right now be hylenex enhanze be used aid injectable drug be not enough make profit analyst be expect halozyme make cent share revenue
86,BAX,follow amy reeve twitter ibd_areeve halozyme therapeutic halo stock rise new high wednesday biotech announce collaboration abbvie abbv be worth more abbvie agree pay upfront milestone payment target plan work used halozyme enhanze platform design aid dispersion absorption injectable drug abbvie also pay unspecified tiered royalty sale product go market enhanze be already be used collaboration roche rhhby pfizer pfe johnson johnson jnj baxter international bax halo rise stock market today late afternoon trading halozyme stock have have strong achieve ibd relative strength rating help clinical trial datum lead drug candidate pegph sunday company interim analysis midstage study pegph metastatic pancreatic cancer push stock new high monday exceed wednesday halozyme only product market right now be hylenex enhanze be used aid injectable drug be not enough make profit analyst be expect halozyme make cent share revenue follow amy reeve twitter ibd_areeve
87,BAX,top rate drugmaker akorn akrx be morning trading monday analyst weigh friday evening news again restate earning early monday company also announce series new executive appointment
88,BAX,street have assume accounting problem first reveal company file extension report march have be resolve akorn issue modest downward revision march friday statement reveal investigation have reveal further problem have result overstatement pretax income tune also firm say result not be issue timely manner
89,BAX,piper jaffray analyst david amsellem run patience downgrade stock neutral
90,BAX,management do not believe accounting issue impact result be sticking guidance be view far too large credibility gap simply take statement face value write research note sunday believe significant management change be need restore akorn credibility further find difficult envision misstep not result change cfo position
91,BAX,monday however bring news hire new corporate controller randall pollard former accounting chief novartis nvs generic unit sandoz
92,BAX,akorn also announce newly create position former allergan vice president kafer be now executive vice president sale marketing former abbott laboratory executive steve lichter be executive vice president pharmaceutical operation former baxter bax quality controller jaspreet gill be evp global quality compliance
93,BAX,leerink analyst jason gerberry writing new management announcement be bit more trusting amsellem still lower price target
94,BAX,view business isn break re encourage management isn change guidance recommend investor take profit strong year date write note sunday
95,BAX,late morning stock market today akorn stock be kill cup base have form late february
96,BAX,follow amy reeve twitter ibd_areeve top rate drugmaker akorn akrx be morning trading monday analyst weigh friday evening news again restate earning early monday company also announce series new executive appointment street have assume accounting problem first reveal company file extension report march have be resolve akorn issue modest downward revision march friday statement reveal investigation have reveal further problem have result overstatement pretax income tune also firm say result not be issue timely manner piper jaffray analyst david amsellem run patience downgrade stock neutral management do not believe accounting issue impact result be sticking guidance be view far too large credibility gap simply take statement face value write research note sunday believe significant management change be need restore akorn credibility further find difficult envision misstep not result change cfo position monday however bring news hire new corporate controller randall pollard former accounting chief novartis nvs generic unit sandoz akorn also announce newly create position former allergan vice president kafer be now executive vice president sale marketing former abbott laboratory executive steve lichter be executive vice president pharmaceutical operation former baxter bax quality controller jaspreet gill be evp global quality compliance leerink analyst jason gerberry writing new management announcement be bit more trusting amsellem still lower price target view business isn break re encourage management isn change guidance recommend investor take profit strong year date write note sunday late morning stock market today akorn stock be kill cup base have form late february follow amy reeve twitter ibd_areeve
97,BAX,variety medical group be rise top ibd industry ranking fact top group friday edition come medical sector include pharmaceutical system equipment health care product manage care medical product group rank just week group have
98,BAX,share cyberonic cybx gap record high thursday company report better expect earning growth say be merge italy sorin move headquarters europe new treasury rule intend curb tax inversion deal stock transaction create global contender start annual revenue
99,BAX,share nuvasive nuva moved higher early trading stock market today maker spinal product receive analyst upgrade cite potential grab more market share particularly internationally
100,BAX,morning research note rbc capital market analyst glenn novarro upgrade nuvasive outperform sector perform also raise price target stock cite san diego base company superior sale outlook improve profitability attractive valuation
101,BAX,nuvasive share rise more year high early thursday
102,BAX,be confident nuva management continue take share worldwide spine market novarro note
103,BAX,not only be nuvasive well position roughly mis minimally invasive spine market say also have plenty runway left expand internationally
104,BAX,particularly true china novarro say nuvasive do not have much infrastructure country currently believe potential chinese announcement occur
105,BAX,meanwhile expect nuvasive continue improve margin so move closer margin rival such globus medical gmed ldr hold ldrh
106,BAX,nuvasive have ibd composite rating belong ibd medical product group rank industry track
107,BAX,top rate stock group be edward lifescience ew composite rating biggest stock market cap be medtronic mdt covidien cov baxter international bax share nuvasive nuva moved higher early trading stock market today maker spinal product receive analyst upgrade cite potential grab more market share particularly internationally morning research note rbc capital market analyst glenn novarro upgrade nuvasive outperform sector perform also raise price target stock cite san diego base company superior sale outlook improve profitability attractive valuation nuvasive share rise more year high early thursday be confident nuva management continue take share worldwide spine market novarro note not only be nuvasive well position roughly mis minimally invasive spine market say also have plenty runway left expand internationally particularly true china novarro say nuvasive do not have much infrastructure country currently believe potential chinese announcement occur meanwhile expect nuvasive continue improve margin so move closer margin rival such globus medical gmed ldr hold ldrh nuvasive have ibd composite rating belong ibd medical product group rank industry track top rate stock group be edward lifescience ew composite rating biggest stock market cap be medtronic mdt covidien cov baxter international bax
108,BAX,greater boston area have see influx fast grow biotechs biogen idec biib have be take lab space trend drive vacancy rate big way way biotech sector be surge ibd medical biom biotech industry group rank ibd track greater boston biotech company
109,BAX,drugmaker aim help person live healthier life aren immune patent loss merck mrk have recently face number patent expiration tuesday report sale slow eighth quarter row earning climb cent share third straight quarter gain result beat view
110,BAX,baxter international bax decide last week split company give stock nice pop analyst applaud move unlock value underperform issue biotechs drugmaker other medical stock have be roll month baxter have be consolidate new company be form medical product division
111,BAX,relative strength rs rating baxter international bax enter new percentile monday get lift ibd proprietary rating identify share price performance worst best score rating show stock price movement trail week stack other stock database decade market research show best stock often have better rs rating early stage move see baxter international continue rebound clear threshold look best stock buy watch start herewhile not currently ideal time jump see stock be able offer clear appropriate buy point company show earning growth latest quarterly report revenue gain come baxter international earn rank peer medical product industry group align technology algn abiom abmd edward lifescience ew be top highly rate stock group related stock be show improve technical action use ibd relative strength rating relative strength line help judge stock
112,BAX,teva pharmaceutical teva mylan myl be group generic drug maker hit thursday consortium hospital say make medicine circumvent rise drug price estimate hospital group be involved effort create nonprofit company provide generic medicine hospital accord new york time goal be avoid rise drug price medicine shortage stock market today generic stock collectively dip fall earlier trade share teva fall close mylan lose other tumble include lannett lci close aclaris therapeutic acrs dip ani pharmaceutical anip dove nearly hospital have struggle shortage drug morphine sodium bicarbonate saline last april department justice serve subpoena number firm include pfizer pfe baxter bax relate saline shortage drugmaker have be political hook rise price particularly older patent drug martin shkreli former head turing pharmaceutical draw ire buy drug used aids patient spiking price tablet ibd take ani pharma lead company generic drug industry group ibd composite rating best possible mean outperform most stock term key growth metric head ibd stock checkup look other strongly rate drug stock valeant pharmaceutical vrx become wall street superstar crash burn early buy older drug then raise price valeant stock be nearly hit bottom april share dip thursday number generic drug maker become subject antitrust investigation price antibiotic diabetes medicine related beware price war big pharma biotech company horizongeneric drug maker face pricing issue other pharmas don twill trump break republican push major drug price reform
113,BAX,stock index show inclination give back gain early afternoon trade tuesday steel infrastructure stock rumble higher nasdaq hustle small cap russell add respectively blue chip dow jone industrial average inched volume stock market today be higher wasting time shake post christmas slowdown steel stock lead day gainer unite state steel rushed ahead carpenter technology crs stab higher steel dynamic stld gain cement group head seventh consecutive daily gain row eagle material exp rise vulcan material vmc echo gain martin marietta material mlm add newsweek story tuesday say congressional republican first priority be infrastructure package blue chip be skip day bullishness most stock dow be top weight stock be little dow be price weight index medical product provider baxter international bax gap clear shallow consolidation related apple buy netflix stock repeat win make dollar save investing tip kidswhen sell great stock upper channel help
114,BAX,here weekly investing action plan need know investor come week upcoming week earning give investor much broader look corporate america economy stalwart tech industrial energy medical consumer sector weigh quarterly result such amazon com amzn alphabet ticker
115,BAX,stock close mixed friday nasdaq composite lag noticeably few sector stand fine performance nasdaq lose hurt weakness semiconductor datum storage internet stock fall dow jone industrial average add manage close day move average be take positive sign russell fall fraction volume be lower compare thursday accord early number loser top winner nyse curiously nasdaq winner lead loser suggest selling be concentrated just certain area composite equifax efx plunge nearly highest volume least many year disclose late thursday hacker have breach computer have steal sensitive information consumer few other financial stock fared much better expect rush hurricane related claim insurance stock lead market marsh mclennan mmc leap buy point base base pattern volume be more double average good sign new york base firm provide insurance reinsurance risk management human resource other service insurance broker industry group be friday best moody mco edge buy point provider credit rating institutional investor see slow trading third less volume normal make suspicious build industry stock well leisure health care industry group also make gain more today trading medical product industry group be show bullish behavior more breakout group friday baxter international bax top buy point flat base resm rmd break past buy point cup handle base price gain be strong volume be disappointingly weak stock still breakout follow boston scientific bsx thursday share medical device maker follow friday lackluster volume consolidated edison ed utility serve new york new jersey area rise buy point flat base volume be average utility stock have be trend higher spdr utility xlu etf record high related cybersecurity stock be rise equifax mass hack
116,BAX,stock variety industry break new high ground wednesday hewlett packard hpq reversed higher surge clear buy point heavy trade stock be now entry highest level more year late tuesday pc maker report fiscal earning
117,BAX,business pay follow path least resistance consumer demand product don offer want change strategy be happened durable medical equipment dme company business model usually focus deliver stationary oxygen concentrator cylinder patient arrival inogen ingn portable oxygen concentrator pocs market change not only do california base company create lighter quieter more efficient product also choose distribute directly customer bypass dme firm middleman pocs work real time remove nitrogen air directly provide oxygen patient inhalation be need have carry move heavy oxygen tank only provide finite amount oxygen need recharge inogen strategy prove be great success so much so patient start ask pocs conventional dme company initial resistance dme finally come view offer inogen pocs key address increase demand customer better inogen see sale business business segment jump first month vs year earlier international sale advanced reseller ride growth be mostly drive reseller jump opportunity provide inogen pocs online store other mean directly customer addition several dme partner inogen get product client base significant portion be really drive pull demand consumer say inogen chief financial officer alison bauerlein ramp direct consumer advertising see significant pull business business domestic sale patient have really start see brand name name re request other business area have grow significantly inogen surprise company direct consumer segment be still largest revenue contributor sale first month be first quarters year inogen gross margin have be impressive oxygen machine rental sell unit third quarter be take share home oxygen market say mike matson analyst needham co re offer more attractive solution patient other company be ve go direct patient be marketing tv ad magazine ad internet site try attract patient be medicare have insurance even be willing pay unit own pocket oxygen therapy market opportunity be inogen say note pocs now use represent less new home oxygen machinein october inogen release home oxygen concentrator call inogen home be lightest liter minute continuous flow oxygen concentrator currently available weigh just pound vs typical home oxygen machine weight pound be meant be used mostly night patient do not yet require portable solution patient represent total oxygen patient also used less power provide monthly electricity saving still very early process say bauerlein re really try optimize be right selling price be right selling strategy so still very early be new market really isn retail market stationary oxygen concentrator point say firm need least quarter determine best strategy be inogen home however concentrator be less complex pricing most likely be cheaper inogen other machine company portable concentrator include inogen latter be latest lightest machine pound retail price start company be work even smaller lighter model inogen expect be release first half goal be offer product be less expensive manufacture say bauerlein inogen go public february share stock nearly double ipo price end year market cap approach inogen rank size name ibd medical product industry group be dominate like medtronic mdt covidien cov baxter international bax group rank performance ibd track inogen outsized stock gain second half vs group rise be factor lift medical product group place half year inogen largest competitor be invacare ivc inova lab respironic unit philips phg analyst matson say risk be rival try improve inogen product trajectory market be pretty long inogen hold patent least year remain provide buffer zone company have be generate positive cash flow finishing third quarter cash cash equivalent also secure access credit facility jpmorgan chase jpm bank lead inogen ipo dec analyst day event inogen reaffirm revenue guidance raise november expect growth year consensus opinion analyst poll thomson reuter call earning share gain cent gain year cent
118,BAX,launch alprolix eloctate come july biogen idec be lead edge first new class hemophilia treatment come year question be interested be justifiably cautious patient try new thing hemophilia be fairly well know due presence europe royal
119,BAX,fast food restaurant operator yum brand yum be upgrade buy drug giant pfizer pfe be downgrade sell wall street analyst tuesday goldman sachs initiate coverage host medical pharmaceutical company rating baxter international bax intuitive surgical isrg buy abbott laboratory hold argus research upgrade yum brand stock buy hold yum operate franchise kfc pizza hut taco bell restaurant yum stock rise stock market today break cup base buy point remain buy zone hit record regular session trading high louisville ky base yum report better expect revenue earning first quarter thank strong sale taco bell citigroup downgrade share pfizer sell stock be tuesday pfizer stock have form saucer handle chart pattern buy point past week new york base pfizer report mixed first quarter result earning top view sale come short goldman initiate coverage baxter buy rating price target start surgical robot maker intuitive surgical buy price target begin coverage abbott lab hold rating price target baxter rise hit fresh time high intuitive surgical rise climb also set record high abbott lab fall related baxter raise guidance hospital market rebound stock hit highpfizer follow baxter get slam subpoena related saline shortagerobotic surgeon maker launch record high strong
120,BAX,pfizer pfe wednesday follow baxter bax receive department justice subpoena widespread antitrust investigation sale marketing saline fluid shortage more year late wednesday pfizer stock be less follow report doj probe accord reuter pfizer confirm receive grand jury subpoena department antitrust division news come just day baxter stock fall less news have receive subpoena expect be part same investigation flu season rage company make intravenous fluid hydrate patient experience delay production delay saline solution price rise accord senator ask federal trade commission investigate matter include probe be baxter hospira acquire pfizer braun ibd take pfizer stock have low ibd composite rating meaning underperform more third stock term key growth metric earning power sale growth visit ibd stock checkup list top rate drugmaker include jazz pharmaceutical stock have cr best possible baxter have call allegation extraordinary motion dismiss related class action lawsuit deal shortage baxter begin import iv fluid facility spain incur cost work comply fda requirement pfizer didn immediately return request comment investor business daily related do baxter hoodwink fda inspector be probe just extraordinary
121,BAX,stock market hold gain afternoon trading monday nasdaq make favorable move chart nasdaq rise be inch back day move average nasdaq look better jump separated bit own day line index largest nonfinancial nasdaq listing never go day average last week netflix nflx largest nasdaq component be highest volume stock move video stream company announce result close today dow jone industrial average be also remain day average meaning still reason be suspicious rebound market volume be tracking lower be surprise give prior session trading slow ahead day weekend also curious be fact only few stock be heavy volume homebuilder continue provide interesting chart horton dhi be try break past buy point cup handle base price volume activity be insufficient view today move rush institutional buy relative strength line be not new high be damper potential entry homebuilder have shot top ibd industry ranking week william lyon home wlh calatlantic group caa also be form cup handle basis be research further health care stock be mixed pharmaceutical hospital tumble variety reason hca holding hca slide double usual volume breaking day move average hospital operator give preliminary first quarter result today report sale year earning share rise number be expectation ibd hospital industry group be worst perform today market hca be week high other be more baxter international bax fall active trading remain price advance have take stock record high report say justice department be investigate sale practice intravenous saline include sell baxter abiom abmd make impella heart pump gap loss big volume stock have be form base fall day line be news wire pharmaceutical eli lilly lly incyte incy plunge day line heavy volume fda decline approve rheumatoid arthritis drug say more clinical trial be necessary related eli lilly incyte stock break key level fda drug setbacknetflix earning close expect
122,BAX,medical stock particularly drugmaker play key role buoy challenged market first half year year date tuesday ibd medical sector industry group show average loss biotechs ethical drugmaker be hardest respectively have left medical group rank
123,BAX,drugmaker tuesday continue turn solid earning report beat pfizer pfe mallinckrodt mnk shire shpg get mixed reaction investor specialty drug hospital product company mallinckrodt make biggest move jump more beat analyst second quarter estimate raise guidance earning share be more thomson reuter survey consensus revenue be more wall street number growth do decelerate somewhat recent quarter top line bottom line vs prior year mallinckrodt also say expect full year ep high end previously guide range put annual earning growth acthar immunology drug mallinckrodt acquire buy questcor couple year shrug critique business depend sky high pricing acthar sale beat consensus estimate brand grow year year attribute volume negative impact price hurt bear thesis write mizuho security analyst irina koffler research note british rare disease company shire climb more stock market today also deliver beat raise contrast mallinckrodt growth have be accelerate sale gain vs just year much come recent acquisition baxalta hemophilia focuse company spun baxter international bax shire say own legacy product grow baxalta rise profit jump share top bottom line beat consensus estimate shire new full year sale guidance be line consensus ep guide be upside midpoint represent growth last year ibd take shire pfizer rank top stock ibd medical ethical drug industry group shire be ep rank stock performance year have be weaker pfizer more info see shire stock checkup pharma giant pfizer drop also notch quarterly beat stock hit year high monday suggest expectation be pretty bullish company do not raise guidance year investor have be wait impatiently pfizer decide go split company future pfizer have promise make announcement year end didn happen tuesday new breast cancer drug ibrance show blockbuster potential selling vs year earlier beating analyst expectation prevnar vaccine pfizer largest product actually miss quarter due timing ex governmental purchase high initial capture rate eligible patient successful launch prevnar elderly population note evercore isi analyst mark schoenebaum email recall previously pfizer communicate expect total worldwide prevnar revenue be close level consensus still model minimal year year growth overall sale rise profit climb together be first back back quarters sale profit growth pfizer have report former blockbuster lipitor go patent
124,BAX,don let name alp sector dividend dog sdog fool exchange trade fund hit record high past week have be remarkably steady performer exclude aug flash crash etf deepest decline have be november january nearly other decline inception year be less share break flat base last monday past buy point primary focus large cap dividend stock etf serve long term sailing rather momentum play fund be design dog dow strategy basically seek component dow jone industrial average highest dividend yield think be dog be just temporarily favor share price eventually catch yield performance alp sector dividend dog take premise apply larger universe namely find stock highest dividend yield respective sector so always have exposure broad sector index select have nearly equal weighting etf stock range weighting accord alp most component have be rebound year even be form price consolidation right now pair health care stock baxter bax johnson johnson jnj have be best perform component baxter make hospital renal disease product be past buy point have advanced buy point insurance firm cincinnatus financial cinf have rally breaking feb etf pay quarterly dividend cent share good annualize yield ibd etf leader index show performance model portfolio exchange trade fund be lead overall market computer algorithm select etfs base relative strength other objective performance rating periodic adjustment market trend condition universe etfs be select include fund list
125,BAX,share medical product maker baxter international bax hit time high tuesday company beat estimate raise guidance baxter earning exclude time item rise year earlier quarter cent share beating analyst consensus cent accord thomson reuter sale decline beating wall street number exclude foreign exchange impact sale rise baxter add cent full year ep guidance now last year company say constant currency sale growth be have previously guide second quarter baxter forecast earning cent share top analyst average estimate cent say sale grow even include fx impact street have expect slight decline baxter stock hit new high early trading stock market today afternoon trading share be less baxter product include iv system dialysis machine surgical equipment be sell mainly hospital market have be look strong earning season accord leerink analyst danielle antalffy now third consecutive growth quarter consecutive quarters low single digit decline serve encourage datum point addition johnson johnson jnj st jude medical stj abbott laboratory report last week support potential trend improve procedure volume overall antalffy write research note fortune hospital stock support view medical hospital group have be fastest rise ibd industry group leap week present
126,BAX,ibd research show buy stock new high market be strong be preferable buy stock new low however find lower entry base isn always bad idea right circumstance be ideal jesse livermore shakeout pattern deliver big gain don have stock make new high pattern involve lows second low undercut first stock be buy rise point first low strong volume stock be high price say share add least point first low want see stock make significant move build position second low tell weak holder be be shake surge past first low tell fund be buy share resistance be minimal livermore time big money operator sometimes start drive second low little selling own want share weak holder drive stock second low be easiest way grab share reduce price back truck reload bed cheaper share big money add position average price get too high manipulation couldn have account even most stock story stock have strong fundamental conviction naturally draw more money stock fuel run financial pool livermore era dark pool today individual investor make mistake look market reality unfair wiser look market term odd be work baxter travenol laboratory bax change name baxter international shape shakeout first low be notch july second low settle week end oct shakeout set buy point oct baxter break past entry daily volume be average stock then retreat almost ideal buy point find traction baxter rise month get gain ve be tough investor hold stock break day line big volume ve book gain
127,BAX,share medical equipment maker cyberonic cybx fall sharply report mixed fourth quarter estimate earning estimate full year be lighter expect rolled variety new device maker implantable device treat epilepsy depression other neurological disease say earning share rise vs year cent penny more estimate revenue grow wall street expect full year cyberonic see ep consensus analyst poll thomson reuter be share company light earning projection come shift management higher spending launch several new product april medical device maker name hoare newly create position chief operate officer neill cruz chief medical officer other medical gear maker include highly rate invisalign clear brace maker align technology algn stock be ibd list top rate stock spine disorder treatment gear maker globus medical gmed cyberonic make highly specialize equipment cyberonic make monitoring device system deliver mild electrical pulse vagus nerve patient neck send signal brain cyberonic new aspiresr brand pulse generator treatment epilepsy depression be approve europe february communication food drug administration determine next step approval aspiresr generator be underway cyberonic ceo dan moore say wednesday earning announcement moore have say earlier company be make significant multiyear investment sale force technology pipeline support rollout cyberonic new centro proguardian system be also near submission regulatory agency approval plunge much time usual trading volume cyberonic share be late morning trading stock market today wednesday small company have be steady eddie grow consistent pace last year annual revenue have grow stock price rise early june high feb year begin retreat sync market correction other company company medical product group medical equipment giant medtronic mdt largest group market cap be fractionally baxter international bax fall align technology globus medical be follow james detar twitter ibd_jdetar
128,BAX,maker medical device be come increase pressure owing fundamental power shift american medicine favore insurance company hospital patient change accord moty avisar president medical system maker surgical theater be base patient be force soar medical cost take control health care let say patient be
129,BAX,baxter international bax announce thursday split biopharma medical product business separate company mid baxter stock jump heavy morning trading stock market today
130,BAX,biopharma arm take last year be devote mainly hemophilia treatment other blood related product branch account less half sale majority profit however be face new competition soon biogen idec biib nordisk nvo expect soon launch longer act hemophilia product require less frequent infusion baxter be work longer act product expect launch next year
131,BAX,medical product division generate sale last year include iv equipment drug delivery system surgical product baxter announcement note company be still integrate acquisition swedish dialysis player gambro complete last september
132,BAX,press release announce split say separation sharpen management focus separate market allow more flexibility decide strategy allocation resource
133,BAX,baxter have establish history execute successful spinoff have continue evaluate separation business response diverge business dynamic rapidly change macro environment say ceo robert parkinson head medical product company statement
134,BAX,move do seem make investor happy baxter stock have lag comparatively recent bull run medical stock thursday move bring new high less pre crash level september sale revenue growth have also be single digit several year now
135,BAX,follow amy reeve twitter ibd_areeve baxter international bax announce thursday split biopharma medical product business separate company mid baxter stock jump heavy morning trading stock market today biopharma arm take last year be devote mainly hemophilia treatment other blood related product branch account less half sale majority profit however be face new competition soon biogen idec biib nordisk nvo expect soon launch longer act hemophilia product require less frequent infusion baxter be work longer act product expect launch next year medical product division generate sale last year include iv equipment drug delivery system surgical product baxter announcement note company be still integrate acquisition swedish dialysis player gambro complete last september press release announce split say separation sharpen management focus separate market allow more flexibility decide strategy allocation resource baxter have establish history execute successful spinoff have continue evaluate separation business response diverge business dynamic rapidly change macro environment say ceo robert parkinson head medical product company statement move do seem make investor happy baxter stock have lag comparatively recent bull run medical stock thursday move bring new high less pre crash level september sale revenue growth have also be single digit several year now follow amy reeve twitter ibd_areeve
136,BAX,baxter international bax announce thursday split biopharma medical product business separate company mid jump start lag stock move seem surprise wall street many investor have always view separation attractive prospect have mostly discount idea term give management
137,BAX,major index wobble early session then moved decisively lower rise trade midday thursday
138,BAX,nasdaq snap lower slip dow jone industrial average shave
139,BAX,nasdaq volume reversed higher rise nyse volume climb trade same time wednesday
140,BAX,stock market today receive welter mixed economic report weekly jobless claim unexpectedly fall upward gdp revision fourth quarter underwhelm just meeting expectation pending home sale post eighth straight decline february dip lowest level october
141,BAX,loss baxter international bax alcoa aa duked top
142,BAX,baxter be announce divide medical device business alcoa be also possibly link court ruling now nix plan overhaul warehouse operation london metal exchange
143,BAX,oil driller producer be rally midwestern oil price climb diamondback energy fang goodrich petroleum gdp more diamondback move lift tight week consolidation new high
144,BAX,video game retailer gamestop gme dive sale earning growth miss consensus forecast management also lower ep guidance expectation
145,BAX,leader continue take hard kick late morning trade
146,BAX,kapstone paper packaging ks be work stock worst weekly loss tumble left share march high
147,BAX,spirit airline save wipe price diving tuesday high very heavy trade
148,BAX,price west texas intermediate crude continue press further barrel mark price cush okla pipeline hub wti be apparently be force higher critically low inventory level cush storage complex new pipeline capacity have shift cush long standing glut gulf coast price be be force oversupply major index wobble early session then moved decisively lower rise trade midday thursday nasdaq snap lower slip dow jone industrial average shave nasdaq volume reversed higher rise nyse volume climb trade same time wednesday stock market today receive welter mixed economic report weekly jobless claim unexpectedly fall upward gdp revision fourth quarter underwhelm just meeting expectation pending home sale post eighth straight decline february dip lowest level october loss baxter international bax alcoa aa duked top baxter be announce divide medical device business alcoa be also possibly link court ruling now nix plan overhaul warehouse operation london metal exchange oil driller producer be rally midwestern oil price climb diamondback energy fang goodrich petroleum gdp more diamondback move lift tight week consolidation new high video game retailer gamestop gme dive sale earning growth miss consensus forecast management also lower ep guidance expectation leader continue take hard kick late morning trade kapstone paper packaging ks be work stock worst weekly loss tumble left share march high spirit airline save wipe price diving tuesday high very heavy trade price west texas intermediate crude continue press further barrel mark price cush okla pipeline hub wti be apparently be force higher critically low inventory level cush storage complex new pipeline capacity have shift cush long standing glut gulf coast price be be force oversupply
149,BAX,stock open red thursday quickly reversed narrow gain weak february home sale datum
150,BAX,nasdaq scrabble nearly dow jone industrial average cling fractional gain trade be mixed stock market today nyse lower nasdaq compare action early wednesday
151,BAX,stock moved lower healthy early reading weekly jobless claim fourth quarter gdp growth estimate revise higher roughly line expectation
152,BAX,pending home sale february be less positive eighth straight monthly decline accord national association realtor read be index lowest mark october nar also revise january number downward group project total exist home sale just sale
153,BAX,stock baxter international bax spiked massive trade blast month consolidation deerfield ill company announce divide business medical device biopharma business see revenue revenue be medical device side company say expect complete spinoff mid
154,BAX,alcoa aa surge big trade move just new high shallow month consolidation
155,BAX,nasdaq baidu bidu swoon cut week move average third straight weekly decline
156,BAX,leader be weak start handful ibd list stock lose ground early trade bottom list ambarella amba kapstone paper packaging ks spirit airline save drop more
157,BAX,qihoo technology qihu unraveled widening loss week slip more buy point cup handle base trigger automatic sell rule
158,BAX,energy stock receive support oil price rise barrel
159,BAX,gold slip ounce undercut mark first time mid february stock open red thursday quickly reversed narrow gain weak february home sale datum nasdaq scrabble nearly dow jone industrial average cling fractional gain trade be mixed stock market today nyse lower nasdaq compare action early wednesday stock moved lower healthy early reading weekly jobless claim fourth quarter gdp growth estimate revise higher roughly line expectation pending home sale february be less positive eighth straight monthly decline accord national association realtor read be index lowest mark october nar also revise january number downward group project total exist home sale just sale stock baxter international bax spiked massive trade blast month consolidation deerfield ill company announce divide business medical device biopharma business see revenue revenue be medical device side company say expect complete spinoff mid alcoa aa surge big trade move just new high shallow month consolidation nasdaq baidu bidu swoon cut week move average third straight weekly decline leader be weak start handful ibd list stock lose ground early trade bottom list ambarella amba kapstone paper packaging ks spirit airline save drop more qihoo technology qihu unraveled widening loss week slip more buy point cup handle base trigger automatic sell rule energy stock receive support oil price rise barrel gold slip ounce undercut mark first time mid february
160,BAX,scott migliori bet big best idea fund allianzgi focuse growth fund be more concentrated now come fund lead manager have stock feb accord morningstar inc month migliori take helm fund
161,BAX,medical product giant baxter international bax be stock market thursday morning new high just beat profit expectation affirm full year guidance baxter early thursday say sale rise year earlier quarter hair analyst consensus accord thomson reuter profit however climb
162,BAX,ligand pharmaceutical lgnd hasn turn profit year drug developer not only expect make money year lift guidance fourth quarter full year la jolla calif base company say last month now expect gaap earning cent share revenue vs
163,BAX,biopharma plasma firm grifol isn let spain financial crisis get
164,BAX,international expansion be key component barcelona base company growth strategy
165,BAX,expansion begin acquisition north carolina base talecris biotherapeutic year marked turn point grifol grfs make largest global manufacturer plasma base protein biological medicine deal be value
166,BAX,ceo victor grifol tell shareholder earlier year talecris make year old firm truly global company more income generate outside spain
167,BAX,other major global player be illinois base baxter international bax australia base csl behr be publicly trade australia
168,BAX,morningstar analyst karen anderson say plasma business be essentially oligopoly baxter csl grifol hold majority world market roughly share
169,BAX,sale generate grifol spain have continue decline slower pace previously austerity measure rein nation high debt
170,BAX,broader portfolio
171,BAX,talecris expand grifol plasma collection platform donor center give new product immunology pulmonology neurology critical care hemostasis
172,BAX,lot country want source plasma believe be highest quality plasma say ben andrew william blair analyst add grifol be extremely well manage have never have product recall
173,BAX,grifol be founder barcelona ceo victor grifol grandfather late scientist jose antonio grifol elder grifol be first blood plasma be remove whole blood deplete red blood cell original lab specialize tool clinical analysis blood transfusion
174,BAX,talecris buyout be complete june company have trade american depositary receipt adr share have climb so far year
175,BAX,andrew say grifol adrs trade more discount share trade madrid exchange part lightly cover analyst management doesn go way court wall street
176,BAX,little bit odd duck great odd duck andrew say grifol stock
177,BAX,way grow
178,BAX,grifol have keep acquire latest deal buy novartis nvs blood testing diagnostic unit transaction expect close first half
179,BAX,novartis blood screening portfolio focus test hiv hepatitis west nile virus other indication draw revenue last year
180,BAX,novartis acquisition make grifol more vertically integrate basically have test be necessary be run blood sample say morningstar anderson
181,BAX,grifol buy araclon biotech advance research development pipeline area outside plasma
182,BAX,araclon spinoff spain university zaragoza be involved diagnostic therapy alzheimer disease
183,BAX,grifol have keep expand outside core expertise blood plasma earlier year buy interest biopharma spanish diagnostic prognostic firm personalize treatment genetically complex disease
184,BAX,also recently take minority stake tigenix biotech base belgium develop therapy used stem cell treat autoimmune inflammatory disease other tigenix new cellular therapy repair knee cartilage be approve use europe
185,BAX,geographic expansion
186,BAX,meanwhile grifol have expand blood separation fractionation plant clayton barcelona intend increase plasma fractionation capacity liter plasma year
187,BAX,company also operate plant los angele melville mexico switzerland australia
188,BAX,third quarter revenue grow year period growth be even faster latin america china overall revenue rise euro grifol report euro only
189,BAX,china demand protein albumin plasma expander be particularly strong china have be import albumin used replenish lose blood treat trauma due problem quality nation supply anderson say
190,BAX,china be huge growth opportunity blood plasma company say analyst andrew believe time china allow additional blood protein come
191,BAX,albumin be part grifol core plasma protein bioscience division account nearly revenue albumin fastest grow product division logged growth more third quarter
192,BAX,firm earning be grow much faster revenue
193,BAX,share earning adrs have grow double digit last quarters third quarter jump cent analyst expect full year profit share last year
194,BAX,see earning rise accord thomson reuter
195,BAX,grifol smaller division be involved diagnostic drive sale blood typing card hospital product diagnostic unit become much larger part grifol business once novartis acquisition be complete take sale deutsche bank analyst europe estimate
196,BAX,note profitability novartis asset have not be disclose majority estimate royalty income alone go away core patent hepatitis testing expire add
197,BAX,still analyst see potential double digit accretion add fall low single digit hepatitis royalty disappear
198,BAX,grifol likely paid premium novartis blood screening business gain more significant footprint diagnostic market deutsche bank analyst say
199,BAX,grifol hospital division get boost recent licensing agreement tennessee base cumberland pharmaceutical cpix market ibuprofen drug intravenous infusion spain portugal several country south america drug be used treat postoperative pain fever biopharma plasma firm grifol isn let spain financial crisis get international expansion be key component barcelona base company growth strategy expansion begin acquisition north carolina base talecris biotherapeutic year marked turn point grifol grfs make largest global manufacturer plasma base protein biological medicine deal be value ceo victor grifol tell shareholder earlier year talecris make year old firm truly global company more income generate outside spain other major global player be illinois base baxter international bax australia base csl behr be publicly trade australia morningstar analyst karen anderson say plasma business be essentially oligopoly baxter csl grifol hold majority world market roughly share sale generate grifol spain have continue decline slower pace previously austerity measure rein nation high debt broader expand grifol plasma collection platform donor center give new product immunology pulmonology neurology critical care hemostasis lot country want source plasma believe be highest quality plasma say ben andrew william blair analyst add grifol be extremely well manage have never have product recall grifol be founder barcelona ceo victor grifol grandfather late scientist jose antonio grifol elder grifol be first blood plasma be remove whole blood deplete red blood cell original lab specialize tool clinical analysis blood transfusion talecris buyout be complete june company have trade american depositary receipt adr share have climb so far year andrew say grifol adrs trade more discount share trade madrid exchange part lightly cover analyst management doesn go way court wall street little bit odd duck great odd duck andrew say grifol stock way growgrifol have keep acquire latest deal buy novartis nvs blood testing diagnostic unit transaction expect close first half novartis blood screening portfolio focus test hiv hepatitis west nile virus other indication draw revenue last year novartis acquisition make grifol more vertically integrate basically have test be necessary be run blood sample say morningstar anderson grifol buy araclon biotech advance research development pipeline area outside plasma araclon spinoff spain university zaragoza be involved diagnostic therapy alzheimer disease grifol have keep expand outside core expertise blood plasma earlier year buy interest biopharma spanish diagnostic prognostic firm personalize treatment genetically complex disease also recently take minority stake tigenix biotech base belgium develop therapy used stem cell treat autoimmune inflammatory disease other tigenix new cellular therapy repair knee cartilage be approve use europe geographic grifol have expand blood separation fractionation plant clayton barcelona intend increase plasma fractionation capacity liter plasma year company also operate plant los angele melville mexico switzerland australia third quarter revenue grow year period growth be even faster latin america china overall revenue rise euro grifol report euro only china demand protein albumin plasma expander be particularly strong china have be import albumin used replenish lose blood treat trauma due problem quality nation supply anderson say china be huge growth opportunity blood plasma company say analyst andrew believe time china allow additional blood protein come albumin be part grifol core plasma protein bioscience division account nearly revenue albumin fastest grow product division logged growth more third quarter firm earning be grow much faster revenue share earning adrs have grow double digit last quarters third quarter jump cent analyst expect full year profit share last year see earning rise accord thomson reuter grifol smaller division be involved diagnostic drive sale blood typing card hospital product diagnostic unit become much larger part grifol business once novartis acquisition be complete take sale deutsche bank analyst europe estimate note profitability novartis asset have not be disclose majority estimate royalty income alone go away core patent hepatitis testing expire add still analyst see potential double digit accretion add fall low single digit hepatitis royalty disappear grifol likely paid premium novartis blood screening business gain more significant footprint diagnostic market deutsche bank analyst say grifol hospital division get boost recent licensing agreement tennessee base cumberland pharmaceutical cpix market ibuprofen drug intravenous infusion spain portugal several country south america drug be used treat postoperative pain fever
200,BAX,baxter international bax hit year high friday rumor swirl company be verge big buyout cite unnamed source wall street journal report baxter be talk buy sweden gambro baxter make drug device focuse disorder blood gambro hemodialysis equipment fill
201,BAX,be successful leader follower trust say don believe messenger win believe message jim kouze santa clara university leadership professor tell ibd kouze fellow santa clara professor barry posner have find person consistently rank honesty competency inspiration top quality seek leader here be
202,BAX,be successful leader follower trust say don believe messenger win believe message jim kouze santa clara university leadership professor tell ibd kouze fellow santa clara professor barry posner have find person consistently rank honesty competency inspiration top quality seek leader here be
203,BAX,stock achieve solid gain wednesday finished session high rise dow jone industrial average nasdaq nyse fared best gain volume increase board accord early datum want hear ibd analysis today market emerge stock click here watch market wrap video
204,BAX,investor interest medical product stock have likely encounter hill hrc free report baxter international bax free report stock present investor better value opportunity right now let take closer look best way find great value stock be pair strong zack rank impressive grade value category style score system proven zack rank emphasize company positive estimate revision trend style score highlight stock specific trait hill baxter international have zack rank buy right now zack rank favor stock have recently see positive revision earning estimate so investor rest assured company have improve earning outlook be just factor value investor be interested value investor be also interested number try true valuation metric help show company be undervalue current share price level value category style score system identify undervalue company look number key metric include long favore ratio ratio earning yield cash flow share variety other fundamental help determine company fair value hrc currently have forward ratio bax have forward also note hrc have peg ratio popular figure be similar widely used ratio peg ratio also consider company expect ep growth rate bax currently have peg ratio notable valuation metric hrc be ratio investor use ratio look stock market value versus book value be defined total asset total liability comparison bax have be just few metric contribute hrc value grade bax value grade hrc bax be impressive stock solid earning outlook base valuation figure feel hrc be superior value option right now
205,BAX,week high level be used indicator stock near level be consider winner investor often wonder high price have make stock overpriced apprehension be not absolutely baseless stock hit week high be not necessarily overpriced fact investor miss top gainer bid avoid stock be trading week high level stock continue momentum keep touch new high time progress so more inform approach understand further upside be left be beneficial case here discuss strategy find right stock borrow basic momentum investing technique bet catchphrase buy high sell higher week high good indicatormany time stock hit week high fail scale higher potential be investor fear stock be overvalue price crash be impending fact overvaluation be quite natural most stock investor focus willingness pay premium have help reach level doesn always mean impending decline factor such robust sale surge profit level earning growth prospect strategic acquisition encourage investor bet stock keep motivated be tangible negative other word momentum continue also string positive development dominate market investor find reaction unwarranted even be company specific drive force set right filterswe run screen week high stock trading high level hold tremendous upside potential screen include parameter shortlist stock strong earning growth expectation sturdy value metric price momentum moreover screen filter stock be relatively undervalue compare peer term earning well sale ensure continuation rally time current price week high be ratio current price highest price stock have trade past week value greater imply stock be trading week high range change price week ensure stock price have moved north past week change price week metric guarantee continue upward price momentum stock past month well price sale lower better used estimate metric measure amount investor put company obtain dollar earning narrow list stock be undervalue compare industry year ep growth help choose stock have higher growth rate industry be meaningful indicator decent earning growth add investor optimism zack rank screening be complete proven zack rank have prove worth inception be fundamental truth stock zack rank strong buy buy have always manage brave adversity beat market see complete list today zack rank stock here current price parameter help screen stock be trading higher volume day share inclusion metric ensure be substantial volume share so trading be easier here be stock make screen insight enterprise inc nsit free report be arizona base global direct marketer brand name computer hardware software focus business business information technology capability company come average quarter positive earning surprise have zack rank baxter international inc bax free report be global diversify healthcare company manufacture market product fight disease hemophilia immune disorder kidney disease other company zack rank deliver average positive surprise last quarters jazz pharmaceutical plc jazz free report be specialty company focuse area sleep hematology oncology company deliver average quarter positive earning surprise have zack rank covenant transportation group inc cvti free report be truckload carrier offer premium transportation service unite state company deliver average positive surprise trail quarters carry zack rank terex corporation tex free report be global equipment manufacturer cater construction infrastructure surface mining industry currently sporting zack rank company deliver average positive surprise last quarters get rest stock list signing now week free trial research wizard start used screen own trading further also create own strategy test first take investment plunge research wizard be great place begin easy use everything be plain language very intuitive start trial research wizard today next time read economic report open research wizard plug find see gem come click here sign free trial research wizard today disclosure officer director employee zack investment research own have sell short security hold long short position option be mentioned material affiliated investment advisory firm own have sell short security hold long short position option be mentioned material disclosure performance information zack portfolio strategy be available https www zack com performancezack restaurant recommendation addition dine special place feast stock share zack special report spotlight recent ipos watch stock offer immediate promise boom sector download free
206,BAX,medical device industry have be benefit favorable consumer behavior grow prevalence minimally invasive surgery demand liquid biopsy test use ensure quick improve patient care shift payment system value base model further consider favorable demographic change market dynamic artificial intelligence ai big datum application increase business investment sector have be go strong broadly speaking latest tax cut job act slash corporate tax rate earlier have also buoy optimism investor additionally senate decision defer implementation industry wide excise tax know medical device couple year have instilled confidence investor tax be effective jan bill also delay cadillac tax tax employer insurance emergo medical device industry be project reach market value boston scientific corporation bsx free report baxter international inc bax free report be close contender space notably stock carry zack rank buy raise investor optimism here make detailed analysis company fundamental determine stock be currently position better medical product space market cap boston scientific be lead manufacturer medical device product used various interventional medical specialty worldwide other hand base deerfield il baxter be lead global medical technology company company have market cap price performancein past year boston scientific share have gain compare industry increase stock have also surpass index increase share baxter have rise period earning zack consensus estimate boston scientific current year earning be peg share reflect year year project growth same baxter be peg indicate year year rise moreover last year datum boston scientific earning share have witness cagr baxter earning be project negative cagr totale hence boston scientific win round sale zack consensus estimate boston scientific current year revenue be peg show year year growth same baxter be pin reflect year year growth boston scientific revenue witness cagr reach baxter revenue depict negative cagr here too boston scientific win baxter factor drive stocksboston scientificover recently report quarters boston scientific demonstrated growth business line geography view also paint bright picture company achieve clinical milestone ranger drug coat balloon watchman left atrial appendage closure device also post suspension lotus valve europe acurate tavr valve platform continue build momentum boston scientific recently announce several acquisition include nxthera nvision urology pelvic health emcision endoscopy securus ep millipede structural heart inorganic expansion plan bode well stock operational growth demand baxter crrt injectable pharmaceutical iv solution peritoneal dialysis therapy be positive buyout recothorm preveleak be noteworthy well recently company get fda approval spectrum iq infusion system baxter surgical portfolio be highly diversify product available more country include exclusive product floseal hemostatic matrix tisseel fibrin sealant coseal surgical sealant vascu guard patch other conclusionour comparative analysis indicate boston scientific be position better baxter consider price performance well earning sale growth other key picksother top rank stock broader medical sector be illumina inc ilmn free report idexx laboratory inc idxx free report illumina sport zack rank strong buy idexx carry zack rank see complete list today zack rank stock here illumina expect long term earning growth idexx have expect long term earning growth rate today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
207,BAX,stock hit week high level be thought be winner level work indicator many investor buy selling stock amateur investor often wonder level make stock overpriced be not totally incorrect stock hit week high be not necessarily overpriced fact decision avoid stock be trading week high level make investor miss most top gainer stock continue momentum keep touch new high time progress so take more inform approach understand have further upside left here discuss strategy find right stock borrow basic momentum investing technique bet catchphrase buy high sell higher week high good indicatormany time stock hit week high fail scale higher potential investor fear stock be overvalue price crash be impending fact overvaluation be quite natural most stock investor focus willingness pay premium have help reach level doesn always mean impending decline factor such robust sale surge profit level earning growth prospect strategic acquisition encourage investor bet stock keep motivated be tangible negative other word momentum continue also string positive development dominate market investor find reaction unwarranted even be company specific drive force set right filterswe run screen week high stock trading high level hold tremendous upside potential screen include parameter shortlist stock strong earning growth expectation sturdy value metric price momentum moreover screen filter stock be relatively undervalue compare peer term earning well sale ensure continuation rally time current price week high be ratio current price highest price stock have trade past week value greater imply stock be trading week high range change price week ensure stock price have moved north past week change price week metric guarantee continue upward price momentum stock past month well price sale lower better used estimate metric measure amount investor put company obtain dollar earning narrow list stock be undervalue compare industry year ep growth help choose stock have higher growth rate industry be meaningful indicator decent earning growth add investor optimism zack rank screening be complete proven zack rank have prove worth inception be fundamental truth stock zack rank strong buy buy have always manage brave adversity beat market see complete list today zack rank stock here current price parameter help screen stock be trading higher volume day share inclusion metric ensure be substantial volume share so trading be easier here be stock make screen jazz pharmaceutical plc jazz free report be specialty company focuse area sleep hematology oncology company deliver average quarter positive earning surprise have zack rank baxter international inc bax free report be global diversify healthcare company manufacture market product fight disease hemophilia immune disorder kidney disease other company zack rank deliver average positive surprise last quarters boise cascade bcc free report be wood product manufacturer build material distributor company deliver average positive surprise trail quarters carry zack rank insight enterprise inc nsit free report be arizona base global direct marketer brand name computer hardware software focus business business information technology capability company come average quarter positive earning surprise have zack rank comfort system usa inc fix free report be provider comprehensive heating ventilation air conditioning installation maintenance repair replacement service currently sporting zack rank company deliver average positive surprise last quarters get rest stock list signing now week free trial research wizard start used screen own trading further also create own strategy test first take investment plunge research wizard be great place begin easy use everything be plain language very intuitive start trial research wizard today next time read economic report open research wizard plug find see gem come click here sign free trial research wizard today disclosure officer director employee zack investment research own have sell short security hold long short position option be mentioned material affiliated investment advisory firm own have sell short security hold long short position option be mentioned material disclosure performance information zack portfolio strategy be available https www zack com performancezack restaurant recommendation addition dine special place feast stock share zack special report spotlight recent ipos watch stock offer immediate promise boom sector download free
208,BAX,suspension controversial medical device tax year medical device industry be currently ride high optimism advame medical device industry lobbying group strongly advocate relief note tax repeal provide huge impetus company channelize turnover strategic consolidation research development also help create new job opportunity accord article publish daily news tax go effect january save device company much year suspension medical device market be undergo substantial transformation age population longer expectancy life grow healthcare awareness emerge economy combine powerful long term tailwind include merger acquisition product innovation have be contribute growth sector boom continue be yet be see far benefit tax repeal have be redirect now meanwhile accord mark bonifacio president bonifacio consult service private equity strategic oem original equipment manufacturer buyer be compete asset sector medical contract manufacturing broaden portfolio investing new technology strongly state start be sluggish respect be due uncertainty change global healthcare market fate obamacare medical device tax now doubt be gradually get clear industry be once again head year significant activity year biggest deal seem be card wall street journal latest rumore news related mammoth medtech space boston scientific bsx stryker corporation syk free report report say rival consider bid consolidation analyst seem be optimistic rumore deal believe colossal merger medtronic mdt free report covidien abbott st jude medical last couple year boston scientific also need make mammoth move maintain foothold highly competitive medical technology space follow company consolidation st jude medical january abbott recently close acquisition alere successful wrap transaction combine company be anticipate emerge lead player point care diagnostic space mega consolidation recent time be medical device major becton dickinson co medical surgical diagnostic patient care device provider bard completion deal january becton dickinson be way expand new area vascular access segment piccs peripherally insert central catheter midline drug delivery port baxter international bax purchase thrombin topical preveleak surgical sealant specialty pharmaceutical company mallinckrodt plc mnk free report varian medical var free report also inked major deal company recently sign agreement acquire australia base global life science company sirtex medical limit total deal value investment strengthen company position interventional oncology therapy apart effort gain foothold emerge economy company recently acquire cooperative cl enterprise lead distributor radiotherapy equipment taiwan johnson johnson jnj free report subsidiary depuy synthe inked deal acquire medical enterprise distribution apart boston scientific announce several strategic acquisition include nxthera nvision urology pelvic health emcision endoscopy securus ep millipede structural heart inorganic expansion plan bode well stock operational growth divestment medical device major continue offload core business line asset be similar one acquire merger focus main segment divesture have be mandate federal trade commission ftc other international trust regulator restrict chance monopoly market earlier month johnson johnson get offer fortive corporation sell subsidiary ethicon inc advanced sterilization product business unit fortive jnj accept proposal be step streamline business strategic roadmap better resource utilization higher shareholder return apart accord massdevice report medtronic recently divest stake lifetech scientific china everbright ltd unnamed investor bd also divest soft tissue core needle biopsy line aspira product line merit medical divestment be related acquisition bard april henry schein hsic announce decision spin company major segment global animal health business believe initiative remain part henry schein strategic plan focus more dental medical business accord company transaction enable make most opportunity dental space order deliver quality clinical care advanced wellness prevention apprehend china drug distribution reform slow company growth region accord reuter report cardinal health sell china business shanghai pharmaceutical hold follow announcement major buyout abbott divest eye care business abbott medical optic amo johnson johnson streamline newly add business line marketer aesthetic treatment system cynosure sell hologic notably hologic acquire outstanding cynosure share approximately emerge market healthcare scenario bright survey report gallup analytic last july reveal adult cite healthcare second major problem face country new presidential administration follow new healthcare reform announcement december gallup poll reveal past decade marked biggest increase uninsured rate meanwhile explode population rise middle class increase governmental awareness health issue emerge geography be face huge demand modern cheaper healthcare option go report guardian international finance corp ifj datum show develop country account global death chronic disease indicate enormous market opportunity recent bcg report share emerge market be currently less quarter global medtech revenue be likely increase nearly third revenue medtech market china currently second largest world be project grow annually india fifth largest medtech market world currently record annual growth pace india emerge strong competitor japan germany give huge potential region long back johnson johnson have set manufacturing center brazil china india company emerge market medical device segment continue grow time faster develop market abbott continue lead emerge market investment trend sale region recent quarters sale key emerge market be double digit drive strength bric well strong growth several country latin america include colombia mexico peru argentina medtronic mdt free report fourth quarter fiscal business latin america middle east africa eastern europe china show sustain strength grow double digit overall medtronic long term outlook emerge market be encourage boston scientific emerge market business register growth first quarter reflect significant increase growth business china be once again remarkable year year key pick spacein medical instrument space be positive abiom inc abmd intuitive surgical inc isrg free report carry zack rank strong buy see complete list today zack rank stock here medical product stock baxter international surmodic inc srdx free report boston scientific orasure technology inc osur free report be also well poise zack rank buy weak linkswe advise investor stay away company offer little growth opportunity term include company estimate revision trend reflect bearish sentiment stock do not look inspiring moment be nephew plc snn tg therapeutic inc tgtx free report nxstage medical inc nxtm free report insys therapeutic inc insy free report carry zack rank sell orthofix international ofix free report eagle pharmaceutical inc egrx hold zack rank strong sell zack ipo watch listbefore look stock mentioned want get head start potential tech ipos be pop zack radar imagine be first wave investor jump company almost unlimited growth potential special report give current scoop go public time have drive valuation year other be little less obvious already show jaw drop growth download ipo watch list today free
209,BAX,global medical device industry have demonstrated strong sustainable growth recent past banking age population increase incidence chronic lifestyle disease increase adoption artificial intelligence ai big datum application upbeat consumer sentiment increase business investment sector appear be pink health go kpmg datum medical device industry global annual sale be forecast rise more year reach nearly cision report say unite state be largest medical device market world present rake more revenue several socio political hazard economic dip medical device company have be ride high innovation increase consolidation emerge market expansion tax cut undoubtedly have be very profitable investment space late here be few major development abolition medtech tax bipartisan year suspension medical device tax impose excise tax medtech manufacturer mark temporary relief be again put effect jan repeal be expect boost hire investment america base medical device manufacturer thus instilling investor optimism ratification tax repeal amendment have encourage massive investment sector uptrend continuesapart tax relief medtech fraternity have also be ride high ongoing merger acquisition trend space fact various report suggest have be key catalyst drive healthcare space late datum provide biospectrum asia activity medtech space surge increase value aggregate more major acquisition recent past include becton dickinson company bdx free report acquisition bard johnson johnson jnj free report buyout actelion pbm health insurer health insurer have be look collaborate pharmacy benefit manager medtech space streamline cost drug supply chain buoy continue capital inflow strategic policy key medical device player have expand customer basis moderate leverage enhance cash flow have also alleviate pricing pressure competition medtech space regard latest buyout announcement express script cigna ci free report come just month drug chain pharmacy giant cvs health corp cvs free report announcement acquire nation third largest health insurer aetna be important digital revolution medtechlatest trend robotic surgery big datum analytic bio printing printing electronic health record ehr predictive analytic real time alert revenue cycle management service medtech space be gain prominence various report suggest strategic application ai sphere healthcare provide impetus productivity company adopt ai technology have witness reduction healthcare cost have also experience improve patient outcome more rise minimally invasive surgery higher demand liquid biopsy test use quick improve patient care shift payment system value base model have be drive profit medical device company late trade war fear grip medtechthe sector have be identify trump imposition higher tariff be now investor radar healthcare include medical equipment be sector likely bear brunt trade dispute go datum provide article christian jone mondaq medtech firm unite state currently sell annually china nation import china total medical device export medical device last year totale create worldwide trade surplus needless say medical device lobby be extremely apprehensive propose tariff chinese product significantly affect international trade zack industry rankwithin zack industry classification medical device be broadly group medical sector zack sector further sub divide industry expand level medical instrument medical product medical dental supply medical info system rank industry zack sector base earning outlook fundamental strength constituent company zack industry rank be top zack classify industry medical info system top medical dental supply top medical instrument bottom medical product backtesting show top zack rank industry outperform bottom factor more analyze zack industry rank different medical device segment be say apart certain medical product stock term outlook aforementioned medical device subsector be overall positive price price performance major zack categorize sub industry be follow past day have gain med instrument space have rise stock space have be trading be varian medical system inc var free report steris plc ste free report edward lifescience corp ew free report medical product subsector industry rank indicated bearish tone sector have increase period player space be haemonetic corp hae free report baxter international inc bax free report boston scientific bsx free report zack ipo watch listbefore look stock mentioned want get head start potential tech ipos be pop zack radar imagine be first wave investor jump company almost unlimited growth potential special report give current scoop go public time have drive valuation year other be little less obvious already show jaw drop growth download ipo watch list today free
210,BAX,have be pay attention share baxter international bax share have be move stock past month bax hit new week high previous session baxter international have gain start year compare move medical sector year date return peer group drive outperformance stock have great record positive earning surprise have beaten zack consensus estimate last quarters last earning report april baxter international report ep versus zack consensus estimate beat consensus revenue estimate current fiscal year baxter international be expect post earning share revenue represent change ep change revenue next fiscal year company be expect earn share revenue represent year year change respectively valuation metricsbaxter international be week high right now future hold bax key aspect question be take look valuation metric order determine company have run ahead front look zack style score give investor variety way comb stock look zack rank security style be represent grade run category value growth momentum be combine vgm score well idea style score be help investor pick most appropriate zack rank stock base individual investment style baxter international have value score stock growth momentum score be respectively give company vgm score term value breakdown stock currently trade current fiscal year ep estimate trail cash flow basis stock currently trade versus peer group average additionally stock have peg ratio isn enough put company top echelon stock cover value perspective baxter international inc price consensus baxter international inc price consensus baxter international inc quotezack rankwe also need look zack rank stock supersede trend style score front fortunately baxter international currently have zack rank buy thank favorable earning estimate revision cover analyst recommend investor select stock carry zack rank strong buy style score look baxter international pass test thus seem bax share have bit more room run term do baxter international stack competition share baxter international have be soar company still appear be decent choice rest industry industry peer be also solid potential pick include surmodic srdx free report haemonetic hae free report stryker syk free report currently have zack rank least vgm score least make well round choice however be worth note zack industry rank group be bottom half ranking so isn good news baxter international still fundamental bax be promising still have potential be week high
211,BAX,genomic health inc ghdx free report report first quarter adjust earning cent share year adjust net loss cent thereby reflect significant improvement bottom line also exceed zack consensus estimate cent report net loss come cent share wider couple cent year revenue detailin report quarter company adopt new asc accounting standard calculate revenue used modify retrospective method accordingly metric be year pre adjust revenue new asc standard have be apply jan adjust constant currency basis top line improve year year quarterly number also surpass zack consensus estimate genomic health inc price consensus ep surprise genomic health inc price consensus ep surprise genomic health inc quote geographically first quarter product revenue unite state rise year pre adjust revenue product revenue growth be fuel rise inu invasive breast oncotype dx breast recurrence score test surge prostate test revenue oncotype dx genomic prostate score gps test international product revenue totale quarter review year year atadjust constant currency year pre adjust tally first quarter company deliver more oncotype dx test result year year margin trendgenomic health gross margin contract basis point bps year year first quarter company also witness rise operate expense escalation research development expense uptick general administrative expense increase selling marketing expense report quarter genomic health operate loss come wider year operate loss accordingly operate margin contract bps financial updategenomic health exit first quarter cash cash equivalent short term marketable security highlight improvement record end company have reaffirm earlier provide outlook genomic health expect full year revenue range reflect growth zack consensus estimate be guide range takegenomic health exit first quarter promising note adjust earning revenue outpace respective consensus mark be also encourage year year rise revenue drive solid performance unite state internationally company prostate cancer space strengthen nccn national comprehensive cancer network prostate cancer guideline additional new datum be increase private coverage oncotype dx gps test moreover company be upbeat commercial launch oncotype dx ar nucleus detect liquid biopsy test metastatic prostate cancer be expect contribute business growth company also witness series upside oncotype dx breast recurrence score test however genomic health sole reliance breast oncotype dx test be concern moreover company rise operate expense challenge zack rank key picksgenomic health carry zack rank hold few better rank stock broader medical sector solid result earning season be intuitive surgical isrg free report cheme corp che free report baxter international inc bax free report intuitive surgical sport zack rank strong buy cheme baxter carry zack rank buy see complete list today zack rank stock here intuitive surgical report first quarter adjust earning share ep beat zack consensus estimate revenue also surpass consensus estimate cheme post first quarter adjust ep outshine zack consensus estimate revenue come beating zack consensus estimate baxter release first quarter adjust ep cent crossed consensus mark revenue also edge past zack consensus estimate medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
212,BAX,cardiovascular system inc csii free report report earning share penny third quarter fiscal year quarterly loss cent figure remain ahead earlier guide range loss cent breakeven moreover bottom line compare favorably zack consensus estimate loss cent net system record revenue fiscal third quarter mark year year increase also metric be guide range moreover top line match zack consensus estimate segment detailscoronary device revenue increase year year unite state coronary unit sell increase partially offset low single digit decline asp average selling price cardiovascular system inc price consensus ep surprise cardiovascular system inc price consensus ep surprise cardiovascular system inc quote meanwhile peripheral device revenue rise year year basis improvement come back continue strength hospital set margingross margin report quarter be basis point bps year year meanwhile selling administrative sg expense inched research development expense be result adjust operate expense increase management operate expense be lower previous projection operate income be operate loss year quarter financial company exit third quarter fiscal cash cash equivalent compare end precede quarter positive note have long term debt company expect revenue range fourth quarter fiscal zack consensus estimate be peg fall company estimate range moreover company be likely earn gross profit accounting revenue operate expense be anticipate fiscal fourth quarter company project net income net earning share be predict cent cent consensus mark be peg couple cent lie company expect range system exit third quarter fiscal solid note year year increase coronary device peripheral device segment overall revenue grow back strength company segment year year also expansion gross margin buoy optimism company be putt effort product innovation investment flip side cardiovascular system face cut throat competition niche space zack rank key system have zack rank hold few better rank stock broader medical sector solid result report cycle be intuitive surgical isrg free report cheme corp che free report baxter international inc bax free report intuitive surgical sport zack rank strong buy cheme baxter carry zack rank buy see complete list today zack rank stock here intuitive surgical report first quarter adjust earning share ep beat zack consensus estimate revenue also surpass consensus estimate cheme post first quarter adjust ep outshine zack consensus estimate revenue come surpass zack consensus estimate baxter release first quarter adjust ep cent crossed consensus mark revenue also exceed zack consensus estimate medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
213,BAX,cooper company inc coo free report post second quarter fiscal adjust earning share beat zack consensus estimate earning also increase year year basis california base specialty medical device company report revenue worth surpass zack consensus estimate revenue improve prior year quarter pro basis defined constant exchange rate include acquisition period meanwhile cooper share have decline industry rise past month stock currently carry zack rank hold cooper company inc price consensus ep surprise cooper company inc price consensus ep surprise cooper company inc quotesegment detailscooper report revenue major segment coopervision cvi coopersurgical csi segment garner revenue worth year year basis cc management overall cvi sale have be drive strong performance silicone hydrogel portfolio clariti myday toric cvi revenue rake cc multifocal generate revenue worth cc single use sphere post revenue worth prior year quarter single use sphere revenue come year geographically segment see strong quarter revenue rise year year basis cc management expect growth momentum be strong second half fiscal growth expect upper single digit revenue rise year year basis emea asia pacific segment post revenue year cc management growth be lead strength paragard fertility solution product offering sub segment office surgical product csi account whopping year year fertility post sale worth year year margin analysisas percentage revenue adjust gross margin csi segment be report quarter basis point bps compare prior year quarter percentage revenue adjust gross margin cvi segment be report quarter higher revenue year quarter second quarter gross profit whole cooper company totale year quarter adjust gross margin be expand bps operate income quarter totale prior year figure adjust operate margin be bps guidance updatedcooper update revenue guidance fiscal company now expect fiscal revenue compare previous range notably zack consensus estimate same be peg lie project range revenue cvi segment be now estimate band compare state previously however csi revenue range have be keep intact fiscal adjust earning share be anticipate zack consensus estimate earning be pin project range wrapped fiscal second quarter solid note strong performance coopervision buoy optimism geographically well company put solid show acquisition paragard drive coopersurgical revenue management be optimistic recently complete acquisition lifeglobal be expect enhance cooper fertility business further continue improvement gross operate margin be promising flip side cooper long term debt have increase significantly raise concern moreover continue acquisition integration risk stiff competition niche space add wo key picksa few better rank stock broader medical space have report solid result season be intuitive surgical isrg free report cheme corporation che free report baxter international inc bax free report intuitive surgical sport zack rank strong buy cheme baxter carry zack rank buy see complete list today zack rank stock here intuitive surgical report first quarter adjust earning share beat zack consensus estimate revenue totale also surpass consensus estimate cheme post first quarter adjust earning share surpass zack consensus estimate revenue come beating zack consensus estimate baxter post first quarter adjust earning share cent beat zack consensus estimate revenue also edge past zack consensus estimate look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
214,BAX,express script hold company esrx free report post first quarter adjust earning share beat zack consensus estimate penny further adjust earning improve year year revenue edge past zack consensus estimate inched year year upside be drive operational cost improvement backed focus technology digital tool home delivery specialty service stock have zack rank sell express script have outperformed industry year time stock have gain period compare industry rise patient claim volume script first quarter witness year year decline patient claim adjust network claim be year year adjust home delivery specialty claim be report quarter year year result net adjust claim first quarter be year year basis decline be primarily drive loss certain public sector client express script hold company price consensus ep surprise express script hold company price consensus ep surprise express script hold company quote margin detailsadjust gross profit first quarter be year year percentage revenue adjust gross margin be flat year year adjust selling general administrative expense be prior year quarter express script get medical care pharmacy benefit roof express script recently announce be get acquire cigna corporation global health insurance company acquisition be expect be conclude dec cigna take express script cash stock transaction worth term deal cigna pay cash share stock newly combine company closure express script shareholder own approximately combine company transaction result total cost synergy guidanceadjust earning share second quarter be estimate range represent growth year year notably zack consensus estimate earning be currently peg be project range company expect total adjust claim second quarter range be attributable core business adjust earning be estimate band significantly previous range share be suspension share repurchase program notably zack consensus estimate earning be currently peged lie significantly guidance revenue be expect band zack consensus estimate revenue be currently peg lie guidance adjust ebitda be expect script end first quarter strong note beating consensus mark count however lackluster guidance be indicate concern stock moreover company face stiff competition raise concern buoy strong result quarter express script enterprise value initiative be estimate range notably management expect cumulative saving nearly earning medtech major glancea few better rank stock broader medical space report solid earning season be baxter international inc bax free report varian medical system inc var free report intuitive surgical inc isrg free report intuitive surgical varian sport zack rank strong buy baxter carry zack rank buy see complete list today zack rank stock here intuitive surgical report adjust earning share surpass zack consensus estimate revenue totale beat zack consensus estimate varian report second quarter fiscal adjust earning share beat zack consensus estimate adjust earning improve year year basis baxter report first quarter adjust earning share cent beat zack consensus estimate improve year quarter figure cent medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
215,BAX,issue update research report bioscrip inc bio free report company struggle reimbursement challenge core business continue grow stock have zack rank hold bioscrip exit first quarter dismal note lower expect earning performance revenue be consensus mark huge year year decline be disappointment downside be due shift company strategy focus grow core revenue mix include contract change unite healthcare september also external challenge reimbursement cut pertain st century cure act hampered growth trend be expect persist well past month share bioscrip have underperform industry stock have lose gain broader industry positive note co base lead infusion service provider have continue progress multus faceted core plan improve finance scheme involve identify execute strategy accelerate core revenue growth build favorable product mix drive operational efficiency raise revenue collection well increase employee effectiveness bioscrip inc price bioscrip inc price bioscrip inc quote additionally company make significant advancement first quarter implement single repeatable model enforce operate cost reduction back solid synergy draw supply chain rationalization growth nursing productivity enhance shipping utilization improve patient board time rapidly change healthcare landscape company have late remain alert grow core infusion service platform clinically focuse customer orientated model apart bioscrip intent drive high growth core infusion service company be engage aggressive cost control currently company aim emerge smaller more focuse organization significant improve profitability better growth prospect improve operate cash flow performance key pickssome better rank stock broader medical sector be intuitive surgical isrg free report align technology inc algn free report baxter international inc bax free report intuitive surgical sport zack rank strong buy align technology baxter carry zack rank buy see complete list today zack rank stock here intuitive surgical have long term expect earning growth rate align technology have long term expect earning growth rate baxter international have long term expect earning growth rate more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
216,BAX,baxter international inc bax free report recently announce fda approval spectrum iq infusion system dose iq safety software order simplify emr electronic medical record administration patient illinois base global medical technology company have partner first databank fdb integrate fdb infusion knowledge evidence base library iv medication dose iq safety software meanwhile baxter exist infusion system sigma spectrum platform have achieve average drug library compliance first day implementation management year unite state be estimate preventable harmful medication error associate injectable medication notably latest development strengthen baxter foothold help protect high risk infusion thereby ensure patient safety spectrum spectrum iq be first system design directional emr integration ascertain precise medication patient system work spectrum infusion pump technology important step make infusion safer be only infusion pump feature line check notification technology give visual notification match infusion pump medication be infuse furthermore system come build dose rate change error prevention feature help clinician protect high risk infusion apart patient system help clinician embed screen barcode technology provide scan prompt help maintain increase auto programming compliance automatically document infusion datum emr moreover system lead cost saving iv intravenous tubing set reduction iv tubing usage market prospectsper study market market healthcare hcit market be expect reach cagr primary growth driver market be high return investment hcit solution government directive need curtail escalate healthcare cost hence be conclude baxter move have be timely strategic price performancein past year baxter share have rally compare industry return zack rank key picksbaxter carry zack rank buy other top rank stock broader medical space be abiom inc abmd free report genomic health inc ghdx free report varian medical system inc var free report abiom have long term growth rate stock sport zack rank strong buy see complete list today zack rank stock here genomic health have expect growth rate current quarter stock sport zack rank varian medical have project long term growth rate stock carry zack rank more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
217,BAX,week high level be generally indicator investor stock level be perceive be winner often investor tend worry stock be overpriced consider high price level apprehension be not absolutely groundless stock hit week high be not necessarily overpriced fact attempt avoid steep price stock be week high mark investor miss top gainer stock maintain momentum keep scaling new high time so more inform approach understand further upside be left be beneficial case here discuss strategy find right stock borrow basic momentum investing technique bet buy high sell higher week high good indicatormany time stock hit week high fail scale higher potential investor fear stock be overvalue price crash be impending fact overvaluation be quite natural most stock investor focus willingness pay premium have help reach level doesn always mean impending decline factor such robust sale surge profit level earning growth prospect strategic acquisition encourage investor bet stock keep motivated be tangible negative other word momentum continue also string positive development dominate market investor find reaction unwarranted even be company specific drive force set right filterswe run screen week high stock trading high level hold tremendous upside potential screen include parameter shortlist stock strong earning growth expectation sturdy value metric price momentum moreover screen filter stock be relatively undervalue compare peer term earning well sale ensure continuation rally time current price week high be ratio current price highest price stock have trade past week value greater imply stock be trading week high range change price week ensure stock price have moved north past week change price week metric guarantee continue upward price momentum stock past month well price sale lower better used estimate metric measure amount investor put company obtain dollar earning narrow list stock be undervalue compare industry year ep growth help choose stock have higher growth rate industry be meaningful indicator decent earning growth add investor optimism zack rank screening be complete proven zack rank have prove worth inception be fundamental truth stock zack rank strong buy buy have always manage brave adversity beat market see complete list today zack rank stock here current price parameter help screen stock be trading higher volume day share inclusion metric ensure be substantial volume share so trading be easier here be stock make screen schweitzer mauduit international inc swm free report be global provider engineer solution advanced material company deliver average quarter positive earning surprise have zack rank insight enterprise inc nsit free report be arizona base global direct marketer brand name computer hardware software focus business business information technology capability company come average quarter positive earning surprise have zack rank baxter international inc bax free report be global diversify healthcare company manufacture market product fight disease hemophilia immune disorder kidney disease other company zack rank deliver average positive surprise last quarters boise cascade bcc free report be wood product manufacturer build material distributor company deliver average positive surprise trail quarters carry zack rank comfort system usa inc fix free report be provider comprehensive heating ventilation air conditioning installation maintenance repair replacement service currently carry zack rank company deliver average positive surprise last quarters get rest stock list signing now week free trial research wizard start used screen own trading further also create own strategy test first take investment plunge research wizard be great place begin easy use everything be plain language very intuitive start trial research wizard today next time read economic report open research wizard plug find see gem come click here sign free trial research wizard today disclosure officer director employee zack investment research own have sell short security hold long short position option be mentioned material affiliated investment advisory firm own have sell short security hold long short position option be mentioned material disclosure performance information zack portfolio strategy be available https www zack com performancezack restaurant recommendation addition dine special place feast stock share zack special report spotlight recent ipos watch stock offer immediate promise boom sector download free
218,BAX,issue update research report gnc holding inc gnc free report be upbeat company strategy strengthen international presence however cut throat competition continue challenge stock currently carry zack rank hold lead global specialty retailer product health wellness include vitamin mineral herbal supplement sport nutrition diet have be underperform industry past year company have lose compare decline industry gnc holding exit first quarter dismal note year year decline adjust earning revenue additionally unite state gnc holding compete heavily advertised national brand large pharmaceutical food company well other retailer lead increase price competition company more participant be enter market positive note gnc holding international business have be key driver growth recent year management expect continue capitalize international revenue growth opportunity addition franchise store exist market expansion new high growth market growth product distribution exist new market regard gnc holding recently announce receipt hayao shareholder vote strategic partnership china joint venture agreement harbin pharmaceutical group hold hayao further company recently enter master franchise agreement rapid nutrition foray australia same time gnc holding have announce plan expand presence india operate collaboration master franchise partner guardian healthcare service pvt ltd development help boost investor faith stock also company have progressed significantly commerce business management commerce business continue grow higher expect moreover company be upbeat shift control third party cloud base company controlled platform key picksa few better rank stock broader medical sector be intuitive surgical isrg free report cooper company inc coo free report baxter international inc bax free report intuitive surgical sport zack rank strong buy cooper company baxter carry zack rank buy see complete list today zack rank stock here intuitive surgical have long term expect earning growth rate cooper company have long term expect earning growth rate baxter international have long term expect earning growth rate more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
219,BAX,share cryolife inc cry free report have gain past week company first quarter earning release stock rally post better expect earning share ep revenue reflectsgrowth product line strong performance geography release company gain significantly outperform industry let delve deeper cryolife earning detail company report adjust ep cent year year however figure better zack consensus estimate net loss cent revenue detailrevenue quarter increase year year revenue also trump consensus estimate primarily drive growth quarter also see strength bioglue tissue process moreover revenue include contribution recently complete acquisition jotec segmental basis product revenue increase year year first quarter segment revenue come bioglue biofoam follow cryolife inc price consensus ep surprise cryolife inc price consensus ep surprise cryolife inc quote preservation service revenue increase quarter review year segment company witness solid growth cardiac tissue business geographical basis company revenue unite state rise international revenue increase operational updatecryolife gross profit report quarter climb year year however gross margin contract basis point bps notably gross margin first quarter include charge associate step basis jotec inventory other distributor general administrative marketing expense first quarter rise year year research development expense shot year year operate expense totale first quarter year year operate loss quarter be compare unfavorably operate profit year quarter financial updatecryolife exit first quarter cash cash equivalent restrict security compare end guidance cryolife continue expect revenue band zack consensus estimate full year revenue stand guide range company also expect adjust ep range cent zack consensus estimate earning be peg cent company guide range takecryolife exit first quarter promising note be encourage note company have be witness growth product line strong geographic performance moreover company have be gain directly selling product end user be also optimistic company focus product innovation completion jotec buyout regard cryolife be highly upbeat continuously advance clinical development biogluechina perclot however escalate operate expense seem be discourage also tough competitive landscape act dampener zack rank other key pickscryolife have zack rank buy other top rank stock broader medical space have report solid result season be intuitive surgical isrg free report cheme corporation che free report baxter international inc bax free report intuitive surgical sport zack rank strong buy cheme baxter carry zack rank see complete list today zack rank stock here intuitive surgical report first quarter adjust ep beat zack consensus estimate revenue totale also surpass consensus estimate cheme release first quarter adjust ep surpass zack consensus estimate revenue come beating zack consensus estimate baxter post first quarter adjust ep cent beat zack consensus estimate revenue also edge past zack consensus estimate more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
220,BAX,home more half world population asia pacific apac have significant unmet healthcare need hold attractive growth potential medtech bigwig add further optimism corner healthcare be trump clear focus market article publish economic time asian healthcare market be expect grow more upside be attribute improve access healthcare facility increase government private investment china trade warmeanwhile investor be concern ongoing trade dispute severely hurt medtech company profit emerge market accuse china unfair trade practice president donald trump have impose tariff import china just day slap punitive duty chinese good be follow immediate retaliation china impose tariff export blow follow trump proposal implement tariff more worth chinese good article christian jone mondaq medtech firm unite state currently sell worth medical device annually china import total go jp morgan report trade war bring collateral damage country closely tie china supply chain include south korea taiwan malaysia singapore thailand india korea relation raise hopeamid trade war uproar trump latest stance rest apac have be breather investor last landmark asia trip trump reveal stronger reliance india strategic partner fact see india heart asia policy keep trump new policy lower drug price have positive impact india bilateral trade relation further help fix price certain exorbitant pharmaceutical medical device emergo article show indian medical device market be value expand moreover business standard article suggest india import medical device unite state grow inr inr meanwhile ty north korea seem be improve recent historic summit president kim jong trump put age old war tactic hold korea summit trump swear provide security guarantee dprk democratic person republic korea complete korean peninsula successful nuclear talk be likely pave way mutually beneficial trading relationship begin point future datum publish korea country commercial guide total import medical device korea gross unite state contribute more furthermore market share represent approximately korean import market choose right economy be gradually focuse lucrative asia pacific market be right time investor cash opportunity market have shortlist few medical device stock have carved niche asian market such stock be likely log massive gain give solid stand apac region present first pick be baxter international bax free report have solid presence asia research hub japan china company renal care team recently launch kaguya peritoneal dialysis technology japan baxter complete acquisition india base claris injectable global generic injectable pharmaceutical company almost buyout bolster baxter foothold generic pharmaceutical space same year baxter sign agreement india base dorizoe lifescience expansion generic injectable pipeline zack rank buy stock have outperformed industry year time company share have rally compare industry rise see complete list today zack rank strong buy stock here next list be align technology algn free report zack rank company invisalign technology have be widely adopt apac region asia pacific region company witness first quarter volume growth lead china japan australia moreover align technology china stand second largest market unite state company also introduce clear aligner solution class ii correction invisalign technology mandibular advancement certain market apac fda approval same be expect second half past year share align technology have sky-rocket compare industry rise investor also consider intuitive surgical inc isrg free report zack rank hold company flagship da vinci general surgery urology procedure have be witness consistent growth asia intuitive surgical also see multispecialty growth china last report quarter recently additional procedure be grant reimbursement ministry health japan earlier year california base manufacturer surgical system announce start operation india distributor vattikuti technology pvt ltd read more intuitive surgical commence direct operation india past year share intuitive surgical have rally whopping industry decline medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
221,BAX,angiodynamic inc ango free report report fourth quarter fiscal adjust earning cent share miss zack consensus estimate penny earning improve year year net sale come marginally miss zack consensus estimate however sale improve prior year figure meanwhile past year share angiodynamic have rally industry decline geographical analysisu net revenue quarter review be constant currency cc management downside be attribute lower sale venous insufficiency piccs rfa radio frequency ablation nanoknife product line international revenue totale cc primarily owing strong performance europe segmental vascular pv businesssale segment come decline year year basis management growth fluid management angiographic catheter angiovac product line be offset decline venous insufficiency thrombolytic business angiovac procedural volume remain strong be year year report quarter however venous insufficiency business continue underperform be due discontinuation exclusive use evlt endovenous laser system product company largest customer vascular access va access net sale be year quarter management growth port dialysis product be offset decline piccs oncology surgery businesssale segment gross significant upside be attribute strong growth solero microwave ablation system however increase sale nanoknife be partially offset lower sale rfa system angiodynamic inc price consensus ep surprise angiodynamic inc price consensus ep surprise angiodynamic inc quotemargin analysisin quarter review gross profit totale year year basis adjust gross margin be expand basis point bps adjust operate income come year year operate loss financial fiscal fourth quarter angiodynamic generate operate cash flow free cash flow fy glancerevenue fiscal totale year period earning share cent inched year revenue core peripheral vascular segment account total sale revenue vascular access contribute oncology surgery represent fy expect fiscal net sale range zack consensus estimate be peg guide range adjust earning share be anticipate band cent zack consensus estimate be pin cent guide range free cash flow be expect exit fourth quarter fiscal dull note solid performance oncology surgery segment be encourage surge international sale buoy optimism company continue witness strong growth oncology ablation solero nanoknife product line fourth quarter company witness significant expansion gross margin increase investment thrombus management portfolio be positive flip side core peripheral vascular vascular access unit raise concern report quarter angiodynamic see persistent headwind venous insufficiency business picc product line decline sale unite state intense competition add wo zack rank key currently carry zack rank hold few better rank medical stock broader medical space be abiom inc abmd free report baxter international bax free report bio rad laboratory bio free report abiom have expect long term earning growth rate stock carry zack rank buy see complete list today zack rank strong buy stock here baxter have project long term earning growth rate stock carry zack rank bio rad have long term earning growth rate stock carry zack rank hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
222,BAX,pacific bioscience california pacb free report report first quarter adjust loss cent share be wider zack consensus estimate penny company report loss cent share year quarter meanwhile stock have lose compare industry decline year time pacific bioscience carry zack rank buy revenue menlo park base manufacturer sequence system post revenue miss zack consensus estimate revenue also drop year quarter primarily due lower instrument revenue quarter review product revenue totale deteriorate prior year quarter meanwhile service other revenue come year year pacific bioscience california inc price consensus ep surprise pacific bioscience california inc price consensus ep surprise pacific bioscience california inc quote furthermore instrument revenue come compare year consumable revenue come slightly year management sequel instrument booking be strong first quarter highest number instrument order introduction system order include instrument order bgi china growth sequel business have partially offset decline rs ii smart cell usage additionally alabama base hudsonalpha institute biotechnology have be used company flagship sequel system have be expand use human clinical research margin profit first quarter be year year basis gross margin be total revenue basis point bps year year operate expense totale slightly prior year quarter contraction be lead lower expense totale first quarter moreover sale general administrative expense quarter be slightly lower prior year quarter financial bioscience cash cash equivalent investment exclude restrict cash totale report quarter figure rise year year bioscience end first quarter dreary note product service revenue fall year year basis due lower instrument revenue however be partially offset strong sequel performance witness record booking quarter adoption system hudsonalpha be also major positive continue instrument order bgi china be encourage furthermore company be well poise expansion smrt sequence product development activity meanwhile highly competitive environment raise concern fall consumer revenue add wo other key pickssome other top rank stock broader medical space have report solid result season be intuitive surgical isrg free report cheme corporation che free report baxter international inc bax free report intuitive surgical sport zack rank strong buy cheme baxter carry zack rank see complete list today zack rank stock here intuitive surgical report first quarter adjust earning share beat zack consensus estimate revenue totale also surpass consensus estimate cheme post first quarter adjust earning share surpass zack consensus estimate revenue come beating zack consensus estimate baxter post first quarter adjust earning share cent beat zack consensus estimate revenue also edge past zack consensus estimate medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
223,BAX,becton dickinson company bdx free report post second quarter fiscal earning beat zack consensus estimate earning also improve constant currency cc becton dickinson also know bd post revenue worth surpass zack consensus estimate revenue rise cc year year basis revenue surge acquisition bard meanwhile bd share have gain compare industry bd currently carry zack rank hold becton dickinson company price consensus ep surprise becton dickinson company price consensus ep surprise becton dickinson company quotesegment detailsbd medicalthe segment post worldwide revenue cc management strong result be drive strength medication delivery solution diabetes care pharmaceutical system unit bd life revenue segment come reflect increase cc revenue growth reflect strong performance diagnostic system bioscience unit however growth preanalytical system unit be negatively impact production issue product line be resolve quarter segment growth be aid flu related revenue diagnostic system unit result stronger flu season comparison prior year bd report quarter segment post worldwide revenue cc segment result reflect strong performance peripheral intervention urology critical care unit solid growth surgery unit geographic resultsussale unite state come cc second quarter bd medical segment account revenue unite state bd life science account revenue bd interventional record unite state outside unite state come cc upside be drive strong performance bd medical bd life science bd interventional segment internationally bd medical post revenue worth bd life science rake international revenue bd interventional contribute margin analysisin report quarter gross profit totale year year bd post operate income year year basis guidancebuoy solid fiscal second quarter performance bd raise fiscal guidance company expect adjust earning share increase estimate benefit foreign currency represent growth approximately fiscal notably zack consensus estimate earning share lie range company raise revenue growth guidance fiscal be also high end previous guidance takebecton dickinson end fiscal second quarter promising note strong growth bd medical be primarily drive medication delivery solution diabetes care pharmaceutical system unit meanwhile acquisition bard have proven accretive fiscal second quarter result internationally bd post strong revenue have maintain global foothold however decline margin raise concern recent product recall foreign exchange volatility be also likely mar company prospect key picksa few better rank stock broader medical space have report solid result season be intuitive surgical isrg free report cheme corporation che free report baxter international inc bax free report intuitive surgical sport zack rank strong buy cheme baxter carry zack rank buy see complete list today zack rank stock here intuitive surgical report first quarter adjust earning share beat zack consensus estimate revenue totale also surpass consensus estimate cheme post first quarter adjust earning share surpass zack consensus estimate revenue come beating zack consensus estimate baxter post first quarter adjust earning share cent beat zack consensus estimate revenue also edge past zack consensus estimate medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
224,BAX,have be pay attention share surmodic srdx free report share have be move stock past month srdx hit new week high previous session surmodic have gain start year compare move medical sector year date return peer group drive outperformance stock have impressive record positive earning surprise have beaten zack consensus estimate last quarters last earning report surmodic report ep versus zack consensus estimate beat consensus revenue estimate current fiscal year surmodic be expect post earning share revenue represent change ep change revenue next fiscal year company be expect earn share revenue represent year year change respectively valuation metricssurmodic be week high right now future hold srdx key aspect question be take look valuation metric order determine company be due pullback level front look zack style score give investor variety way comb stock look zack rank security style be represent grade run category value growth momentum be combine vgm score well idea style score be help investor pick most appropriate zack rank stock base individual investment style surmodic have value score stock growth momentum score be respectively give company vgm score surmodic inc price consensus surmodic inc price consensus surmodic inc quotezack rankwe also need look zack rank stock supersede trend style score front fortunately surmodic currently have zack rank buy thank favorable earning estimate revision cover analyst recommend investor select stock carry zack rank strong buy style score look surmodic fit bill thus seem srdx share still be poise more gain ahead do surmodic stack competition share surmodic have be move higher company still appear be decent choice rest industry industry peer be also solid potential pick include baxter international bax free report steris plc ste free report varian medical system var free report currently have zack rank least vgm score least make well round choice however be worth note zack industry rank group be bottom half ranking so isn good news surmodic still fundamental srdx be promising still have potential be week high
225,BAX,president donald trump call summit north korean leader kim jong last thursday be quite shocker abandonement summit plan dealt blow underpenetrated emerge market asia be solid source revenue more base multinational company effect political mayhem cause msci broadest index asia pacific share outside japan south korea kospi japan nikkei plummet major wall street index dow jone industrial average lose ground well consider trend downward movement white house decide conduct meeting unite state announce plan send pre advance team singapore prepare trump kim summit jun medtech appear be very few sector shelter investor political tension shrug current volatility medical product industry have return call fall fact analyst believe medtech sector be able strengthen foothold faster rate meeting go plan be be number base medtech company operate asia post success summit company be able spread network north korea augment overall production research statista medtech market asia pacific region be estimate reach worth buoy encourage projection rather be interesting see medical product company be place political turmoil medtech stock gainmeanwhile medical product company have already be gain organic growth innovation higher consolidation tax abolition well focus emerge market include japan south korea china vietnam india philippine more fact stakeholder medical universe have be eyee market last couple year company be bullish grow medical awareness economic prosperity age population increase wealth government focus healthcare infrastructure expansion medical insurance coverage apac space take look lead medtech player be gain prospect apac market becton dickinson company bdx free report popularly know bd particularly focus broader emerge market india china brazil turkey economic healthcare sector be grow rapidly particular safety engineer product continue drive growth emerge market believe exposure market boost top line turn accelerate ep growth zack rank hold company share have return year significantly higher index gain baxter international bax free report solid presence asia precisely india be worth mention company have research hub japan china recently baxter complete acquisition india base claris injectable global generic injectable pharmaceutical company almost zack rank buy stock have outperformed index year time stock have return intuitive surgical inc isrg free report grow interest emerge market specifically apac region bode well past year company procedure performance asia project consistent strength company register solid growth china japan korea zack rank strong buy company share have return year see complete list today zack rank stock here boston scientific corporation bsx free report growth strategy comprise pursuit development opportunity outside unite station strengthen global presence inclusive emerge market backdrop flatten decline sale growth develop market unite state europe boston scientific be fortify foothold emerge market brazil russia india china bric first quarter business emerge market register growth business china be once again remarkable year year company be currently project improvement performance china banking recent approval synergy zack rank stock have return year thing remember thing be not so easy appear be american never forget former president george bush refer north korea axis evil sponsored terrorism have solid access nuclear weapon further north korea multiple trial nuclear warhead have dampen country relationship analyst believe unforeseen summit not solve age old problem further guarantee kim jong tremendous anger open hostility not offend trump anymore do last week however trump team be expect reach agreement settle north korean nuclear other issue meeting today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
226,BAX,share orthofix international ofix free report have lose past week company first quarter earning release apr better expect bottom line number share drop due lower earning outlook company period company have also significantly underperform industry belong stock have lose industry gain let delve deeper earning detail orthofix company report first quarter adjust earning share ep cent continue operation figure be ahead zack consensus estimate bottom line surge year year primarily strong sale growth company biostim extremity fixation spine fixation strategic business unit sbu exclude time item net income continue operation first quarter come cent share versus net loss continue operation cent thereby show remarkable year year improvement sale detailsorthofix first quarter sale improve constant exchange rate cer almost line zack consensus estimate result company adoption revenue recognition accounting change begin orthofix note convert consolidated revenue first quarter new standard growth have be cer report quarter sale be primarily drive strong performance company sbus namely biostim extremity fixation spine fixation partly offset year year decline biologic business sbu first quarter company post biostim sale reflect same cer growth prior year period extremity fixation sale be quarter review improvement cer first quarter company realize continue uptake new product commendable performance most company global market include unite state orthofix international price consensus ep surprise orthofix international price consensus ep surprise orthofix international quoteorthofix report spine fixation sbu sale reflect cer growth year earlier quarter uptick be attribute product launch adopt strategic initiative biologic sbu sale totale same cer year quarter decline result contractual reduction marketing service fee percentage orthofix receive mtf biologic marginsin first quarter gross margin contract basis point bps unfavorable sale mix impact quarterly gross margin sale marketing expense rise year year general administrative expense be company witness decrease research development expense overall adjust operate margin expand bps owing increase operate expense cash exit first quarter cash cash equivalent compare end first quarter net cash used operate activity be compare year have lower earning view expect biologic sale be flat less low single digit full year due contractual decrease marketing service fee company be go receive mtf biologic adjust ep continue operation be expect range fall earlier project band zack consensus estimate full year adjust ep stand company project range full year net sale projection have be increase band earlier prediction be zack consensus estimate full year revenue be peg lie upper end guide range takeorthofix exit first quarter mixed note earning exceed zack consensus estimate sale almost match consensus mark investor be upset poor biologic prospect continue be drag overall performance remainder year accordingly company have reduce full year earning expectation apart currency fluctuation competitive landscape macroeconomic headwind continue challenge company moreover higher cost operate expense be matter grave concern orthofix also heavy dependence third party final distribution product expose company heighten risk positive note top line be substantially drive strength extremity fixation well spine fixation business be expect continue term back sale force enhancement expand distributorship network introduction product zack rank key picksorthofix carry zack rank sell better rank stock broader medical space have post solid result earning season be intuitive surgical isrg free report cheme corp che free report baxter international inc bax free report intuitive surgical sport zack rank strong buy cheme baxter carry zack rank buy see complete list today zack rank stock here intuitive surgical report first quarter adjust ep beating zack consensus estimate revenue totale also surpass consensus estimate cheme post first quarter adjust ep outshine zack consensus estimate revenue come outpace zack consensus estimate baxter post first quarter adjust bottom line cent exceed zack consensus estimate top line come edge past zack consensus estimate medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
227,BAX,week high level generally work indicator investor stock level be perceive be winner notably investor often wonder stock be overpriced consider high price level apprehension be not absolutely baseless stock hit week high be not necessarily overpriced fact investor miss top gainer attempt avoid steep price stock be week high mark however stock maintain momentum keep scaling new high time so take more inform approach understand further upside be left here discuss strategy find right stock borrow basic momentum investing technique bet buy high sell higher week high good indicatormany time stock hit week high fail scale higher potential due investor fear stock be overvalue price crash be impending fact overvaluation be quite natural most stock investor focus willingness pay premium have help reach level doesn always mean impending decline factor such robust sale surge profit level earning growth prospect strategic acquisition encourage investor bet stock keep motivated be tangible negative other word momentum continue also string positive development dominate market investor find reaction unwarranted even be company specific drive force set right filterswe run screen week high stock trading high level hold tremendous upside potential screen include parameter shortlist stock strong earning growth expectation sturdy value metric price momentum moreover screen filter stock be relatively undervalue compare peer term earning well sale ensure continuation rally time current price week high be ratio current price highest price stock have trade past week value greater imply stock be trading week high range change price week ensure stock price have moved north past week change price week metric guarantee continue upward price momentum stock past month well price sale lower better used estimate metric measure amount investor put company obtain dollar earning narrow list stock be undervalue compare industry year ep growth help choose stock have higher growth rate industry be meaningful indicator decent earning growth add investor optimism zack rank screening be complete proven zack rank have prove worth inception be fundamental truth stock zack rank strong buy buy have always manage brave adversity beat market see complete list today zack rank stock here current price parameter help screen stock be trading higher volume day share inclusion metric ensure be substantial volume share so trading be easier here be stock make screen schweitzer mauduit international inc swm free report be global provider engineer solution advanced material company deliver average quarter positive earning surprise have zack rank insight enterprise inc nsit free report be arizona base global direct marketer brand name computer hardware software focus business business information technology capability company come average quarter positive earning surprise have zack rank baxter international inc bax free report be global diversify healthcare company manufacture market product fight disease hemophilia immune disorder kidney disease other company zack rank deliver average positive surprise last quarters fortinet inc ftnt free report be provider network security appliance unify threat management utm network security solution enterprise service provider government entity worldwide company deliver average positive surprise trail quarters carry zack rank comfort system usa inc fix free report be provider comprehensive heating ventilation air conditioning installation maintenance repair replacement service currently have zack rank company deliver average positive surprise last quarters get rest stock list signing now week free trial research wizard start used screen own trading further also create own strategy test first take investment plunge research wizard be great place begin easy use everything be plain language very intuitive start trial research wizard today next time read economic report open research wizard plug find see gem come click here sign free trial research wizard today disclosure officer director employee zack investment research own have sell short security hold long short position option be mentioned material affiliated investment advisory firm own have sell short security hold long short position option be mentioned material disclosure performance information zack portfolio strategy be available https www zack com performancezack restaurant recommendation addition dine special place feast stock share zack special report spotlight recent ipos watch stock offer immediate promise boom sector download free
228,BAX,baxter international inc bax free report be schedule report second quarter earning jul market open expect company see steady growth back international venture majorly drive second quarter result raise guidance strategic collaboration be other tailwind last report quarter baxter post adjust earning share cent beat zack consensus estimate improve year quarter cent quarter be report zack consensus estimate revenue be peg reflect year year rise zack consensus estimate adjust earning share be peg cent indicate increase baxter international inc price ep surprise baxter international inc price ep surprise baxter international inc quotestrong international presence likely drive resultsbaxter have strong presence foreign market help company gain traction last report quarter company international sale account impressive total revenue baxter advanced surgery team recently launch tisseel prima europe furthermore japan company renal care team launch kaguya peritoneal dialysis technology last report quarter baxter see higher volume shipment iv solution mexico unite state company look forward reallocate additional iv solution select south america manufacturing facility management help revamp production process manufacturing facility unite state puerto rico other factor playrais guidancebaxter have raise guidance company expect sale growth constant currency cc project adjust earning share continue operation range full year zack consensus estimate be peg guide range second quarter company expect sale growth approximately cc baxter expect adjust earning continue operation cent zack consensus estimate be pin cent high end guide range strategic buyoutsbaxter have be banking strategic acquisition collaboration enhance exist product portfolio recently baxter complete acquisition preveleak mallinckrodt view boost surgical portfolio hemostat sealant notably company buy thrombin topical preveleak surgical sealant product line mallinckrodt buyout do not prove accretive last report quarter management expect deal be modestly reward acquisition claris injectable limit baxter expect revenue worth lately baxter announce partnership international society nephrology isn spread awareness chronic kidney disease awareness therapy emerge market reflect baxter focus specialize renal care be part baxter hospital product segment have be underperform last year baxter expect sale previous guidance however guide figure be much lower model predictsour quantitative model do not predict earning beat baxter quarter be stock need have positive earning esp zack rank strong buy buy hold be able beat estimate have be illustrated earning esp baxter have earning esp uncover best stock buy sell re report earning esp filter zack rank baxter carry zack rank stock worth lookhere be few medical stock worth consider have right combination element post earning beat quarter varian medical var free report have earning esp stock carry zack rank see complete list today zack rank stock here mckesson corporation mck free report have earning esp stock carry zack rank becton dickinson company bdx free report have earning esp stock carry zack rank hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
229,BAX,intuitive surgical inc isrg free report have announce start direct operation india distributor vattikuti technology pvt ltd post announcement intuitive surgical share price rise close iin past month share company have rally significantly outperform industry decline stock sport zack rank strong buy notably vattikuti provide high technology solution healthcare ally industry be authorize distributor da vinci surgical system india vattikuti management company plan install total da vinci robot year india courtesy robust demand country robot cost evidently drive intuitive surgical overseas revenue significantly silicon valley base pioneer field robotic assist minimally invasive surgery set sixth international headquarters bengaluru india employee sale marketing field service engineering business operation support customer country latest development not only ascertain wider collaboration opportunity intuitive surgical india surgical community also fortify company foothold asia da vinci international last report quarter intuitive surgical ous outside unite state system placement be include europe japan internationally company continue enjoy substantial opportunity japan south korea china flagship da vinci system witness continue growth urological procedure europe asia multispecialty growth china moreover additional procedure be grant reimbursement ministry health japan additionally da vinci surgical system receive regulatory clearance pmda pharmaceutical medical device agency japan be showcased large surgical society meeting shortly thereafter management intuitive surgical have install da vinci system so far india market prospectsper research business standard india surgical robotic market be estimate see cagr scale worth compare rise incidence chronic disease increase geriatric population grow demand minimally invasive surgery technological advancement field medical surgery be factor be fuel demand surgical robotic system hence be conclude intuitive surgical move have be timely strategic other key pickssome other top rank medical stock be abiom inc abmd free report varian medical var free report baxter international inc bax free report abiom have expect long term earning growth rate stock sport zack rank see complete list today zack rank stock here varian medical have project long term earning growth rate stock carry zack rank buy baxter have expect long term earning growth rate stock carry zack rank today stock zack hottest strategy hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free intuitive surgical inc isrg free report have announce start direct operation india distributor vattikuti technology pvt ltd post announcement intuitive surgical share price rise close iin past month share company have rally significantly outperform industry decline stock sport zack rank strong buy notably vattikuti provide high technology solution healthcare ally industry be authorize distributor da vinci surgical system india vattikuti management company plan install total da vinci robot year india courtesy robust demand country robot cost evidently drive intuitive surgical overseas revenue significantly silicon valley base pioneer field robotic assist minimally invasive surgery set sixth international headquarters bengaluru india employee sale marketing field service engineering business operation support customer country latest development not only ascertain wider collaboration opportunity intuitive surgical india surgical community also fortify company foothold asia da vinci international last report quarter intuitive surgical ous outside unite state system placement be include europe japan internationally company continue enjoy substantial opportunity japan south korea china flagship da vinci system witness continue growth urological procedure europe asia multispecialty growth china moreover additional procedure be grant reimbursement ministry health japan additionally da vinci surgical system receive regulatory clearance pmda pharmaceutical medical device agency japan be showcased large surgical society meeting shortly thereafter management intuitive surgical have install da vinci system so far india market prospectsper research business standard india surgical robotic market be estimate see cagr scale worth compare rise incidence chronic disease increase geriatric population grow demand minimally invasive surgery technological advancement field medical surgery be factor be fuel demand surgical robotic system hence be conclude intuitive surgical move have be timely strategic other key pickssome other top rank medical stock be abiom inc abmd free report varian medical var free report baxter international inc bax free report abiom have expect long term earning growth rate stock sport zack rank see complete list today zack rank stock here varian medical have project long term earning growth rate stock carry zack rank buy baxter have expect long term earning growth rate stock carry zack rank today stock zack hottest strategy hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free intuitive surgical inc isrg free report have announce start direct operation india distributor vattikuti technology pvt ltd post announcement intuitive surgical share price rise close past month share company have rally significantly outperform industry decline stock sport zack rank strong buy notably vattikuti provide high technology solution healthcare ally industry be authorize distributor da vinci surgical system india vattikuti management company plan install total da vinci robot year india courtesy robust demand country robot cost evidently drive intuitive surgical overseas revenue significantly silicon valley base pioneer field robotic assist minimally invasive surgery set sixth international headquarters bengaluru india employee sale marketing field service engineering business operation support customer country latest development not only ascertain wider collaboration opportunity intuitive surgical india surgical community also fortify company foothold asia da vinci international accomplishment last report quarter intuitive surgical ous outside unite state system placement be include europe japan internationally company continue enjoy substantial opportunity japan south korea china flagship da vinci system witness continue growth urological procedure europe asia multispecialty growth china moreover additional procedure be grant reimbursement ministry health japan additionally da vinci surgical system receive regulatory clearance pmda pharmaceutical medical device agency japan be showcased large surgical society meeting shortly thereafter management intuitive surgical have install da vinci system so far india market prospect research business standard india surgical robotic market be estimate see cagr scale worth compare rise incidence chronic disease increase geriatric population grow demand minimally invasive surgery technological advancement field medical surgery be factor be fuel demand surgical robotic system hence be conclude intuitive surgical move have be timely strategic other key pick other top rank medical stock be abiom inc abmd free report varian medical var free report baxter international inc bax free report abiom have expect long term earning growth rate stock sport zack rank see complete list today zack rank stock here varian medical have project long term earning growth rate stock carry zack rank buy baxter have expect long term earning growth rate stock carry zack rank today stock zack hottest strategy hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
230,BAX,be sign respite ongoing market uncertainty due apprehension trade war hand asian stock have start revive improvement north korea relationship other hand investor be restrain possibility trade loss due propose china trade restriction medical device catch trade war stormgoing datum provide article christian jone mondaq medtech firm unite state currently sell annually china nation import china total billionin medical device export medical device last year totale create worldwide trade surplus needless say medical device lobby be extremely apprehensive propose tariff chinese product significantly affect international trade medtech trade group advame make more specific comment claim chinese tariff account more half medtech import region massdevice article trade group state industry propose additional tariff import nearly bn medical technology product be wrong action wrong time advame counter unite state trade representative ustr claim china unfair trade practice medical device harm export significantly group argue trade china medical device ustr list be fact slight surplus accordingly propose tariff diagnostic product other medical device make unite state china be not drop result trade imbalance rbc capital market estimate propose tariff get implement cost medical device industry year go latest update financial express report bipartisan group lawmaker have urge trade representative robert lighthizer remove worth medical device list chinese product propose trump administration additional tariff investor trouble risk trade war largest economy heighten investment medical device stock be take backseat propose imposition additional tariff chinese product china retaliatory effort have result widespread share loss so far medical device sector bearish emerge market trade outlook have dealt severe blow bigwig note sector have gain significantly profit earn number medical device company bric nation regard note stock medtronic plc mdt free report ge healthcare ge free report other be witness considerable weakness mar talk china trade war start do round note medtronic earlier buy orthopedic device maker china kanghui holding then have be consistently shipping product unite state operation shipment be now subject additional tariff definitely hamper company china business ge healthcare have also urge administration remove certain part list chinese product additional tariff go mass device report china produce part be essential number ge device include ultrasound machine patient monitor mri machine ct machine ray machine be produce ge own facility china other be produce local chinese company medtech stock counter trade restriction hazardconcern implementation trade tariff medtech product have be weigh stock lately even market have not yet show steady plunge such fear be likely dampen investor sentiment go forward have shortlist medtech stock spite tumultuous market condition be well poise strong fundamental timely strategic development selection be also backed good zack growth score zack rank have narrow choice help new style score system research show stock growth score combine zack rank strong buy buy offer best investment opportunity value investing space see complete list today zack rank stock here baxter international inc bax free report company have strong presence overseas market have such business relation china hence spite consider international diversification core component company strategy company very well sidestep volatility china trade war continue enjoy bountiful scope offer emerge market company fact be benefit develop country incremental investment health care system baxter have growth score zack rank company have impressive long term expect growth rate higher industry varian medical system inc var free report second quarter fiscal varian medical global market share growth be drive order base share gain emea fact varian medical be award contract truebeam system stockholm sweden further company sign agreement acquire australia base sirtex focuse interventional oncology therapy apart varian medical have recently announce open new facility jundiaí brazil extend global manufacturing training footprint region varian medical have business greater china company huge global base outside country shield severe damage occur result trade restriction varian medical have growth score zack rank abiom inc abmd free report just baxter have strong international foothold abiom do not have significant presence china fourth quarter fiscal germany japan witness strong adoption exclusive impella product line germany revenue grow fourth quarter fiscal japan abiom exceed expectation expect add revenue fiscal abiom have growth score zack rank more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
231,BAX,steris plc ste free report report fourth quarter fiscal adjust earning share ep year year ahead zack consensus estimate report ep come cent significant improvement cent year adjust ep figure full year be year period also zack consensus estimate couple cent steris generate revenue fiscal fourth quarter year year moreover top line exceed zack consensus estimate fiscal revenue come marginal improvement year period annual figure be line consensus mark quarter detailorganic revenue growth constant currency be year year fiscal fourth quarter mainly drive balanced growth segment company steris plc price consensus ep surprise steris plc price consensus ep surprise steris plc quote company operate segment healthcare product healthcare specialty service apply sterilization technology life science revenue healthcare product increase year year constant currency organic basis quarter review service revenue grow consumable revenue rise capital equipment revenue be flat year year revenue healthcare specialty service segment be constant currency organic basis fourth quarter register final impact linen business divestiture year year revenue apply sterilization technology rise backed increase demand core medical device customer revenue life science segment grow growth service revenue rise capital equipment revenue consumable revenue be flat year year marginsadjusted gross margin improve basis point bps year year report quarter steris gross margin expansion be fuel favorable product mix price basis point improvement divestiture currency have unfavorable impact basis point gross margin steris witness year year decline selling general administrative expense research development expense rise accordingly adjust operate margin expand bps year year basis report quarter financial detailssteris exit fiscal cash cash equivalent compare end fiscal company have long term debt end fiscal fourth quarter compare end fourth quarter fiscal full year company generate cash flow operation year period free cash flow be compare prior year guidancesteris expect constant currency organic revenue growth fiscal prior fiscal zack consensus estimate fiscal revenue be peg adjust ep outlook fiscal have be project range consensus estimate fiscal adjust ep lie guide range takesteris exit fourth quarter fiscal promising note earning revenue beating respective zack consensus estimate be also encourage favorable underlie market trend new product service offering further growth free cash flow reserve be indicative company strong cash balance company have also make certain divestment organizational change be expect better align operation zack rank key pickssteris have zack rank hold better rank stock broader medical space have report solid result earning season be intuitive surgical isrg free report cheme corporation che free report baxter international inc bax free report intuitive surgical sport zack rank strong buy cheme baxter carry zack rank buy see complete list today zack rank stock here intuitive surgical report first quarter adjust ep beat zack consensus estimate revenue totale also surpass consensus estimate cheme post first quarter adjust ep surpass zack consensus estimate revenue come outpace zack consensus estimate baxter post first quarter adjust bottom line cent beat zack consensus estimate top line come edge past zack consensus estimate wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
232,BAX,baxter international bax free report be currently top perform stock medtech space company raise guidance global expansion be major tailwind share upin past year baxter share have rally compare industry growth zack rank buy stock currently have growth score reflect possibility outperformance long haul research show stock growth score combine zack rank strong buy be better pick most last day zack consensus estimate baxter current quarter earning share rise cent baxter international inc price consensus baxter international inc price consensus baxter international inc quotewhat make attractive pick raise guidancebaxter have raise guidance company expect sale growth cc expect adjust earning share continue operation range full year zack consensus estimate be peg guide range second quarter company expect sale growth approximately cc baxter expect adjust earning continue operation cent zack consensus estimate be pin cent high end guide range acquisition recently complete acquisition hemostat sealant product mallinckrodt plc widen surgical portfolio company buy thrombin topical preveleak surgical sealant product line mallinckrodt baxter also recently collaborate international society nephrology isn spread awareness chronic kidney disease international launchesbaxter aim accelerate growth offer service overseas company advanced surgery team recently begin rollout tisseel prima europe japan baxter renal team have initiate launch kaguya peritoneal dialysis technology want more industry other top rank stock medical product space be stryker corp syk free report bio rad laboratory bio free report boston scientific corp bsx free report stryker long term expect earning growth be stock carry zack rank see complete list today zack rank stock here bio rad long term project earning growth be stock carry zack rank boston scientific have expect long term earning growth stock carry zack rank today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
233,BAX,have be pay attention share baxter international bax free report share have be move stock past month bax hit new week high previous session baxter international have gain start year compare move medical sector year date return peer group drive outperformance stock have impressive record positive earning surprise have beaten zack consensus estimate last quarters last earning report april baxter international report ep versus zack consensus estimate beat consensus revenue estimate current fiscal year baxter international be expect post earning share revenue represent change ep change revenue next fiscal year company be expect earn share revenue represent year year change respectively valuation metricsbaxter international be week high right now future hold bax key aspect question be take look valuation metric order determine company have run ahead front look zack style score provide investor additional way sort stock look zack rank security style be represent grade run category value growth momentum be combine vgm score well idea style score be help investor pick most appropriate zack rank stock base individual investment style baxter international have value score stock growth momentum score be respectively give company vgm score term value breakdown stock currently trade current fiscal year ep estimate trail cash flow basis stock currently trade versus peer group average additionally stock have peg ratio isn enough put company top echelon stock cover value perspective baxter international inc price consensus baxter international inc price consensus baxter international inc quotezack rankwe also need look zack rank stock supersede trend style score front fortunately baxter international currently have zack rank buy thank favorable earning estimate revision cover analyst recommend investor select stock carry zack rank strong buy style score look baxter international meet list requirement thus seem bax share have potential week month come do baxter international stack competition share baxter international have be move higher company still appear be decent choice rest industry industry peer be also look good include biolife solution blfs free report surmodic srdx free report varian medical system var free report currently have zack rank least vgm score least make well round choice however be worth note zack industry rank group be bottom half ranking so isn good news baxter international still fundamental bax be promising still have potential be week high
234,BAX,have be month last earning report baxter international inc bax free report share have add time frame recent positive trend continue lead next earning release be bax due pullback dive investor analyst have react late let take quick look most recent earning report order get better handle important catalyst recent earningsbaxter international report first quarter adjust earning share cent beat zack consensus estimate improve year quarter cent figure surpass company guidance cent last quarters company deliver positive earning surprise average be baxter post sale edge past zack consensus estimate cc revenue rise year year basis baxter have zack rank buy company have outperformed industry year time baxter share have return higher industry gain roughly geographical report operate result geographic segment americas north south america emea europe middle east africa apac asia pacific whole sale rise year year operational basis international sale increase almost operational basis strong demand company continuous renal replacement therapy crrt injectable pharmaceutical advanced surgery product iv solution peritoneal dialysis therapy boost sale worldwide americas baxter report sale cc year year basis emea sale gross cc year year basis apac baxter report sale cc year year basis segmental detailsrenal productssale segment increase cc year year basis renal product sale be support improve performance major product line therapy globally notably solid performance chronic acute renal therapy drive sale segment medication deliverysale segment be flat year year cc notably segment include company iv therapy infusion pump administration set drug reconstitution device segment be year year cc notably pharmaceutical include company premixed oncology drug platform inhaled anesthesia well critical care product pharmacy compound service nutritionsale segment be flat year year cc notably segment include sale parenteral nutrition pn therapy advanced surgerysale segment totale year year cc segment cover company biological product medical device used surgical procedure hemostasis tissue sealing adhesion prevention march baxter complete acquisition hemostat sealant product mallinckrodt plc expand exist surgical portfolio especially intraoperative bleed notably company buy thrombin topical preveleak surgical sealant product line mallinckrodt notably development be not accretive first quarter adjust earning however baxter expect deal be modestly accretive adjust earning acute therapiessale segment be year year cc sale crrt other organ support therapy focuse icu boost segmental revenue quarter review othersale segment totale year year cc baxter pharmaceutical partner business be include segment margin register gross profit first quarter year year percentage revenue adjust gross margin contract basis point bps first quarter adjust operate income increase year year quarter percentage revenue operate margin contract bps first quarter guidancebaxter raise financial outlook company expect sale growth cc expect adjust earning continue operation range share full year second quarter company expect sale growth approximately cc company expect adjust earning continue operation band cent have estimate be move then past month investor have witness upward trend fresh estimate have be revision higher current quarter compare lower baxter international inc price consensus baxter international inc price consensus baxter international inc quotevgm scoresat time bax have great growth score grade same score momentum front however stock be allocate grade value side putt middle investment strategy overall stock have aggregate vgm score aren focuse strategy score be be interested base score stock be more suitable growth momentum investor value investor outlookestimate have be broadly trend upward stock magnitude revision look promising notably bax have zack rank hold expect line return stock next few month
235,BAX,medical product industry have be see steady growth late ever increase grey population long life expectancy increase demand technologically superior medical device industry have also gain recent deferral medical device tax accord article publish xtalk medical device tax be responsible reduction spending decline overall sale thus company expect ramp spending likely lend competitive edge long haul baxter international bax free report stryker corporation syk free report be close contender medical product space notably stock carry zack rank buy see complete list today zack rank stock here here make detailed analysis company fundamental determine stock be currently better position market cap baxter be global medical technology company meanwhile michigan base stryker be largest medical device company operate global orthopedic market company have market cap factor drive stocksstryker robotic arm assist mako surgery platform have be consistently drive top line last report quarter platform record new robot installation globally robust demand baxter crrt injectable pharmaceutical iv solution peritoneal dialysis therapy be major positive price share rally year time edge past stryker return medical product industry return same time frame estimate zack consensus estimate baxter current year earning share be peg year year consensus mark stryker current year earning be pin reflect improvement year year baxter international inc price consensus baxter international inc price consensus baxter international inc solid growth projection clearly show baxter winner here zack consensus estimate baxter current year revenue be peg year year same stryker be pin call growth stryker corporation price consensus stryker corporation price consensus stryker corporation quotethus stryker have competitive edge current year sale estimate be take consideration fundamental growth storyin year time baxter earning share witness negative cagr totale however stryker earning have see cagr time frame come past year baxter revenue have register negative cagr totale stryker revenue have see cagr totale here too stryker win baxter conclusionour comparative analysis indicate stryker be position better baxter consider current year sale expectation fundamental other key picksa couple other top rank stock broader medical space be genomic health ghdx free report inogen inc ingn free report genomic health have expect earning growth rate stock flaunt zack rank inogen have expect long term earning growth rate sport zack rank today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
236,BAX,cerner corporation cern free report report adjust first quarter earning cent share year quarter figure be line zack consensus estimate revenue rise year year miss zack consensus estimate stock have zack rank hold cerner underperform industry year time stock have lose compare industry return booking year year upside revenue be primarily attribute increase booking first quarter booking be year year basis company register strong booking business office service however subscription booking be lower expect cerner corporation price consensus cerner corporation price consensus cerner corporation quotesegment detailsinstead report revenue category system sale support maintenance service cerner report segment first quarter license software first quarter fall year year basis lower expect subscription booking mar growth segment subscription account revenue worth year year basis professional service increase year year management strong performance segment be likely enhance revenue cycle position manage service segment revenue be year year support maintenance revenue be year year reimburse travel sale amount year quarter marginsgross margin first quarter be almost flat year year operate margin report quarter be contract basis point bps year year basis downside be cause surge operate expense rise year year growth be drive personnel expense related revenue generate associate cash item financial positioncerner exit first quarter free cash flow operate cash flow totale long term debt include capital lease obligation be slightly sequential basis view downbeatcerner expect second quarter revenue zack consensus estimate same be higher project range second quarter adjust earning share be project range cent range be lower zack consensus estimate cent revenue be project range range zack consensus estimate same be significantly higher projection full year adjust earning share be estimate range lag zack consensus estimate further company expect second quarter new business booking range exit first quarter tepid note miss consensus mark top line front revenue come expectation due software issue technology resale lesser expect subscription booking delay va contract downbeat guidance indicate concern stock further lower margin technology resale result higher mix device resale be concern additionally cerner have be face macroeconomic challenge cutthroat competition niche space surge operate expense also add wo international growth be likely boost company prospect australia canada middle east ireland germany cerner witness strong cash flow record booking believe company have growth opportunity revenue cycle management rcm population health ambulatory market base product strength enviable track record add new client solid growth healtheintent platform also hold promise further company recently report suite development ehr platform earning medtech major glancea few better rank stock broader medical space report solid earning season be baxter international inc bax free report varian medical system inc var free report intuitive surgical inc isrg free report intuitive surgical varian sport zack rank strong buy baxter carry zack rank buy see complete list today zack rank stock here intuitive surgical report adjust earning share surpass zack consensus estimate revenue totale beat zack consensus estimate varian report second quarter fiscal adjust earning share beat zack consensus estimate adjust earning improve year year basis baxter report first quarter adjust earning share cent beat zack consensus estimate improve year quarter figure cent medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
237,BAX,accuray incorporate aray free report report loss cent share third quarter fiscal cent wider zack consensus estimate cent wider year figure total revenue quarter increase year year beating zack consensus estimate segment detailsproduct revenue product revenue decline same japan decline roughly third quarter year year decline total product revenue company continue witness strength radixact service revenue service revenue amount report quarter year year courtesy increase upgrade purchase service contract gross order update gross order performance third quarter fiscal be last quarter order growth be primarily drive tomotherapy array product radixact system order accuray incorporate price consensus ep surprise accuray incorporate price consensus ep surprise accuray incorporate quoteother platform drife sale radixact be company latest device contribute handsomely revenue radixact system account tomotherpay order quarter review further system be be accept true workhorse product market courtesy significantly improve product performance functional efficacy broad case mix versatility suite software upgradation series software upgradation have be growth driver accuray upgrade be primarily focuse improvise imaging faster plan capability well system connectivity further software enhancement involved improvisation cyberknife treatment plan efficiency regard accuray have introduce ctrue iterative reconstruction enhance ct imaging capability radixact annual estro meeting be hold barcelona geographical gain improve management revenue growth third quarter attribute european american apac region contribution order performance emea japan have also be strong margin detailsin quarter review total gross margin be roughly flat year year product gross margin increase report quarter compare year quarter be attribute increase revenue contribution cyberknife system radixact system service gross margin third quarter be compare year quarter operate expense totale versus year quarter increase be primarily lead investment research development sale marketing financial exit third quarter cash cash equivalent compare second quarter fiscal guidance company revise previous guidance company expect revenue previous range zack consensus estimate fiscal revenue be high end guide range guidance gross order growth have be maintain rise approximately year year basis company expect adjust ebitda previously provide range takeaccuray report mixed third quarter fiscal further company lower ebitda expectation largely due strategic investment lower expect gross margin however accuray continue ride market solid response radixact platform company revamp software flip side long sale implementation cycle cyberknife tomotherapy system majorly affect company top line increase operate expense result research development activity be also concern price have be outperform industry past month stock have gain industry decline zack rank key picksaccuray carry zack rank hold few better rank stock broader medical sector report solid result season be intuitive surgical isrg free report cheme corporation che free report baxter international inc bax free report intuitive surgical sport zack rank strong buy cheme baxter carry zack rank buy see complete list today zack rank stock here intuitive surgical report first quarter adjust earning share ep beat zack consensus estimate revenue totale also surpass consensus estimate cheme post first quarter adjust ep surpass zack consensus estimate revenue come beating zack consensus estimate baxter post first quarter adjust ep cent beat zack consensus estimate revenue also edge past zack consensus estimate wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
238,BAX,inogen inc ingn free report report adjust first quarter earning share cent beating zack consensus estimate whopping earning also rise same margin year figure cent total revenue report quarter come beating zack consensus estimate revenue surge prior year quarter notably total unit be sell reflect increase year year basis meanwhile past month inogen share have rally industry decline inogen inc price consensus ep surprise inogen inc price consensus ep surprise inogen inc quotesegmental analysissale revenue come year year rental revenue totale business business domestic sale be year upside be attribute company private label partner traditional home medical equipment provider international sale segment come year year basis primarily continue adoption company european partner favorable currency rate direct consumer sale rise year year management upside be attribute increase sale representative headcount associate consumer spending marginsgross profit report quarter be year year total gross margin be net revenue basis point bps year year contraction gross margin be primarily lead lower sale revenue unit rental gross margin partially offset reduce cost sale revenue unit quarter review operate expense increase operate margin percentage revenue contract bps be mainly impact upside research development expense totale quarter adjust ebitda come indicate year year growth financial conditioninogen exit quarter cash cash equivalent marketable security worth compare last report guidancebuoy solid first quarter result inogen raise outlook revenue guidance range be represent growth result notably zack consensus estimate full year revenue lie range direct consumer be expect be fastest grow channel company net income guidance full year be represent growth inogen also raise guidance adjust ebitda represent growth result company further expect net positive cash flow additional equity capital require meet current operate plan exit first quarter solid note beating consensus mark count strong sale unite state europe raise optimism raise guidance also paint bright picture flip side decline margin owing surge expense raise concern decline rental revenue add wo additionally management expect rental revenue decline zack rank key picksinogen carry zack rank hold few better rank stock broader medical sector report solid result season be intuitive surgical isrg free report cheme corporation che free report baxter international inc bax free report intuitive surgical sport zack rank strong buy cheme baxter carry zack rank buy see complete list today zack rank stock here intuitive surgical report first quarter adjust earning share beat zack consensus estimate revenue totale also surpass consensus estimate cheme post first quarter adjust earning share surpass zack consensus estimate revenue come beating zack consensus estimate baxter post first quarter adjust earning share cent beat zack consensus estimate revenue also edge past zack consensus estimate wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
239,BAX,amedisys inc am free report report earning share ep cent first quarter year adjust ep cent bottom line also remain well ahead zack consensus estimate cent first quarter net service revenue gross year year top line also beat zack consensus estimate quarter company home health division net service revenue totale first quarter reflect improvement year year medicare revenue rise year year medicare revenue improve year year amedisys inc price consensus ep surprise amedisys inc price consensus ep surprise amedisys inc quote hospice division net service revenue gross year year include medicare revenue medicare revenue recently company integrate additional operate segment business namely personal care corporate personal care net service revenue totale represent increase year number meanwhile corporate segment do not register revenue end first quarter company gross margin contract basis point bps quarter review climb gross profit expense salary benefit inched other expense rise adjust operate income report quarter reflect surge year tally adjust operate margin expand bps year figure amedisys exit first quarter cash cash equivalent compare end company long term obligation exclude current portion be end first quarter dec net cash provide operate activity first month be compare year period takeamedisys end first quarter promising note earning revenue exceed respective zack consensus estimate home health hospice division company witness encourage growth medicare medicare revenue amedisys be currently explore opportunity segment be also impressed company solid performance recently launch personal care segment favorable demographic trend strategic acquisition also bode well company however escalate operate expense decline gross margin continue raise concern also intense competitive landscape regulatory concern persistently challenge home health hospice industry zack rank key picksamedisys carry zack rank hold few better rank stock broader medical space have report robust earning figure report cycle be intuitive surgical isrg free report cheme corp che free report baxter international inc bax free report intuitive surgical sport zack rank strong buy cheme baxter carry zack rank buy see complete list today zack rank stock here intuitive surgical report first quarter adjust ep beat zack consensus estimate revenue totale also surpass consensus estimate cheme post first quarter adjust ep outpace zack consensus estimate revenue come higher zack consensus estimate baxter first quarter adjust ep cent better zack consensus estimate revenue also edge past consensus mark look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
240,BAX,phibro animal health corporation pahc free report report adjust earning share ep cent third quarter fiscal year year adjust ep surpass zack consensus estimate cent accord company year year improvement be primarily drive higher gross profit reduce interest expense lower effective income tax rate report ep cent be year quarter lower net income net salesin report quarter net sale totale year year improvement be drive sale growth animal health mineral nutrition performance product segment sale segmentsnet sale animal health segment increase report quarter volume increase nutritional specialty vaccine product group segment nutritional specialty product grow principally volume growth product poultry dairy industry further sale vaccine increase majorly global volume growth phibro animal health corporation price consensus ep surprise phibro animal health corporation price consensus ep surprise phibro animal health corporation quote moreover sale medicated feed additive mfa other grow primarily strength international business domestic net sale mfa other rise volume growth certain product international net sale increase drive growth most region include benefit recent buyout additional penetration cattle sector net sale mineral nutrition segment increase higher average selling price result increase underlie raw material commodity price net sale performance product segment rise higher average selling price volume copper base product operational updatephibro third quarter gross profit increase year year gross margin expand basis point bps selling general administrative expense rise operate margin contract bps quarter financial update year date phibro generate cash flow operation compare year capital expenditure amount period reflect reduction year period fy view have reaffirm guidance fiscal company expect generate net sale current zack consensus estimate fall guide range phibro project adjust ep band current zack consensus estimate be also company guide range takephibro end third quarter fiscal solid note company witness considerable improvement segment moreover company believe continuous investment portfolio enhancement development organizational capability have start pay further improve gross margin favorable product mix buoy optimism moreover company be busy arrange fund third party invest development technology product be also upbeat phibro foraying companion animal space signing agreement develop innovative product canine lyme disease vaccine used novel delivery method zack rank key picksphibro have zack rank hold few better rank stock broader medical space have report solid result season be intuitive surgical isrg free report cheme corporation che free report baxter international inc bax free report intuitive surgical sport zack rank strong buy cheme baxter carry zack rank buy see complete list today zack rank stock here intuitive surgical report first quarter adjust ep beat zack consensus estimate revenue totale also surpass consensus estimate cheme post first quarter adjust ep surpass zack consensus estimate revenue come beating zack consensus estimate baxter post first quarter adjust ep cent beat zack consensus estimate revenue also edge past zack consensus estimate look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
241,BAX,davita inc dva free report report first quarter adjust operate earning share beating zack consensus estimate cent earning increase year year basis total revenue increase year year miss zack consensus estimate davita carry zack rank hold business detailsnet dialysis related lab patient service revenue first quarter be year year other revenue be year year basis davita see impressive result kidney care business net consolidated revenue segment be year year adjust kidney care operate income be year year operate division davita davita kidney care focus set worldwide standard clinical social operational practice kidney care adjust dialysis related lab service operate income first quarter be dialysis treatment first quarter be treatment day represent increase year year davita inc price consensus ep surprise davita inc price consensus ep surprise davita inc quote company patient care cost be approximately cent treatment compare last report quarter investor notice company major segment davita medical group dmg be track divestment optum subsidiary unitedhealth group inc transaction be subject regulatory approval other customary close condition result dmg business operation have be report discontinue quarter review share repurchase updatedure first quarter davita repurchase total share approximately average price share davita have repurchase share year date basis represent nearly company total share outstanding also include approximately stock repurchase guidancedavita reiterate guidance company project kidney care consolidated operate income range operate cash flow continue operation be estimate range effective tax rate be expect range end first quarter mixed note adjust earning beating zack consensus estimate revenue miss same company see impressive result kidney care business lately operate division davita davita kidney care focus clinical social operational practice worldwide company effort control expense hold promise compelling inorganic growth story be positive flip side sluggishness other business be major headwind davita company be face adverse effect pricing pressure medical industry rise medicare insurance cost company major segment davita medical group have be track divestment optum subsidiary unitedhealth group inc further high debt level adverse effect healthcare reform increase medicare advantage beneficiary be concern earning medtech major glancea few better rank stock broader medical space report solid earning season be baxter international inc bax free report varian medical system inc var free report intuitive surgical inc isrg free report intuitive surgical varian sport zack rank strong buy baxter carry zack rank buy see complete list today zack rank stock here baxter report first quarter adjust earning share cent beat zack consensus estimate improve year quarter figure cent varian report second quarter fiscal adjust earning share beat zack consensus estimate adjust earning improve year year basis intuitive surgical report adjust earning share surpass zack consensus estimate revenue totale beat zack consensus estimate look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
242,BAX,petm express inc pet free report announce earning share ep cent fourth quarter fiscal year quarter cent also bottom line surpass zack consensus estimate cent year year upside be drive higher gross profit margin further tax cut owing recent tax reform provide impetus full year ep be reflect increase year ep figure also beat zack consensus estimate net sale report quarter rise year year however sale miss consensus estimate accord lead pet pharmacy americas sale upside be result increase reorder net sale totale full year year net sale however miss zack consensus estimate petm express inc price consensus ep surprise petm express inc price consensus ep surprise petm express inc quotein report quarter reorder sale increase year year basis new order sale decline average order value be approximately quarter compare year earlier quarter note variation average order value be mainly shift sale higher price item company seasonality business be mainly proportion flea tick heartworm medication product mix spring summer be consider peak season fall winter represent season quarter review petm acquire new customer year roughly order be generate compare prior year quarter gross margin expand basis point bps year year quarter review general administrative expense be year year however advertising expense decline adjust operate expense however rise depreciation expense nevertheless adjust operate margin quarter expand bps year quarter petm exit fiscal cash cash equivalent compare end fiscal company also declare quarterly dividend cent share payable shareholder record takepetm exit fiscal fourth quarter mixed note however be encourage growth reorder sale quarter further expand gross margin due shift higher margin product next generation medication buoy optimism company be also strive implement strategy revitalize top line include increase focus advertising efficiency boost new order sale well shift sale higher margin item also expand product line zack rank key pickspetm have zack rank hold few better rank stock broader medical space have report solid result season be intuitive surgical isrg free report cheme corporation che free report baxter international inc bax free report intuitive surgical sport zack rank strong buy cheme baxter carry zack rank buy see complete list today zack rank stock here intuitive surgical report first quarter adjust ep beat zack consensus estimate revenue totale also surpass consensus estimate cheme post first quarter adjust ep surpass zack consensus estimate revenue come beating zack consensus estimate baxter post first quarter adjust ep cent beat zack consensus estimate revenue also edge past zack consensus estimate look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
243,BAX,hologic inc holx free report report second quarter fiscal adjust earning share ep cent year year line low end company cent guidance adjust ep be also par zack consensus estimate report basis company record net loss share net income second quarter fiscal notably report figure include cash impairment charge goodwill process research development associate hologic cynosure business revenue detailrevenue gross quarter year year constant exchange rate cer top line surpass zack consensus estimate company guidance solid contribution breast health international business drive top line geographically revenue unite state grow year year exclude blood screening medical aesthetic revenue decline marginally international revenue be cer strong contribution cynosure exclude blood screening medical aesthetic international revenue increase constant currency hologic inc price consensus ep surprise hologic inc price consensus ep surprise hologic inc quotesegment detailrevenue diagnostic segment total revenue decline year year cer second quarter segment molecular diagnostic revenue increase cer global growth molecular diagnostic be primarily drive new product revenue continue solid uptake aptima woman health product cytology perinatal revenue also show improvement cer revenue breast health segment inched cer revenue growth unite state be roughly flat report quarter upside be lead higher service new product revenue international revenue however climb year year mark third consecutive quarter growth exceed revenue gyn surgical business be cer medical aesthetic business quarter report revenue reflect total revenue revenue skeletal health accounting rest increase cer operational updatein fiscal second quarter hologic gross margin contract basis point bps adjust gross margin also decrease bps due divestiture blood screening business geographic mix revenue low margin cynosure product hologic adjust operate expense amount year year adjust operate margin contract massive bps financial updatehologic exit second quarter fiscal cash cash equivalent compare end first quarter fiscal total long term debt be end report quarter compare first quarter fiscal quarter company generate operate cash flow compare year guidancehologic have update fiscal financial guidance company currently expect adjust revenue compare previous range company expect revenue grow range compare previously provide range cer zack consensus estimate revenue be guide range adjust ep guidance remain unchanged call growth zack consensus estimate adjust ep be peg guide range third quarter fiscal hologic expect adjust revenue represent annualize decline cer zack consensus estimate revenue be peg project range adjust ep be estimate cent reflect annualize growth zack consensus estimate third quarter adjust ep be pin cent company guidance takehologic exit second quarter fiscal mixed note growth geographical region buoy optimism however be disappoint decline revenue diagnostic segment blood screening divestiture be also likely impede growth company further company lower revenue guidance fiscal reduce sale expectation cynosure business raise concern zack rank key pickshologic carry zack rank sell few better rank stock broader medical sector report solid result season be intuitive surgical isrg free report cheme corporation che free report baxter international inc bax free report intuitive surgical sport zack rank strong buy cheme baxter carry zack rank buy see complete list today zack rank stock here intuitive surgical report first quarter adjust ep beat zack consensus estimate revenue totale also surpass consensus estimate cheme post first quarter adjust ep steering past zack consensus estimate revenue come beating zack consensus estimate baxter post first quarter adjust ep cent beat zack consensus estimate revenue also edge past zack consensus estimate medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
244,BAX,allscript healthcare solution inc mdrx free report post first quarter adjust earning share cent share miss zack consensus estimate penny however earning improve year figure cent revenue report quarter come miss zack consensus estimate however revenue improve year year quarter review booking grow share allscript have lose compare industry decline past month allscript carry zack rank hold allscript healthcare solution inc price consensus ep surprise allscript healthcare solution inc price consensus ep surprise allscript healthcare solution inc quotesegment detailssoftware delivery support segment totale year year basis management recur software revenue consist subscription recur transaction support new maintenance increase year year large part growth be drive consolidation enterprise information solution eis business client servicesrevenue segment come recur service revenue increase year year drive addition eis revenue cycle service other multiyear service offering marginsgross margin first quarter be compare prior year quarter total operate expense be year year basis year year increase be attribute acquisition eis business mckesson corporation additionally company record legal transaction related other cost quarter review adjust ebitda totale first quarter financial exit quarter cash flow compare year quarter free cash flow totale year year basis latest have announce definitive agreement acquire healthgrid hold company healthgrid mobile enterprise patient engagement platform business management expect close deal second quarter stock repurchase updatestock repurchase totale first quarter allscript anticipate revenue notably zack consensus estimate revenue be peg lie expect range earning share be expect cent cent reflect increase year year zack consensus estimate earning share be pin cent lie guide range adjust ebitda be expect year year takeallscript have dull start first quarter earning revenue miss estimate however strong segmental revenue buoy optimism year year rise booking be also major positive company ride plethora strategic acquisition partnership be likely prove accretive earning quarters ahead flip side decline margin rise operate expense raise concern company be also expose integration risk intense competition niche space add wo key picksa few better rank stock broader medical space have report solid result season be intuitive surgical isrg free report cheme corporation che free report baxter international inc bax free report intuitive surgical sport zack rank strong buy cheme baxter carry zack rank buy see complete list today zack rank stock here intuitive surgical report first quarter adjust earning share beat zack consensus estimate revenue totale also surpass consensus estimate cheme post first quarter adjust earning share surpass zack consensus estimate revenue come beating zack consensus estimate baxter post first quarter adjust earning share cent beat zack consensus estimate revenue also edge past zack consensus estimate today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
245,BAX,dexcom inc dxcm free report report loss cent share first quarter line zack consensus estimate also figure be narrower loss cent report year quarter stock have zack rank hold total revenue grow year quarter revenue surpass zack consensus estimate segmental detailssensor revenue other revenue total revenue grow year year basis transmitter revenue increase prior year quarter tally receiver revenue grow year year dexcom inc price consensus ep surprise dexcom inc price consensus ep surprise dexcom inc detailsdexcom generate gross margin percentage revenue contract basis point bps year year margin be pressure due inventory change shift ous medicare international business display continue growth quarter year year basis research development expense totale quarter year year selling general administrative expense totale report quarter increase year year guidancedexcom raise full year guidance company expect revenue range previous range meanwhile zack consensus estimate revenue be currently peg be significantly lower guide estimate gross profit margin be project band report operate expense exclude investment intensive program be expect increase first quarter adjust earning meet zack consensus estimate solid contribution sensor revenue transmitter revenue receiver revenue be key catalyst moment glucose monitoring market represent significant commercial opportunity dexcom dexcom opportunity alternative market such intensive diabetes management space hospital gestational pre diabetes obesity be likely provide company competitive edge medtech space further company next generation fully disposable cgm system be also progresson flip side cutthroat competition market blood glucose monitoring device be headwind dexcom moment believe company margin continue be pressure come quarters owing high product development cost rise expenditure research development lower expect margin transmitter sale be also cause concern earning medtech major glancea few better rank stock broader medical space report solid earning season be baxter international inc bax free report varian medical system inc var free report intuitive surgical inc isrg free report intuitive surgical varian sport zack rank strong buy baxter carry zack rank buy see complete list today zack rank stock here intuitive surgical report adjust earning share surpass zack consensus estimate revenue totale beat zack consensus estimate varian report second quarter fiscal adjust earning share beat zack consensus estimate adjust earning improve year year basis baxter report first quarter adjust earning share cent beat zack consensus estimate improve year quarter figure cent today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
246,BAX,bruker corporation brkr free report report adjust earning share ep cent first quarter year figure also adjust ep beat zack consensus estimate couple cent report basis earning come cent share increase year year basis revenue detailbruker logged revenue first quarter year year moreover top line surpass zack consensus estimate exclude positive effect acquisition favorable impact change foreign currency rate bruker report year year organic revenue growth bruker corporation price consensus ep surprise bruker corporation price consensus ep surprise bruker corporation quote geographically european revenue improve high single digit year year report quarter north america revenue grow mid single digit asia pacific apac metric be low single digit due shipment acceptance delay related biospin apac customer management company register organic revenue growth drive strength nano best bruker biospin group revenue decline modestly first quarter level exclude impact currency translation biospin nmr have slow start year delay system shipment acceptance revenue nano group increase mid single digit constant exchange rate fuel strong uptick industrial research market calid revenue be high single digit organic basis strong performance daltonic mass spec business margin trenda percentage revenue gross margin quarter review expand basis point bps selling general administrative expense increase research development expense rise year year overall adjust operate margin improve bps financial positionbruker exit first quarter cash cash equivalent short term investment end mar net cash used operate activity be compare year period guidancebruker reiterate guidance full year company still expect revenue growth approximately include nearly organic revenue growth company project year year expansion bps adjust operate margin bruker still anticipate adjust ep range previous band zack consensus estimate remain ahead company guidance takebruker exit first quarter solid note strong year year increase revenue well earning additionally improvement gross operate margin buoy optimism company strategic acquisition activity have also be encourage further be upbeat company current focus product development higher flip side competitive landscape macroeconomic headwind continue challenge company zack rank key picksbruker carry zack rank hold few better rank stock broader medical space have report robust earning figure report cycle be intuitive surgical isrg free report cheme corp che free report baxter international inc bax free report intuitive surgical sport zack rank strong buy cheme baxter carry zack rank buy see complete list today zack rank stock here intuitive surgical report first quarter adjust ep beat zack consensus estimate revenue totale also surpass consensus estimate cheme post first quarter adjust ep exceed zack consensus estimate revenue come outpace zack consensus estimate baxter first quarter adjust ep cent better zack consensus estimate revenue also edge past consensus mark more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
247,BAX,abiom inc abmd free report report fourth quarter fiscal earning share cent beat zack consensus estimate earning improve huge year quarter past month abiom share have gain industry decline abiom have zack rank buy revenue detail revenue report quarter come beating zack consensus estimate revenue also increase prior year quarter management upside be drive patient utilization growth year year basis reorder performance continue be strong quarter reorder increase prior year quarter translate reorder rate approximately average combine inventory hospital impella impella cp rise slightly unit site versus prior quarter last year abiom inc price consensus ep surprise abiom inc price consensus ep surprise abiom inc quoteimpella heart pump worldwide revenue quarter review totale year year unite state impella rake year quarter outside unite state fourth quarter revenue generate impella heart pump be whopping year year significant contribution come germany record revenue year year recently impella line clinch plethora regulatory approval fda margin quarter review gross margin be basis point bps year year operate income quarter gross year year basis operate margin be expand bps financial condition abiom balance sheet have be strong end fiscal company generate cash cash equivalent marketable security end fourth quarter company be currently debt free fy glance infiscal total revenue be fiscal fiscal worldwide impella heart pump revenue totale show increase year year unite state impella revenue totale outside unite state revenue impella heart pump totale year year revenue come germany year year basis full year gross margin be bps year year operate income full year come operate margin be operate margin expand bps cash cash equivalent totale fiscal fy outlook fiscal company expect total revenue range reflect increase prior fiscal notably zack consensus estimate revenue be peg lie project range full year tax rate be expect conclusion abiom end fiscal solid note flagship impella line continue drive growth string fda approval be encourage expansion operate margin be also major positive company also have solid global foothold buoy optimism however decline gross margin raise concern company continue face foreign exchange volatility intense competition niche space add wo other key pick other top rank stock broader medical space have report solid result season be intuitive surgical isrg free report cheme corporation che free report baxter international inc bax free report intuitive surgical sport zack rank strong buy cheme baxter carry zack rank see complete list today zack rank stock here intuitive surgical report first quarter adjust earning share beat zack consensus estimate revenue totale also surpass consensus estimate cheme post first quarter adjust earning share surpass zack consensus estimate revenue come beating zack consensus estimate baxter post first quarter adjust earning share cent beat zack consensus estimate revenue also edge past consensus markof more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
248,BAX,surmodic inc srdx free report report adjust earning cent share second quarter fiscal year year zack consensus estimate be loss penny revenue quarter increase beating zack consensus estimate stock have zack rank buy surmodic have outperformed industry year time stock have return compare industry rise return be also higher index return segmental report revenue segment medical device diagnostic ivd medical devicein report quarter sale improve due lower hydrophilic royalty revenue notably royalty license fee revenue totale year quarter uptick royalty license fee revenue reflect surmodic strength hydrophilic coating royalty further company gain license fee income recently announce collaboration abbott medical device product sale rise report quarter solid medical device sale medical device customer research development revenue decline year year basis unit generate operate income second quarter fiscal compare operate income year quarter ivdin quarter review sale increase upside come back strong growth stabilization biofx microarray antigen product sale operate income segment be report quarter compare second quarter fiscal surmodic inc price consensus ep surprise surmodic inc price consensus ep surprise surmodic inc quotemargin detailsproduct gross margin contract basis point bps second quarter product sale compare year period margin quarter suffer expense irish facility infrastructure lower medical device product gross margin second quarter fiscal expense be net sale higher net sale year quarter sg expense second quarter fiscal be revenue bps higher year year raise guidance fiscal surmodic expect fiscal revenue range previous band company expect fiscal earning share negative cent cent compare previous estimate negative cent cent zack conensus estimate be currently peg loss cent share exit second quarter fiscal solid note beating zack consensus estimate count further solid performance diagnostic segment gain strong growth stabilization biofx microarray antigen product sale hold promise surmodic issue solid guidance fiscal company solid initiative strengthen research development program bode well flip side company witness significantly high operate loss product sale decline due shipment issue particularly medical device segment further foreign exchange wo related creagh medical buyout have be major dampener surmodic drug coat balloon face stiff competition niche space company margin be expect stay pressure thank expense irish facility infrastructure lower medical device product gross margin earning medtech major glancea few better rank stock broader medical space report solid earning season be baxter international inc bax free report varian medical system inc var free report intuitive surgical inc isrg free report intuitive surgical varian sport zack rank strong buy baxter carry zack rank see complete list today zack rank stock here baxter report first quarter adjust earning share cent beat zack consensus estimate improve year quarter figure cent varian report second quarter fiscal adjust earning share beat zack consensus estimate adjust earning improve year year basis intuitive surgical report adjust earning share surpass zack consensus estimate revenue totale beat zack consensus estimate more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
249,BAX,baxter international inc bax free report report third quarter adjust earning share cent beat zack consensus estimate cent improve year figure cent baxter currently have zack rank buy figure be also company guide range cent cent interestingly last quarters company deliver positive earning surprise average be baxter post sale beating zack consensus estimate constant currency cc revenue increase year year basis sale be year year international sale increase cc almost baxter international inc price consensus ep surprise baxter international inc price consensus ep surprise baxter international inc quote segmental detailssale hospital product segment climb cc year year basis hospital product sale quarter be drive solid sale fluid system select anesthesia critical care product hospital sale be also drive solid demand injectable pharmaceutical hospital pharmacy compound service meanwhile sale increase cc renal product segment renal product sale be support improve performance major product line therapy globally quarterly acquire claris third quarter baxter complete acquisition india base claris injectable global generic injectable pharmaceutical company almost december baxter have initiate agreement management acquisition bolster baxter foothold generic pharmaceutical space new patient enrolled third quarter baxter register patient new clinical trial unique expand hemodialysis therapy enabled theranova dialyzer treatment chronic acute renal failure fact baxter be expect launch hemodialysis enabled theranova australia new france germany switzerland belgium end year hurricane deal blow management baxter announce possibility shortfall supply certain product next quarter be company be still grapple limit production manufacturing site puerto rico hurricane marium however company have be grant regulatory approval fda special importation product facility ireland australia canada mexico maintain product supply balance market international foothold fortify baxter launch oxiris set continuous renal replacement therapy crrt sepsis management protocol select market europe middle east africa quarter notably oxiris leverage company flagship prismaflex system be expect lend baxter competitive edge global market guidance full year baxter estimate sale growth approximately cc adjust earning full year be expect band diluted share previous band baxter expect fourth quarter revenue face negative impact approximately thank operational disruption result hurricane marium adjust earning fourth quarter be expect band cent cent diluted share net sale fourth quarter be expect rise cc other company solid earning surgical inc isrg free report post adjust earning share third quarter beating zack consensus estimate stellar revenue growth stock have zack rank petm express inc pet free report adjust announce earning share cent second quarter fiscal year quarter also earning surpass zack consensus estimate stock have zack rank strong buy see complete list today zack rank stock here abbott free report report third quarter adjust earning continue operation cent share year year third quarter worldwide sale come year year abbott carry zack rank zack hide tradeswhile share many recommendation idea public certain move be hide everyone select member portfolio service peek curtain today view start now next month invite follow zack private buy sell real time value momentum stock etf option mover insider trade company be report positive earning surprise ve call accuracy even look portfolio so exclusive be normally close new investor click here zack secret trade
250,BAX,headquarter deerfield illinois baxter international inc bax free report be global medical product service company company hospital product business manufacture product used delivery fluid drug patient renal portfolio be mainly patient kidney failure disease healthcare provider currently baxter international have zack rank buy change follow third quarter earning report have just release see complete list today zack rank strong buy stock here have highlighted key detail just release announcement earning baxter adjust earning cent share beat zack consensus estimate cent increase cent year quarter revenue baxter post sale beating zack consensus estimate revenue constant currency cc revenue increase almost year year basis baxter international inc price ep surprise baxter international inc price ep surprise baxter international inc quotekey stat report quarter baxter finally complete acquisition claris injectable limit come segmental revenue hospital product sale increase cc renal product increase year quarter major factor hospital product sale quarter be drive solid sale fluid system select anesthesia critical care product hospital sale be also favorably impact solid demand injectable pharmaceutical hospital pharmacy compound service renal product sale be drive improve performance major product line therapy globally meanwhile baxter project fourth quarter revenue be negatively impact approximately courtesy temporary operational disruption result hurricane marium adjust earning fourth quarter be expect band cent cent diluted share however full year baxter estimate sale growth approximately cc adjust earning full year be expect band diluted share stock price share have rise roughly year date broader industry have gain same time frame however follow earning release share price do not show movement pre market trading session check back later full baxter international report later zack hide tradeswhile share many recommendation idea public certain move be hide everyone select member portfolio service peek curtain today view start now next month invite follow zack private buy sell real time value momentum stock etf option mover insider trade company be report positive earning surprise ve call accuracy even look portfolio so exclusive be normally close new investor click here zack secret trade
251,BAX,cardinal health inc cah free report report third quarter fiscal adjust earning share miss zack consensus estimate adjust earning fall year year revenue increase year year basis almost edge past zack consensus estimate cardinal health have zack rank hold last month share cardinal health have outperformed industry stock have return industry rise segmental revenue increase year year basis segment witness strong growth specialty business gain large number pharmaceutical distribution customer however segment witness expiration large mail order customer contract divestiture company china distribution business pharmaceutical witness decline profit thank generic pharmaceutical pricing medical segmentrevenue segment improve primarily higher contribution new exist customer acquisition patient recovery business medical segment profit increase cardinal health inc price consensus ep surprise cardinal health inc price consensus ep surprise cardinal health inc quotemargin profit increase year year percentage revenue gross margin expand basis point bps net revenue company slash guidance fiscal adjust earning share current range be significantly lower previous estimate downside be cause company effective tax rate associate cordis business zack consensus estimate revenue be peg takecardinal health exit quarter tepid note adjust earning miss consensus mark company witness encourage performance medical segment pharmaceutical segment register strong growth specialty business gain large number pharmaceutical distribution customer further company be banking strategic buyout joint venture supply agreement drive growth growth business profit pharmaceutical segment be hurt generic pharmaceutical pricing huge investment pharmaceutical platform lackluster generic performance be likely mar cardinal health operational efficiency upcoming quarters intense competition customer concentration be other bottleneck recently company close divestiture cardinal health china distribution earning medtech major glancea few better rank stock broader medical space report solid earning season be baxter international inc bax free report varian medical system inc var free report intuitive surgical inc isrg free report intuitive surgical varian sport zack rank strong buy baxter carry zack rank buy see complete list today zack rank stock here intuitive surgical report adjust earning share surpass zack consensus estimate revenue totale beat zack consensus estimate varian report second quarter fiscal adjust earning share beat zack consensus estimate adjust earning improve year year basis baxter report first quarter adjust earning share cent beat zack consensus estimate improve year quarter figure cent medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
252,BAX,medical group wmgi free report report first quarter adjust loss penny significantly narrower zack consensus estimate loss cent notably loss share year quarter be cent first quarter revenue come beat zack consensus estimate revenue also improve constant currency cc management represent estimate basis point bps increase year quarter past month share medical have gain industry decline medical carry zack rank hold medical group price consensus ep surprise medical group price consensus ep surprise medical group quotesegment detailslower segment post worldwide revenue year year sale unite state totale international sale come management lower extremity business witness improvement straight year flat sale upside be attribute growth total ankle return growth core lower extremity business furthermore have be continue progress ortholoc ankle small bone fracture product launch upper segment totale prior year quarter unite state sale totale internationally segment rake revenue worth management growth be drive growth company shoulder business quarter also see strong contribution flagship product simpliciti shoulder perform reversed glenoid management be positive blueprint acquisition be anticipate drive growth shoulder line product biologic sale be year international revenue segment rise sale drop sport med segment post worldwide sale year year basis however segment sale shot international sale sunk marginsin quarter review gross margin be bps year earlier quarter operate expense however rise increase sg selling general administrative research development expense ebitda margin expansion be bps pave way improvement balance sheet detailswright medical exit first quarter cash cash equivalent guidancewright medical reiterate revenue guidance band represent growth cc zack consensus estimate revenue be peg give range company expect adjust loss share cent zack consensus estimate same be pin cent again be project range full year adjust ebitda be anticipate range viewpointwright medical exit first quarter promising note year year loss have narrow revenue have tick solid performance upper lower extremity segment buoy optimism international sale segment be high be major positive acquisition blueprint have also proven beneficial consistent innovation be likely broaden company product portfolio moreover improvement gross margin be noteworthy flip side rise operate expense be concern decline sale biologic sport business be discourage distribution issue europe asia foreign currency volatility add wo key picksa few better rank stock broader medical space have report solid result season be intuitive surgical isrg free report cheme corporation che free report baxter international inc bax free report intuitive surgical sport zack rank strong buy cheme baxter carry zack rank buy see complete list today zack rank stock here intuitive surgical report first quarter adjust earning share beat zack consensus estimate revenue totale also surpass consensus estimate cheme post first quarter adjust earning share surpass zack consensus estimate revenue come beating zack consensus estimate baxter post first quarter adjust earning share cent beat zack consensus estimate revenue also edge past zack consensus estimate wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
253,BAX,medtronic plc mdt free report report fourth quarter fiscal adjust earning share ep beating zack consensus estimate adjust earning rise year year adjustment quarter primarily include impact restructure charge intangible asset amortization debt redemption premium acquisition related item adjust foreign exchange tailwind cent adjust ep be adjustment company report net earning share compare cent previous year full year adjust ep come improvement year number also exceed zack consensus estimate share total revenue report quarter gross organic basis report basis top line surpass zack consensus estimate organic revenue quarter include adjustment divestiture patient care deep vein thrombosis compression nutritional insufficiency business cardinal health positive impact foreign currency fiscal worldwide revenue be organic basis report basis also remain ahead zack consensus estimate quarter review sale total revenue fall year year adjust divestiture develop market revenue totale total revenue reflect increase organically report emerge market revenue total revenue amount organically report segment company currently generate revenue major group viz cardiac vascular group cvg minimally invasive therapy group mitg restorative therapy group rtg diabetes group cvg comprise cardiac rhythm heart failure crhf coronary structural heart csh aortic peripheral vascular division apv mitg now include surgical innovation si respiratory renal rgr division divestiture patient care deep vein thrombosis compression nutritional insufficiency enteral fee business rtg comprise spine brain therapy specialty therapy pain therapy segment diabetes group incorporate intensive insulin management iim intensive diabetes therapy ndt diabetes service solution dss division cvg revenue improve constant exchange rate cer report drive strong low teen growth csh mid single digit growth apv low single digit growth crhf cer crhf sale totale year year cer report come back low single digit growth arrhythmia management apart double digit growth af solution mechanical circulatory support tyrx infection control also contribute growth csh revenue be cer report back low constant currency growth transcatheter aortic valf result strong global uptake corevalve evolut pro platform moreover continue uptake resolute onyx drug eluting stent unite state japan revive coronary business apv revenue register growth cer report drive low single digit growth aortic peripheral mid teen growth endovenous medtronic plc price consensus ep surprise medtronic plc price consensus ep surprise medtronic plc quotein mitg worldwide sale reach mark year year increase cer report basis high single digit growth si low single digit growth rgr comparable cer basis rtg worldwide revenue be year year cer report low double digit growth brain therapy pain therapy mid single digit growth specialty therapy low single digit growth spine business moreover revenue diabetes group increase cer report marginsgross margin report quarter expand basis point bps rise gross profit adjust operate margin contract bps year year owing rise research development expense uptick selling general administrative expense other expense report quarter totale compare year quarter company have provide fiscal earning revenue guidance full year organic revenue growth be expect be range currency fluctuation be expect negatively impact top line current zack consensus estimate revenue be peg fiscal adjust ep be expect range growth year number mid point range assume cent benefit foreign exchange zack consensus estimate share fall upper end guide range takemedtronic exit fiscal solid note better expect fourth quarter performance company demonstrated improve segmental performance cer growth business segment however escalate cost continue be concern moreover major business group contribute solid top line growth cer highlighted sustainability group region addition display successful integration achievement synergy target be also encourage company solid growth trend unite state well healthy global acceptance advanced therapy apart product innovation company be focuse geographical diversification business zack rank peer have zack rank hold few better rank stock report solid result earning season be abiom inc abmd free report baxter international inc bax free report quest diagnostic inc dgx free report abiom sport zack rank strong buy baxter quest diagnostic carry zack rank buy see complete list today zack rank stock here abiom report fourth quarter fiscal earning share cent huge improvement year quarter revenue rise baxter post first quarter adjust earning share cent improvement year quarter figure cent revenue quarter rise year year basis constant exchange rate quest diagnostic report first quarter adjust ep year number revenue moved year year wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
254,BAX,smart beta exchange trade fund spdr russell low volatility focus etf onev free report debut offer broad exposure large cap etfs category equity market be smart beta etfs etf industry have long be dominate product base market cap weight index strategy create reflect market particular market segment investor believe market efficiency consider market cap index replicate market return low cost convenient transparent way other hand investor believe be possible beat market superior stock selection opt invest class fund track cap weight strategy popularly know smart beta attempt pick stock have better chance risk return performance cap weight index be base certain fundamental characteristic combination such area offer many different investment choice such simplest equal weighting fundamental weighting volatility momentum base weighting methodology however not strategy deliver superior result fund sponsor fund be manage state street global advisor onev have be able amass asset make average size etfs large cap etfs onev fee expense seek match performance russell low volatility focuse factor index russell low volatility focuse factor index reflect performance segment large capitalization equity security demonstrate combination core factor high value high quality low size characteristic focus factor comprise low volatility characteristic cost other expensessince cheaper fund tend produce better result more expensive fund assume other factor remain equal be important investor pay attention etf expense ratio operate expense annual basis be onev make cheaper product space onev month trail dividend yield be sector exposure top holdingsit be important delve etf holding investing many upside kind fund diversify exposure minimize single stock risk most etfs be very transparent product disclose holding daily basis represent portfolio fund have heaviest allocation consumer discretionary sector industrial financial round top look individual holding baxter international inc bax free report account total asset follow sysco corporation syy free report equity residential eqr free report onev top holding account total asset management performance riskso far year etf have lose be last year onev have trade past week period etf have beta standard deviation trail year period holding effectively diversify company specific risk russell low volatility focus etf be reasonable option investor seek outperform large cap etfs segment market however be other etfs space investor consider ishare core etf ivv free report track index spdr etf spy free report track index ishare core etf have asset spdr etf have ivv have expense ratio spy charge investor look cheaper lower risk option consider traditional market cap weight etfs aim match return large cap etfs bottom lineto learn more product other etfs screen product match investment objective read article latest development etf investing universe please visit zack etf center
255,BAX,baxter international inc bax free report report first quarter adjust earning share cent beat zack consensus estimate improve year quarter figure cent figure come company guidance cent last quarters company deliver positive earning surprise average be baxter post sale edge past zack consensus estimate constant currency cc revenue rise year year basis baxter have zack rank buy company have outperformed industry year time baxter share have return higher industry rally roughly geographical report operate result base reportable geographic segment americas north south america emea europe middle east africa apac asia pacific whole sale inched year year operational basis international sale increase almost operational basis strong demand company continuous renal replacement therapy crrt sale injectable pharmaceutical advanced surgery product iv solution peritoneal dialysis therapy boost sale worldwide americas baxter report sale cc year year basis emea baxter report sale cc year year basis apac baxter report sale cc year year basis baxter international inc price consensus ep surprise baxter international inc price consensus ep surprise baxter international inc quotesegmental detailsrenal productssale segment increase cc year year basis renal product sale be support improve performance major product line therapy globally notably solid performance chronic acute renal therapy drive sale segment medication deliverysale segment be remain constant year year cc notably segment include company iv therapy infusion pump administration set drug reconstitution device segment be year year cc notably pharmaceutical include company premixed oncology drug platform inhaled anesthesia well critical care product pharmacy compound service nutritionsale segment be line year year cc notably segment include sale company parenteral nutrition pn therapy advanced surgerysale segment be year year cc segment include company biological product medical device used surgical procedure hemostasis tissue sealing adhesion prevention march baxter complete acquisition hemostat sealant product mallinckrodt plc expand exist surgical portfolio especially intraoperative bleed notably company buy thrombin topical preveleak surgical sealant product line mallinckrodt notably development be not accretive first quarter adjust earning however baxter expect deal be modestly accretive adjust earning acute therapiessale segment be year year cc sale crrt other organ support therapy focuse icu boost segmental revenue quarter review othersale segment be year year cc baxter pharmaceutical partner business be include segment margin register gross profit first quarter year year percentage revenue adjust gross margin contract basis point bps first quarter adjust operate income increase year year quarter percentage revenue operate margin contract bps first quarter guidancebaxter raise financial outlook company expect sale growth cc expect adjust earning continue operation range share full year second quarter company expect sale growth approximately cc company expect adjust earning continue operation band cent end first quarter solid note beating consensus mark count strong demand crrt sale injectable pharmaceutical advanced surgery product iv solution peritoneal dialysis therapy boost sale worldwide latest strategic buyout recothorm preveleak be noteworthy recently company get fda approval bivalirudin percent sodium chloride injection flip side baxter expect pharmaceutical business be flat year year basis due increase competition select product segment further foreign currency headwind intense competition have be dampening company performance long baxter performance last year lack luster lower sale threat integrate pharmacy solution franchise business earning medtech major glancea few other top rank stock broader medical space report solid earning season be laboratory corporation america holding lh free report cheme corporation che free report intuitive surgical inc isrg free report intuitive surgical sport zack rank strong buy labcorp cheme carry zack rank see complete list today zack rank stock here labcorp report adjust earning share beating zack consensus estimate revenue be exceed zack consensus estimate cheme post adjust earning share outpace zack consensus estimate revenue come beating zack consensus estimate intuitive surgical report adjust earning share surpass zack consensus estimate revenue totale also surpass zack consensus estimate more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
256,BAX,heart earning season wasn informative enough thursday open bell also see economic headline read hit doorstep bulk durable good order core capital equipment advanced trade good course weekly initial jobless claim number be right now await impact figure regular day trading today jobless claim once again ratchete far year long range be indicative robust domestic labor market morning be lowest read ve see year neil first set foot moon mark precipitous drop claim slightly revise previous week continue claim also recede historic lows last week reach previous read also very low number fact haven see continue claim get anywhere week last summer dual hurricane hit mainland employment continue amaze astound durable good come tick higher expect march strong upward revision february however strip transportation cost march number plummet defense ex aircraft actually go negative core capital equipment order sank healthy february march shipment vs order ratio so appear new airplane order have completely cover economic metric last month trade balance surprised upside march lower analyst have be expect revise february be relative good news certainly better see earlier year tough get excited deficit close bell today expect quarterly earning result amazon amzn free report intel intc free report expedia expe free report other ahead today open be such huge amount earning report hit tape re go keep just few zack rank buy sell stock morning zack rank buy rate cme group cme free report top earning estimate penny share quarterly revenue narrowly miss zack consensus revenue be still year year company book time record order quarter more cme earning click here chicagoland medtech major baxter international bax free report also zack rank stock beat bottom line nearly cent share revenue surpass expect baxter strength be core renal care segment year year company also raise full year guidance more bax earning click here zack rank sell base southwest airline luv free report manage meet bottom line estimate cent share quarterly sale miss project prasm key airline metric fall guidance prasm be more luv earning click here finally company hsy free report zack rank ahead earning report also meet estimate share top revenue expectation post compare zack consensus trail quarters show average earning beat roughly more hsy earning click here
257,BAX,thursday april heart earning season wasn informative enough thursday open bell also see economic headline read hit doorstep bulk durable good order core capital equipment advanced trade good course weekly initial jobless claim number be right now await impact figure regular day trading today jobless claim once again ratchete far year long range be indicative robust domestic labor market morning be lowest read ve see year neil first set foot moon mark precipitous drop claim slightly revise previous week continue claim also recede historic lows last week reach previous read also very low number fact haven see continue claim get anywhere week last summer dual hurricane hit mainland employment continue amaze astound durable good come tick higher expect march strong upward revision february however strip transportation cost march number plummet defense ex aircraft actually go negative core capital equipment order sank healthy february march shipment vs order ratio so appear new airplane order have completely cover economic metric last month trade balance surprised upside march lower analyst have be expect revise february be relative good news certainly better see earlier year tough get excited deficit close bell today expect quarterly earning result amazon amzn free report intel intc free report expedia expe free report other ahead today open be such huge amount earning report hit tape re go keep just few zack rank buy sell stock morning zack rank buy rate cme group cme free report top earning estimate penny share quarterly revenue narrowly miss zack consensus revenue be still year year company book time record order quarter more cme earning click here chicagoland medtech major baxter international bax free report also zack rank stock beat bottom line nearly cent share revenue surpass expect baxter strength be core renal care segment year year company also raise full year guidance more bax earning click here zack rank sell base southwest airline luv free report manage meet bottom line estimate cent share quarterly sale miss project prasm key airline metric fall guidance prasm be more luv earning click here finally company hsy free report zack rank ahead earning report also meet estimate share top revenue expectation post compare zack consensus trail quarters show average earning beat roughly more hsy earning click here mark vickerysenior editorquestion comment article author click here medical stock buy nowzack name company poise ride medical breakthrough be target cure leukemia aids muscular dystrophy hemophilia other condition new product field be already generate substantial revenue even more wondrous treatment be pipeline early investor realize exceptional profit click here see stock
258,BAX,dentsply sirona inc xray free report report adjust earning share ep cent first quarter beating zack consensus estimate however metric fall year year net sale increase year year also figure surpass zack consensus estimate however metric decline constant currency cc exchange rate stock carry zack rank hold dentsply price movement have be unfavorable past year stock have lose compare unfavorably industry rise net sale exclude precious metal impact net sale company precious metal dental alloy product be used third party construct crown bridge material be subject risk fluctuation precious metal price avoid impact fluctuate price dentsply report net sale precious metal content show actual performance independent precious metal price volatility net sale segment be year year dentsply sirona inc price consensus ep surprise dentsply sirona inc price consensus ep surprise dentsply sirona inc quotesegmental business be organized report segment dental healthcare consumable technology dental healthcare segment comprise preventive restorative instrument endodontic laboratory dental product well consumable medical device product net sale improve segment decline cc technology equipment consist dental implant cad cam system imaging system treatment center orthodontic product metric increase segment year year basis however revenue be cc geographic detailsin quarter sale unite state fall year year revenue area fall cc net sale europe increase cc net sale rest world climb cc margin profit report quarter be year year however percentage revenue gross margin contract basis point bps operate income fall quarter operate margin quarter contract bps net revenue guidance management expect adjust earning share range previous range notably zack consensus estimate earning be currently peg share significantly higher management expectation revenue be project rise cc zack consensus estimate revenue be currently peg exit first quarter solid note beating zack consensus estimate count robust performance company flagship dental implant cad cam system imaging system treatment center orthodontic product platform hold considerable promise long haul emerge market asia pacific middle east offer healthy growth opportunity long term basis remain vastly untapped low dental product penetration company agreement medtech bigwig patterson company canada be likely drive sale dentsply recently witness rebound sale asia particularly japan strong growth russia flip side lower guidance be indicative loom concern company higher capital expenditure product development tough competition be expect exert pressure margin unfavorable foreign exchange rate integration risk be major headwind term earning medtech major glancea few better rank stock broader medical space report solid earning season be baxter international inc bax free report varian medical system inc var free report intuitive surgical inc isrg free report intuitive surgical varian sport zack rank strong buy baxter carry zack rank buy see complete list today zack rank stock here baxter report first quarter adjust earning share cent beat zack consensus estimate improve year quarter figure cent varian report second quarter fiscal adjust earning share beat zack consensus estimate adjust earning improve year year basis intuitive surgical report adjust earning share surpass zack consensus estimate revenue totale beat zack consensus estimate more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
259,BAX,idexx laboratory inc idxx free report report first quarter earning share ep year year report basis comparable constant exchange rate cer basis current zack consensus estimate adjust ep be peg cent company upside report ep be drive revenue growth solid operate margin gain impressive benefit tax reform revenue detailrevenue rise year year organic basis surpass zack consensus estimate upside be drive strong global gain companion animal group cag diagnostic recur revenue include double digit organic revenue gain consumable reference lab well strong acceptance rapid assay veterinary software service diagnostic imaging system further steady overall growth contribute top line idexx laboratory inc price consensus ep surprise idexx laboratory inc price consensus ep surprise idexx laboratory inc quotesegmental analysisidexx derive revenue operate segment cag water livestock poultry dairy lpd other first quarter cag revenue rise organically year year water segment revenue be prior year quarter organically lpd revenue grow organically revenue other segment rise organically marginsgross profit increase report quarter further gross margin expand basis point bps rise cost revenue sale marketing expense rise general administrative expense increase research development expense rise operate margin quarter improve bps financial positionidexx exit first quarter cash cash equivalent compare end net cash provide operate activity report quarter be compare year quarter guidanceidexx have reaffirm revenue outlook company have update revenue organic growth guidance previous however idexx continue expect revenue growth report basis zack consensus estimate revenue be peg guide range management also raise ep guidance earlier support continue operate margin expansion align long term goal update outlook represent ep growth report basis compare state previously zack consensus estimate adjust ep be peg takeidexx exit first quarter solid note moreover solid year year growth organic revenue raise ep guidance be encourage stellar performance be drive strong sale cag business companion animal market fundamental remain solid tremendous global runway growth management innovation base multus modality global strategy enabled enhance commercial capability accelerate recur cag diagnostic revenue growth moreover strong top line growth quarter be drive considerable contribution rest business segment zack rank other key picksidexx have zack rank buy few other top rank stock broader medical space have report solid result season be intuitive surgical isrg free report cheme corp che free report baxter international inc bax free report intuitive surgical sport zack rank strong buy cheme baxter carry zack rank see complete list today zack rank stock here intuitive surgical report first quarter adjust ep beat zack consensus estimate revenue totale also surpass consensus estimate cheme post first quarter adjust ep surpass zack consensus estimate revenue come beating zack consensus estimate baxter post first quarter adjust ep cent beat zack consensus estimate revenue also edge past zack consensus estimate today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
260,BAX,qiagen qgen free report first quarter adjust earning share ep come cent year year figure beat zack consensus estimate cent constant exchange rate cer company report adjust earning cent revenue detailnet sale actual rate first quarter grow year year basis cer also top line surpass zack consensus estimate region wise sale americas revenue grow cer revenue europe middle east africa increase further revenue asia pacific japan rise year year exclude business portfolio change sale top emerge market exhibit growth year year cer quarter review qiagen price consensus ep surprise qiagen price consensus ep surprise qiagen quotesegment detailqiagen primarily generate revenue molecular diagnostic apply testing pharma academia represent net sale respectively report quarter molecular diagnostic sale be cer sale derive apply testing remain flat cer pharma sale rise cer first quarter academia sale improve grow demand operational updateadjusted operate income exclude restructure charge increase year year first quarter also adjust operate margin expand basis point financial updateqiagen exit first quarter cash cash equivalent end net cash operate activity report quarter be year quarter moreover company report first quarter free cash flow compare year quarter qiagen announce new commitment january return shareholder open market repurchase return shareholder end notably share be repurchase frankfurt stock exchange guidanceqiagen have maintain guidance total net sale growth cer guidance also include decrease hpv test sale have adverse impact total net sale growth further sale second half acquisition stat dx be take account zack consensus estimate revenue be peg moreover adjust ep guidance have be reiterate cer consensus estimate earning be guide range further favorable currency movement be expect have positive impact net sale growth penny cent share adjust ep company also provide financial guidance second quarter net sale be expect grow cer adjust ep be expect cent cer underlie basis zack consensus estimate earning stand cent share coincide high end company guide range further favorable currency movement be expect have positive impact second quarter net sale growth penny adjust ep takeqiagen end first quarter solid note be impressed year year growth majority segment company also deliver strong performance respect operate margin meanwhile commitment return more shareholder increase repurchase reflect solid cash position expectation favorable currency movement also buoy optimism be also upbeat qiagen recent receipt fda pre market approval partosure notably test help assess risk spontaneous preterm birth patient symptom preterm labor further company plan market test unite state encouragingly note partosure test have already be successfully launch country europe middle east asia latin america flip side competitive landscape strong reliance collaboration remain major overhang zack rank key picksqiagen have zack rank hold few better rank stock broader medical space have report solid result season be intuitive surgical isrg free report cheme corp che free report baxter international inc bax free report intuitive surgical sport zack rank strong buy cheme baxter carry zack rank buy see complete list today zack rank stock here intuitive surgical report first quarter adjust ep beat zack consensus estimate revenue totale also surpass consensus estimate cheme post first quarter adjust ep surpass zack consensus estimate revenue come beating zack consensus estimate baxter post first quarter adjust ep cent beat zack consensus estimate revenue also edge past zack consensus estimate today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
261,BAX,cvs health corporation cvs free report first quarter adjust earning share ep surge year year exceed zack consensus estimate quarter adjust ep consider additional adjustment net interest expense propose aetna acquisition report ep continue operation come cent share surge year period net revenue first quarter increase year year however lag zack consensus estimate quarter detailspharmacy service revenue increase report quarter drive growth specialty claim volume higher pharmacy network volume well brand inflation be however partially offset increase generic dispense continue price compression cvs health corporation price consensus ep surprise cvs health corporation price consensus ep surprise cvs health corporation quotepharmacy network claim processed quarter climb day equivalent basis backed net new business growth also mail choice claim processed count be day equivalent basis continue adoption maintenance choice offering revenue cvs health retail ltc be year year accord company increase same store prescription day equivalent basis partnership pbm health plan inclusion number additional medicare part network year brand inflation be partially offset continue reimbursement pressure increase generic dispense rate front end same store sale increase year year drive basis pointsfavorable impactof shift sale associate easter holiday first quarter second quarter apart seasonal cough cold positively impact front store sale basis point approximately however be adversely affected soft customer traffic pharmacy same store sale increase report quarter increase pharmacy same store prescription volume be drive increase pharmacy same store prescription volume partially offset negative impact approximately basis point due recent generic introduction generic dispense rate proportion generic prescription total number prescription dispense increase approximately bps pharmacy service segment bps retail ltc segment gross profit improve accordingly gross margin expand bps total operate margin quarter expand bps cvs health exit first quarter cash cash equivalent short term investment compare end end first quarter net cash used operate activity be compare year outlookcvs health currently expect deliver full year adjust ep band also have reiterate adjust operate profit growth guidance range company have also provide guidance second quarter cvs health expect deliver adjust ep range apart adjust operate profit growth be expect range flat takecvs health end first quarter mixed note earning be ahead zack consensus estimate revenue remain consensus number however year year growth top line be drive strong pharmacy service segment benefit upside specialty service also strong year year retail ltc comparison be encourage company currently be move forward completion aetna deal zack rank key pickscvs health have zack rank hold few better rank stock broader medical sector report solid result season be intuitive surgical isrg free report cheme corp che free report baxter international inc bax free report intuitive surgical sport zack rank strong buy cheme baxter carry zack rank buy see complete list today zack rank stock here intuitive surgical report first quarter adjust earning share ep beat zack consensus estimate revenue also surpass consensus estimate cheme post first quarter adjust ep surpass zack consensus estimate revenue come beating zack consensus estimate baxter post first quarter adjust ep cent beat zack consensus estimate revenue also edge past zack consensus estimate look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
262,BAX,maintain streak positive earning surprise corporation abc free report post adjust earning share second quarter fiscal beating zack consensus estimate improve year year upside be attribute strong growth pharmaceutical distribution segment world courier business revenue improve almost report quarter figure surpass zack consensus estimate stock have zack rank hold segmental distribution segmentrevenue segment be year year basis operate income be year year pharmaceutical distribution witness favorable result quarter courtesy ofsolid expansion revenue gross profit include acquisition however lower sale pharmedium operate loss profarma unit partially offset growth corporation price consensus ep surprise corporation price consensus ep surprise corporation quote other segment include consult service abcs world courier mwi veterinary supply revenue segment come year year growth segment be drive consolidation specialty joint venture brazil revenue mwi abcs growth canadian operation world courier business however operate income segment be quarter year year downside be primarily cause lackluster performance abcs lash group margin analysisin quarter review register gross profit year year basis percentage revenue gross margin be basis point bps prior year quarter increase gross profit pharmaceutical distribution service boost company margin second quarter operate expense be year year upside be cause buyout duplicate cost implementation new information technology system register operate income year year percentage revenue operate margin contract bps guidance fiscal expect revenue growth range year year basis notably zack consensus estimate revenue be currently peg year year company expect adjust earning share range notably zack consensus estimate earning be currently peg share fall guidance expect adjust operate expense increase range previous range adjust operate income growth be expect be flat year year end second quarter fiscal solid note strong growth pharmaceutical distribution segment strong guidance instill investor optimism stock further joint venture brazil strength mwi unit abcs growth canadian operation prospect world courier business be key positive moment further recent takeover largest independent wholesaler unite state be also positive flip side sluggishness abcs lash group be concern face headwind thank slowdown hepatitis revenue conversion brand drug lower price generic further temporary slowdown pharmedium growth be expect mar company bottom line regard company face lower expect production pharmedium facility earning medtech major glancea few better rank stock broader medical space report solid earning season be baxter international inc bax free report varian medical system inc var free report intuitive surgical inc isrg free report intuitive surgical varian sport zack rank strong buy baxter carry zack rank buy see complete list today zack rank stock here intuitive surgical report adjust earning share surpass zack consensus estimate revenue totale beat zack consensus estimate varian report second quarter fiscal adjust earning share beat zack consensus estimate adjust earning improve year year basis baxter report first quarter adjust earning share cent beat zack consensus estimate improve year quarter figure cent look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
263,BAX,astute investor always opt plan be likely yield high return irrespective market condition efficiency level measure company capability transform available input output be often consider important parameter used gauge company potential rake handsome return company favorable efficiency level be expect provide stellar return be believe be positively correlated price performance key ratio identify become difficult measure efficiency level company be reason consider popular efficiency ratio select stock efficiency ratio be inventory turnover ratio month cost good sell cog quarter average inventory be consider most popular efficiency ratio indicate company ability maintain suitable inventory position high value indicate company have relatively low level inventory compare cog low value show company be face decline sale result excess inventory receivables turnover be ratio month sale quarter average receivables show company potential extend credit collect debt term credit high receivables turnover ratio account receivable turnover ratio debtor turnover ratio be desirable show company be capable collect account receivables have quality customer asset utilization ratio indicate company capability convert asset output be thus widely know measure efficiency level be calculate divide total sale past month last quarter average total asset ratio high asset utilization indicate company be efficient operate margin efficiency measure be ratio operate income past month sale same period measure company ability control operate expense hence high value ratio indicate company manage operate expense more efficiently peer screening parametersin addition mentioned ratio have add favorable zack rank strong buy buy screen objective make strategy more profitable see complete list today zack rank stock here inventory turnover receivables turnover asset utilization operate margin greater industry average value ratio higher industry average indicate efficiency level company be higher peer use few criterium have narrow universe stock only here be stock make screen marine product corporation mpx free report design manufacture sell recreational fiberglas powerboat sportboat deckboat cruiser jet boat sport fishing market worldwide company hold zack rank have average quarter positive earning surprise nutrisystem inc ntri free report provide weight management product service woman man unite state company zack rank have average quarter positive earning surprise exelixis inc exel free report engage discovery development new medicine enhance care outcome person cancer zack rank company have average quarter positive earning surprise see complete list today zack rank stock here illumina inc ilmn free report provide sequence array base solution genetic analysis company sport zack rank have average quarter positive earning surprise baxter international inc bax free report provide portfolio healthcare product company have zack rank have average quarter positive earning surprise get rest stock list signing now week free trial research wizard start used screen own trading further also create own strategy test first take investment plunge research wizard be great place begin easy use everything be plain language very intuitive start research wizard trial today next time read economic report open research wizard plug find see gem come click here sign free trial research wizard today disclosure officer director employee zack investment research own have sell short security hold long short position option be mentioned material affiliated investment advisory firm own have sell short security hold long short position option be mentioned material disclosure performance information zack portfolio strategy be available https www zack com performancezack restaurant recommendation addition dine special place feast stock share zack special report spotlight recent ipos watch stock offer immediate promise boom sector download free
264,BAX,third quarter earning season have commence encourage note most sector release participant total market cap october latest earning preview total earning member rise higher revenue member line release quarterly result week be decidedly bullish equity market be gradually demonstrate sequential improvement medical broader sector zack sector be expect put impressive show quarter expect earning growth rate sector be revenue growth comparison report earning growth rate second quarter be quite impressive revenue growth medical product political medical product space broader medical universe have be precarious game republican day courtesy president trump repeat failure repeal replace obamacare however major medtech player have be pin hope abolition infamous medical device sale tax elimination tax be far be achieve consider tax issue investor interested medical product space likely keenly await earning report medtech bigwig baxter international inc bax free report varian medical var free report thermo fisher scientific inc tmo free report laboratory corporation america holding lh free report notably company be expect release earning result oct third quarter baxter anticipate sale growth constant currency cc adjust earning share be forecast range cent versus year figure cent believe company solid sale medical product segment be key driver third quarter notably zack consensus estimate segment stand year year basis read more baxter international earning store solid prospect quantitative model do not conclusively show beat company give combination zack rank buy earning esp be model stock need have positive earning esp zack rank strong buy hold beat earning baxter international inc price consensus baxter international inc price consensus baxter international inc quotewe be upbeat varian medical oncology business be estimate account company total revenue fourth quarter fiscal company have be address tier mid tier market edge truebeam vitalbeam product have also be winning international contract oncology space fourth quarter fiscal varian expect adjust earning share range revenue be likely increase year year basis read more varian medical earning be surprise store contrary zack consensus estimate varian medical revenue stand year year consensus estimate earning be peg year year proven model do not predict earning beat company season thank earning esp zack rank see complete list today zack rank stock here varian medical system inc price consensus varian medical system inc price consensus varian medical system inc quotelaboratory corporation also know labcorp continue face softness covance drug development business third quarter however be upbeat company expectation improvement covance drug development arm start second half be reflect third quarter performance read more card labcorp earning season zack consensus estimate labcorp third quarter revenue stand year year labcorp be concern cms center medicare medicaid service proposal related protect access medicare act pama believe reimbursement pressure affect company performance third quarter well fact proven model do not predict earning beat company season be labcorp have zack rank earning esp uncover best stock buy sell re report earning esp filter laboratory corporation america holding price consensus laboratory corporation america holding price consensus laboratory corporation america holding quotethermo fisher be gear solid third quarter result primarily drive analytical instrument segmental growth third quarter company expect see positive impact electron microscopy business well strong volume leverage productivity zack consensus estimate analytical instrument operate income be peg line last quarter report number total revenue estimate segment be impressive level read more expect thermo fisher earning quantitative model predict earning beat thermo fisher stock currently have zack rank earning esp zack consensus estimate revenue be third quarter year year basis thermo fisher scientific inc price consensus thermo fisher scientific inc price consensus thermo fisher scientific inc quotetoday stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
265,BAX,baxter international inc bax free report be schedule report third quarter earning oct open bell last report quarter company deliver positive earning surprise take quarter average let see thing be shape prior release factor playwe be encourage company guidance third quarter full year third quarter baxter anticipate sale growth constant currency adjust earning share be forecast range cent versus year figure cent also full year company project earning band share continue operation special item full year earning late baxter international have accelerate pace acquisition strategic collaboration enhance product portfolio thereby open significant long term opportunity also several recent fda approval be likely drive growth yet be report third quarter company estimate revision trend be also encourage current year baxter international witness upward estimate revision movement opposite direction last month however lower sale threat company integrate pharmacy solution franchise third quarter decline sale be expect impact top line low single digit also foray group purchasing organization gpos unite state intensify competition company earning whispersour quantitative model doesn point earning beat quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp earning esp baxter international be be most accurate estimate zack consensus estimate be peg cent uncover best stock buy sell re report earning esp filter zack rank baxter international carry zack rank increase predictive power esp however company esp make surprise prediction difficult caution stock zack rank sell rate go earning announcement especially company be see negative estimate revision baxter international inc price ep surprise baxter international inc price ep surprise baxter international inc quotestock considerhere be company consider model show have right combination element post earning beat upcoming quarter abbott free report have earning esp carry zack rank see complete list today zack rank stock here align technology inc algn free report have earning esp carry zack rank henry schein inc hsic free report have earning esp carry zack rank wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
266,BAX,idexx laboratory inc idxx free report be schedule report first quarter result open bell last quarter company deliver positive earning surprise notably stock have outperformed zack consensus estimate precede quarters average beat be let take look thing be shape prior announcement key catalyst idexx be expect continue gain momentum first quarter courtesy strong global rise companion animal group cag diagnostic revenue last time upside be drive consistent strong double digit growth reference lab consumable owing high single digit increase register rapid assay sale management vouch trend be retain further idexx laboratory inc price ep surprise idexx laboratory inc price ep surprise idexx laboratory inc quote be also upbeat idexx enhance commercial capability unite state maintain recur revenue growth cag diagnostic expect first quarter result reflect rise productivity new sale representative establish fresh customer relationship also anticipate company report exceptional customer retention rate reference lab well instrument consumable unite state worldwide zack consensus estimate cag diagnostic revenue represent improvement last report quarter notably idexx revenue growth projection quarter be report highlight organic gain overall zack consensus estimate total quarterly revenue be peg other factor predict influence idexx first quarter result be pin considerable hope progress water business lie growth trajectory late backed encourage test result unite state well benefit draw global go direct initiative moreover business witness organic growth last quarter management also eye gain favorable regulatory development pertain wastewater unite state drink water europe company earlier state be perfectly track continue high single digit organic revenue boost business consensus mark water revenue stand yet be report quarter idexx carry expand global footprint have be significantly draw advantage bountiful opportunity emerge companion animal diagnostic market further management consistent share buyback underscore robust free cash flow reserve believe outcome endeavor bear reflection first quarter conference call flip side foreign currency fluctuation be major headwind concern be company heavy reliance third party distributor purchasing dynamic distributor leave significant impact company sale instrument consumable well rapid assay product moreover idexx have be witness rise operate expense due increase head count higher investment portfolio development expansion unite state internationally additionally competitive landscape domestic overseas market weigh idexx performance thus struggle gain market traction be drag first quarter result here quantitative model predict proven zack model company favorable zack rank strong buy buy hold have higher chance beating estimate also have positive earning esp idexx have zack rank increase predictive power esp however company earning esp leave surprise prediction inconclusive caution sell rate stock go earning announcement especially company be see negative estimate revision uncover best stock buy sell re report earning esp filter stock worth lookhere be few medical stock worth consider right combination element surpass estimate time baxter international inc bax free report have earning esp be zack rank player laboratory corporation america holding lh free report have earning esp zack rank stryker corporation syk free report have earning esp be rank player see complete list today zack rank stock here make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
267,BAX,haemonetic corporation hae free report report adjust earning share ep cent fourth quarter fiscal rise year year bottom line however be par zack consensus estimate report basis haemonetic post net earning cent share net loss cent year fiscal adjust ep come prior fiscal total revenuesrevenue be year year constant exchange rate cer report quarter top line also exceed zack consensus estimate year year growth be backed strong result north america improve international result fiscal revenue totale prior fiscal cer haemonetic corporation price consensus ep surprise haemonetic corporation price consensus ep surprise haemonetic corporation quoterevenue product report operate result business franchise plasma haemostasis management cell process blood center plasma report revenue total revenue be year year cer revenue bloodcenter total revenue decline cer hemostasis management franchise revenue total revenue rise cer revenue cell process be cer total revenue fourth quarter adjust gross margin be basis point bps year year favorable mix currency reduce cash inventory charge adjust operate income be quarter show decline year year adjust operate margin contract bps year year quarter review financial exit fiscal cash cash equivalent compare fiscal end company generate operate cash flow end fiscal compare fiscal end fiscal company report free cash flow transformation restructure cost vcc capital expenditure compare year capital expenditure have be record year lower fiscal issue fiscal revenue guidance company expect full year revenue growth plasma revenue growth be expect band hospital revenue be expect rise blood center revenue be likely decline zack consensus estimate revenue be peg company expect adjust ep band zack consensus estimate be guide range takehaemonetic exit fourth quarter fiscal mixed note continue momentum new business generation geographical expansion have help company deliver strong result however be disappoint company sluggish blood center business moderate overall growth encourage progress plasma hospital company also seem be upbeat receipt major regulatory clearance plasma business drive top line fiscal also company strong cash position boost investor confidence zack rank key pickshaemonetic have zack rank hold few better rank stock broader medical space have report solid result season be intuitive surgical isrg free report cheme corporation che free report baxter international inc bax free report intuitive surgical sport zack rank strong buy cheme baxter carry zack rank buy see complete list today zack rank stock here intuitive surgical report first quarter adjust ep beat zack consensus estimate revenue totale also surpass consensus estimate cheme post first quarter adjust ep surpass zack consensus estimate revenue come beating zack consensus estimate baxter post first quarter adjust ep cent beat zack consensus estimate revenue also edge past zack consensus estimate wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
268,BAX,baxter international inc bax free report have be healthy growth trajectory late strategic acquisition product development bullish outlook have be provide company competitive edge medtech solid prospect zack rank buy stock be attractive pick moment past month share baxter have grow compare industry increase current level be also higher index rise stock have market cap company next year earning growth rate be also favorable compare industry rally company deliver positive earning surprise last quarters also have long term expect earning growth rate baxter have impressive growth score well growth style score highlight vital metric company financial obtain clearer picture quality sustainability growth research show stock style score combine solid zack rank strong buy hold offer best investment opportunity let find recent positive trend be sustainable solid earningsbaxter end first quarter solid note beating consensus mark earning revenue adjust earning come cent share cent prior year quarter revenue be year year constant currency cc geographically sale inched year year meanwhile international sale increase year year company deliver strong result back solid performance core renaland pharmaceutical business renal unit sale increase year year basis pharmaceutical sale rise raise guidancebuoy solid first quarter earning result baxter lift financial outlook second quarter company expect sale growth approximately cc company expect adjust earning continue operation band cent also project sale growth cc anticipate adjust earning share continue operation range full year strategic buyout have be long help baxter gain market traction recently company complete consolidation thrombin topical preveleak surgical sealant product line mallinckrodt deal be expect widen baxter surgical portfolio hemostat sealant transaction have not be accretive first quarter earning company still estimate be so buyout india base claris injectable limit have provide baxter robust portfolio generic injectable molecule currently approve unite state upward estimate revision company estimate revision trend current year have be positive past couple month analyst moved north none opposite direction earning estimate have be raise same time frame other key picksother top rank stock broader medical sector include intuitive surgical isrg free report illumina inc ilmn free report amedisys inc am free report intuitive surgical illumina sport zack rank strong buy amedisys carry zack rank see complete list today zack rank stock here intuitive surgical have expect long term earning growth rate illumina expect long term earning growth amedisys project long term earning growth make fortune shift electric car here stock idea consider much petroleum year lithium power soon shake world create millionaire reshape geo politic soon electric vehicle evs be cheaper gas guzzler be already reach mile single charge battery price plummet charge station set multiply company stand stock buy accord zack research not think see ticker free
269,BAX,first quarter earning season have take center stage member elite index have report financial number so far latest earning preview performance index participant indicate increase total earning higher revenue beat ratio have be impressive well company surpass bottom line expectation beating top line mark medical sector zack sector have put stellar show so far sector be expect rise revenue growth earning season await medical product stock medical product industry have be gain prominence late courtesy increase life expectancy rate age population change market dynamic use technologically superior device fact industry be not dependent just medical advancement solely nowadays rely technological advancement microelectronic instrumentation biotechnology software development industry well view trend investor sentiment have be solid medical product company fact industry have return compare rally year time further bipartisan suspension medical device tax have give significant boost sector first quarter meanwhile medtech bigwig baxter international bax free report ecolab ecl free report have report upbeat first quarter number company have beaten consensus estimate count strong outlook now let take look company be set release result becton dickinson company bdx free report second quarter fiscal result be likely show strong outcome core bd medical segment management steady growth sub segment medication procedural solution pharmaceutical system be expect be growth propeller however improvement other segment lead improve result read more bd medical drive becton dickinson earning zack consensus estimate second quarter earning be peg reflect year year growth bd have earning esp zack rank hold zack quantitative model stock advantageous combination solid zack rank strong buy buy positive earning esp have higher chance beating estimate uncover best stock buy sell re report earning esp filterbecton dickinson company price ep surprise becton dickinson company price ep surprise becton dickinson company quotecardinal health inc cah free report third quarter fiscal result be likely reflect decline core pharmaceutical segment growth other segment be likely make decline partially however raise guidance buoy optimism furthermore medical segment be expect post solid number medical glove unit result witness softness quarter be report read more store cardinal health earning zack consensus estimate third quarter earning be peg reflect decline year year company have earning esp zack rank see complete list today zack rank stock here cardinal health inc price ep surprise cardinal health inc price ep surprise cardinal health inc quoteteleflex incorporate tfx free report first quarter earning be expect be strong back vascular unit north america emea sale be also likely be high zack consensus estimate earning be pin indicate year year growth teleflex have earning esp zack rank teleflex incorporate price ep surprise teleflex incorporate price ep surprise teleflex incorporate quoteabiom inc abmd free report be likely see strong fourth quarter fiscal back flagship product line impella notably last report quarter impella revenue rise internationally impella revenue increase whopping plethora regulatory approval impella impella cp be encourage moreover increase guidance buoy optimism zack consensus estimate earning be cent reflect year year growth company have earning esp zack rank abiom inc price ep surprise abiom inc price ep surprise abiom inc quotelook stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
270,BAX,masimo corporation masi free report report adjust earning cent share first quarter outperform zack consensus estimate cent bottom line improve year quarter figure cent stock have zack rank buy revenue improve year quarter beat zack consensus estimate segmental analysisproduct revenue product revenue deliver strong quarter double digit growth product revenue be quarter year year product revenue also witness impressive growth overseas market new product include nomoline capnography rainbow noninvasive blood constituent monitoring sedline brain function monitoring organ oximetry contribute result company worldwide direct product revenue total product revenue increase first quarter oem sale total product revenue increase first quarter notably january masimo receive ce mark rd rainbow lite set sensor enable use oxygen reserve index rpvi management be improve rainbow base version pvi be less costly rainbow sensor masimo corporation price consensus ep surprise masimo corporation price consensus ep surprise masimo corporation quote royalty other revenuesfirst quarter royalty other revenue fall prior year quarter margin analysistotal gross profit first quarter be year year gross margin be net revenue basis point bps year year product gross margin expand bps net revenue revenue be estimate previous projection zack consensus estimate revenue be peg significantly lower guide figure total product revenue be estimate previously issue guidance royalty other revenue be estimate adjust earning share be expect previous guidance zack consensus estimate adjust earning significantly lower guide estimate exit first quarter strong note beating consensus mark count solid guidance raise investor optimism stock company have be gain strong segmental revenue improve product revenue margin expand product portfolio wider adoption invasive patient monitoring technology be major catalyst masimo set pulse oximetry business represent considerable growth opportunity international market moreover masimo receive noteworthy ce fda clearance quarter include clearance domestic use new rad telehealth monitor way audio video capability flip side lackluster performance royalty other revenue unit be concern furthermore company face fierce competition oem distributor medical device bigwig mar top line long haul earning medtech major glancea few other top rank stock broader medical space report solid earning season be intuitive surgical inc isrg free report varian medical system inc var free report baxter international inc bax free report intuitive surgical varian sport zack rank strong buy baxter carry zack rank buy see complete list today zack rank stock here intuitive surgical report adjust earning share surpass zack consensus estimate revenue totale beat zack consensus estimate varian report second quarter fiscal adjust earning share beat zack consensus estimate adjust earning improve year year basis baxter report first quarter adjust earning share cent beat zack consensus estimate improve year quarter figure cent today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
271,BAX,share price deerfield il base baxter international inc bax free report scale new week high share sep then close bit lower company have gain past month much better rise past month zack rank hold stock have steadily outshined broader industry stock price have climb substantially higher broader industry gain stock have market cap almost also company estimate revision trend current quarter be favorable past month estimate have moved downward revision magnitude estimate revision same time period increase cent share company also have quarter average positive earning surprise baxter international inc price consensus baxter international inc price consensus baxter international inc quotegrowth catalystslong term outlook upbeat buoy stellar growth earning sale second quarter company raise long term outlook baxter estimate sale growth approximately compound annual basis notably adjust operate margin full year be expect be approximately revenue much previously issue guidance baxter expect full year adjust diluted earning band share fact baxter raise full year expectation sale growth approximately cc constant currency adjust earning share continue operation be forecast range third quarter baxter estimate sale rise cc adjust earning share be project cent bracket broad product spectrum latest week high come back company impressive product line baxter have exciting product portfolio improve exist product new product development namely more convenient kidney dialysis solution regenerative tissue product next generation sigma spectrum infusion pump last quarter baxter launch new version ak hd system platform offer way connectivity capability meet need potential patient favorable tiding regulatory front be well regulatory front baxter last quarter company receive clearance regulatory authority regard propose acquisition claris injectable additionally fda approval new premixed injectable be key catalyst company new product home pd technology also get fda nod second quarter platform leverage baxter flagship amia automate peritoneal dialysis apd system sharesource telehealth platform recently baxter achieve regulatory milestone advanced dialysis technology good news be company receive significant guidance fda clarify regulatory pathway home peritoneal dialysis pd solution system improve patient access same key picksa few better rank stock broader medical sector be edward lifescience corp ew free report idexx laboratory inc idxx free report cogentix medical inc notably edward lifescience sport zack rank strong buy idexx laboratory cogentix medical have zack rank buy see complete list today zack rank stock here edward lifescience deliver average earning beat trail quarters company have long term expect earning growth rate idexx laboratory deliver average earning beat trail quarters have long term expect earning growth rate cogentix medical register positive earning surprise last quarter stock represent stellar return last year trade profit big league trump policy stock spark interest look company prime make substantial gain washington change course today zack reveal ticker benefit new trend streamline drug approval tariff lower taxe higher interest rate spending surge defense infrastructure see buy recommendation now
272,BAX,nxstage medical inc nxtm free report recently announce subsidiary nxstage kidney care be partner dialyze direct support need patient need site skilled nursing facility snf dialysis treatment ohio initiative reduce transportation cost re hospitalization rate provide dialysis care site nxstage now leverage system platform dialyze direct unique model treat geriatric snf patient end stage renal disease esrd site dialysis snf be hassle free counter organizational operational challenge dialysis center care facility nxstage system help avoid hassle regular transportation patient site dialysis center almost thrice week result site dialysis snf have be significantly favorable patient have witness reduction mortality hospitalization furthermore patient higher flexibility be eligible rehabilitation therapy social activity notably base dialyze direct provide innovative staff assist home hemodialysis service geriatric patient skilled nursing facility snf future trendsdata market market reveal global hemodialysis peritoneal dialysis market be expect reach worth multiply cagr management niche market especially snf space have substantial opportunity improve overall cost care furthermore increase rate esrd case patient enhance probability nxstage outperformance niche space term regard major player hemodialysis market include davita healthcare partner inc dva free report baxter international inc bax free report nxstage get acquiredearlier month german dialysis provider fresenius medical care fms free report sign agreement acquire outstanding share nxstage share transaction have be value be subject close approval nxstage stockholder other customary condition note nxstage have be gain prominence market late product nxstage pureflow dialysis preparation system nx connect health nxstage system zack minute stock pick secretsince zack system have more double average gain year compound rebalance exclusive fee turn thousand million dollar here something even more remarkable master proven system go single class seminar then apply portfolio little minute month learn secret
273,BAX,baxter international inc bax free report recently announce launch comprehensive asset tracking solution devicevue solution be used company proprietary pump system sigma spectrum infusion system aid clinician biomedical engineer quickly find unused pump view location status datum pc ipad iphone be bullish development provide edge sigma spectrum compare other smart pump market stock performance solidover past month baxter have gain compare favorably broader industry increase moreover current level be higher gain same time frame baxter be poise gain expand product portfolio increase penetration international market accretive acquisition be also key catalyst long haul company long term expect earning growth rate hold promise regard baxter have diverse portfolio improve exist product new product development namely more convenient kidney dialysis solution regenerative tissue product next generation sigma spectrum infusion pump recently notably deerfield il base company launch new version ak hd system platform offer way connectivity capability meet need potential patient baxter be medical technology company engage principally development manufacture sale medical device instrument system reagent company focus product launch be significant catalyst view additionally expansion plan especially emerge overseas market acquisition drive strategy hold considerable promise flipside lower demand healthcare product intense competition significant exposure foreign exchange volatility higher debt level major headwind zack rank stock considerbaxter have zack rank hold better rank medical stock include sonova hold sonvy free report idexx laboratory inc idxx free report cogentix medical inc company hold zack rank buy see complete list today zack rank strong buy stock here sonova represent solid return last year company have long term expect earning growth rate idexx laboratory have average earning beat trail quarters have long term expect earning growth rate cogentix medical come positive earning surprise last quarter stock represent stellar return last year today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
274,BAX,integer holding corporation itgr free report post first quarter adjust earning share cent share miss zack consensus estimate however earning rise year year revenue totale beating zack consensus estimate revenue also increase year year basis organically share integer holding have rally industry decline year time integer holding currently carry zack rank hold integer holding corporation price consensus ep surprise integer holding corporation price consensus ep surprise integer holding corporation quotesegment detailscardio segment continue see strong top line growth revenue come year year organically upside be drive continue strong demand integer own product rise demand contract manufacturing component advanced surgical orthopedic portable medicalin quarter review segment post revenue prior year quarter organically management growth be drive increase portable medical product spinal implant continue ramp new product well accelerate sale customer part inventory build program notably integer holding have plan divestiture segment product line medplast llc cardiac segment rake revenue worth year quarter organically management neuromodulation market remain key driver long term growth product line total medical sale account organic year year basis marginsgross profit quarter come year year gross margin be basis point bps company operate income totale year year basis operate margin be bps upside be attribute company reduction operate expense totale adjust ebitda increase financial holding exit quarter cash flow operation translate free cash flow notably report quarter company paid debt guidancebuoy stellar first quarter integer holding have post impressive guidance company expect adjust earning share reflect growth notably zack consensus estimate be peg range revenue be anticipate indicate growth zack consensus estimate be pin be give range company expect cash flow operation free cash flow company further expect pay debt adjust ebitda company have raise expect range approximately full year adjust effective tax rate be expect holding have strong start high organic year year growth earning revenue cardio vascular arm deserve special mention here strategic divestment advanced surgical orthopedic portable medical wing medplast llc be expect prove accretive quarters ahead company also have multus year plan long term development raise guidance contract operate expense clear debt be other major positive however recent loss major customer intense competition niche space raise concern key picksa few better rank stock broader medical space have report solid result season be intuitive surgical isrg free report cheme corporation che free report baxter international inc bax free report intuitive surgical sport zack rank strong buy cheme baxter carry zack rank buy see complete list today zack rank stock here intuitive surgical report first quarter adjust earning share beat zack consensus estimate revenue totale also surpass consensus estimate cheme post first quarter adjust earning share surpass zack consensus estimate revenue come beating zack consensus estimate baxter post first quarter adjust earning share cent beat zack consensus estimate revenue also edge past zack consensus estimate today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
275,BAX,look broad exposure large cap blend segment equity market consider spdr russell low volatility focus etf onev free report passively manage exchange trade fund launch fund be sponsored state street global advisor have amassed asset make average size etfs attempt match large cap blend segment equity market large cap blendlarge cap company usually have market capitalization consider more stable option large cap company boast more predictable cash flow be less volatile mid small cap counterpart typically hold combination growth value stock blend etfs also demonstrate quality see value growth investment costswhen consider etf total return expense ratio be important factor cheaper fund significantly outperform more expensive counterpart long term other factor remain equal annual operate expense etf be make cheaper product space have month trail dividend yield sector exposure top holdingsit be important delve etf holding investing many upside kind fund diversify exposure minimize single stock risk most etfs be very transparent product disclose holding daily basis etf have heaviest allocation consumer discretionary sector portfolio industrial financial round top look individual holding sysco corporation syy free report account total asset follow baxter international inc bax free report equity residential eqr free report top holding account total asset management performance riskonev seek match performance russell low volatility focuse factor index fee expense russell low volatility focuse factor index reflect performance segment large capitalization equity security demonstrate combination core factor high value high quality low size characteristic focus factor comprise low volatility characteristic etf have lose so far year be last year past week period have trade holding effectively diversify company specific risk russell low volatility focus etf carry zack etf rank hold be base expect asset class return expense ratio momentum other factor thus onev be good option seek exposure large cap etfs area market investor also want consider other etf option space ishare core etf ivv free report spdr etf spy free report track similar index ishare core etf have asset spdr etf have ivv have expense ratio spy charge bottom lineretail institutional investor increasingly turn passively manage etfs offer low cost transparency flexibility tax efficiency kind fund be also excellent vehicle long term investor learn more product other etfs screen product match investment objective read article latest development etf investing universe please visit zack etf center
276,BAX,nuvasive inc nuva free report report first quarter adjust earning share ep cent reflect rise year quarter figure however miss zack consensus estimate cent solid contribution international business strong case volume growth hardware businessle year year improvement earning include time item company report first quarter net loss cent share net income cent share year rise litigation liability associate company lawsuit former sale agent lead net loss revenue report quarter come constant exchange rate cer year figure be par zack consensus estimate report quarter revenue spinal hardware business increase lead rise case volume roughly contribution product launch xlif modulus tlx reline small stature cohere further continue growth reline posterior fixation system drive top line however rise pricing pressure product mix have offset case volume growth revenue growth surgical support business be roughly flat first quarter primarily due weakness biologic portfolio persistent slowdown service business case volume growth however international business record growth cer report basis sixth consecutive time solid contribution key geography nuvasive inc price consensus ep surprise nuvasive inc price consensus ep surprise nuvasive inc quotein report quarter be increase cost good sell exclude amortization intangible asset expense accordingly gross profit decline moreover company report basis point bps year year contraction gross margin sale marketing administrative expense go research development expense rise nuvasive record adjust operate income report quarter reflect decline year quarter adjust operate margin contract bps quarter company exit first quarter cash cash equivalent end outlooknuvasive reiterate guidance guidance have be adjust recent buyout safepassage full year benefit tax reform suspension medical device tax company expect revenue range reflect organic growth moreover report basis company expect revenue growth inclusive recently acquire safepassage zack consensus estimate be guide range foreign exchange rate be expect prove favorable nuvasive fact company expect foreign exchange rate have positive impact almost year compare state previously nuvasive continue expect full year adjust ep current zack consensus estimate fall guide range additionally adjust operate margin year be expect have disappointing first quarter thank softness business however solid show international business more growth sixth consecutive quarter buoy optimism further management believe addition lateral single position surgery expand lateral procedural solution offering enhancement advanced material science portfolio help company improve performance rest year moreover initial launch surgical intelligence platform help nuvasive strengthen position company also expect see bps improvement gross margin second half result focus house manufacturing facility regard company be also upbeat increase production ohio manufacturing expectation higher adjust operate profit margin reflect focus operational efficiency house manufacturing facility well moreover be upbeat recently complete buyout safepassage contribute revenue growth first quarter zack rank key picksnuvasive have zack rank sell few better rank stock broader medical sector report solid result season be intuitive surgical isrg free report cheme corporation che free report baxter international inc bax free report intuitive surgical sport zack rank strong buy cheme baxter carry zack rank buy see complete list today zack rank stock here intuitive surgical report first quarter adjust ep beat zack consensus estimate revenue totale also surpass consensus estimate cheme post first quarter adjust ep steering past zack consensus estimate revenue come beating zack consensus estimate baxter post first quarter adjust ep cent beat zack consensus estimate revenue also edge past zack consensus estimate look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
277,BAX,penumbra inc pen free report report first quarter adjust earning share cent adjust loss cent year quarter moreover bottom line remain well ahead zack consensus estimate loss cent total revenue report quarter surge year year constant exchange rate cer exceed zack consensus estimate geographically first quarter revenue unite state represent total sale gross year period meanwhile international sale total sale improve year year cer penumbra inc price consensus ep surprise penumbra inc price consensus ep surprise penumbra inc quote product category revenue neuro product grow cer quarter review revenue peripheral vascular product business rise first quarter reflect increase cer year year operational updatepenumbra first quarter gross margin be represent basis point bps contraction year year however gross profit climb research development expense totale sale general administrative expense amount year year operate profit report quarter come versus operate loss prior year quarter financial update penumbra exit first quarter cash cash equivalent compare end outlookpenumbra have raise guidance revenue company now expect total revenue range compare earlier provide projection zack consensus estimate lag guide range takepenumbra exit first quarter better expect result year year comparison earning be favorable moreover company witness strong growth geography well product line company be focuse product innovation research development flip side escalate cost expense be weigh bottom line penumbra be active player fast grow interventional therapy space fact company product primarily cater unmet clinical need major market neuro peripheral vascular zack rank key pickspenumbra have zack rank hold few better rank stock broader medical space have report solid financial figure report cycle be intuitive surgical isrg free report cheme corp che free report baxter international inc bax free report intuitive surgical sport zack rank strong buy cheme baxter carry zack rank buy see complete list today zack rank stock here intuitive surgical report first quarter adjust ep beat zack consensus estimate revenue totale also surpass consensus estimate cheme post first quarter adjust ep surpass zack consensus estimate revenue come beating zack consensus estimate baxter post first quarter adjust ep cent outpaced zack consensus estimate revenue also edge past zack consensus estimate hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
278,BAX,pure play growth value investor have thing common strategize long term investment yet approach growth goal make totally distinct other come stock pick course financial plan execution value investor miss chance bet stock have bright long term prospect growth investor often end investing expensive stock consequently investor often wonder resort distinctive strategy follow approach combine best investing track oracle omaha past few decade gradual shift be pure play value investor garp growth reasonable price investor give answer regard take note strategic mingle growth value investing principle give mixed investing strategy be get popular pass day garper look be stock be somewhat undervalue have solid sustainable growth potential investopedium here lie importance not so popular fundamental metric price earning growth peg ratio be categorize value investing strategy follow principle growth value investing peg ratio be defined price earning earning growth rateit relate stock ratio future earning growth rate alone only give idea stock be trading discount peg add growth element help find stock have solid future potential lower peg ratio preferably less be always better garp investor say example stock ratio be expect long term growth rate be company peg come ratio indicate undervaluation future growth potential unfortunately ratio be often neglected due investor limitation calculate future earning growth rate stock be drawback used peg ratio doesn consider very common situation change growth rate such forecast first year very high growth rate follow sustainable lower growth rate long term hence peg base investing turn be even more reward other relevant parameter be also take consideration here be screening criterium winning strategy peg ratio less industry medianp ratio used less industry median more accurate valuation purpose zack rank strong buy buy good market condition bad stock zack rank have proven history success market capitalization greater help focus company have strong liquidity average day volume greater substantial trading volume ensure stock be easily tradable percentage change earning estimate revision week greater upward estimate revision add optimism suggest further bullishness value score less equal research show stock style score combine zack rank hold offer best upside potential here be stock qualify screening baxter international inc bax free report be renown medical product company believe baxter expand product pipeline be key growth catalyst newly launch product sigma spectrum infusion pump amia apd cycler sharesource way connectivity be expect drive top line growth term baxter be impressive value investment pick zack rank value style score company long term expect earning growth rate be project be coca cola femsa kof free report franchise bottler produce market distribute sell coca cola trademark beverage company offer portfolio product include sparkling beverage still beverage juice sport energy drink well tea water isotonic dairy product apart zack rank value style score stock also have impressive long term expect growth rate banco bilbao vizcaya argentarium bbva free report bbva compass rank top largest commercial bank base deposit market share rank largest bank alabama texas arizona stock also be impressive value investment pick zack rank value style score apart discount peg stock also have impressive long term expect growth rate fibrium celulose fbr free report eucalyptus pulp producer work meeting grow global demand forestry product sustainable manner have impressive expect year growth rate have value style score carry zack rank see complete list today zack rank stock here teekay offshore partner too free report company operate marine midstream space ownership general partner portion outstanding limit partner interest teekay lng partner teekay offshore partner company hold zack rank have value style score also have impressive expect growth rate next fiscal get rest stock list start putt other idea test be do research wizard stock pick backtesting software research wizard be great place begin easy use everything be plain language very intuitive start research wizard trial today next time read economic report open research wizard plug find see gem come click here sign free trial research wizard today disclosure officer director employee zack investment research own have sell short security hold long short position option be mentioned material affiliated investment advisory firm own have sell short security hold long short position option be mentioned material disclosure performance information zack portfolio strategy be available https www zack com performance zack restaurant recommendation inaddition dine special place feast stock share zack special report spotlight recent ipos watch stock offer immediate promise boom sector download free
279,BAX,baxter international inc bax free report report second quarter adjust earning share cent steer past zack consensus estimate cent be way better year figure cent figure be also company guidance cent cent interestingly last quarters company deliver positive earning surprise average be baxter post sale marginally beating zack consensus estimate constant currency cc revenue increase year year basis sale be year year international sale increase cc almost baxter international inc price consensus baxter international inc price consensus baxter international inc quotemajor factor positive tiding regulatory front quarter have be favorable baxter regulatory front company receive clearance regulatory authority regard propose acquisition claris injectable notably baxter be expect close transaction end july furthermore fda approval new premixed injectable be key catalyst company new product home pd technology also get fda nod second quarter platform leverage baxter flagship amia automate peritoneal dialysis apd system sharesource telehealth platform partnership second quarter baxter sign agreement india base dorizoe lifescience expansion generic injectable pipeline duo be expect develop more generic injectable product include infective oncolytic cardiovascular medicine however financial term deal have be keep wrapped post deal closure baxter leverage dorizoe expertise accelerate launch generic molecule deal combine baxter manufacturing leadership hospital channel strength dorizoe technical expertise thereby boost baxter foothold niche spacebaxter also announce research development collaboration lead institution mayo clinic ramot tel aviv university product launch second quarter baxter launch anew version ak hd system platform offer way connectivity capability meet need potential patient segment detailshospital product sale segment climb cc year year basis hospital product sale quarter be drive solid sale fluid system select anesthesia critical care product hospital sale be also drive solid demand parenteral nutrition therapy international bio surgery product renal product sale increase cc segment renal product sale be drive solid demand center hemodialysis hd product international acute renal care sale global sale peritoneal dialysis pd therapy guidance raise full year estimate sale growth approximately cc adjust earning share continue operation be forecast band third quarter baxter estimate sale growth cc adjust earning share be forecast range cent cent long term outlookbuoyed stellar growth earning sale company raise long term outlook baxter estimate sale growth approximately compound annual basis notably adjust operate margin full year be expect be approximately revenue much higher previously issue guidance baxter expect full year adjust diluted earning band share share have have impressive run bourse year date basis company have gain roughly higher broader industry addition almost moreover current level compare favorably return same time frame together long term expect earning growth rate almost instill confidence investor currently baxter have zack rank buy other key picksa few other top rank stock broader medical sector be edward lifescience corporation ew free report cryolife inc cry free report fresenius medical care corporation fms free report notably fresenius medical care sport zack rank strong buy edward lifescience cryolife have zack rank buy see complete list today zack rank stock here fresenius medical care represent impressive return last year company deliver solid earning surprise last report quarter edward lifescience have long term expect earning growth rate notably stock have impressive year return cryolife yielded strong return last year stock deliver positive earning surprise last report quarter hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
280,BAX,maintain streak positive earning surprise perkinelmer inc pki free report report first quarter adjust earning cent share beating zack consensus estimate base waltham lead medtech company report adjust revenue approximately beat zack consensus estimate revenue also surpass year quarter figure stock carry zack rank buy perkinelmer have outperformed industry year time stock have return higher industry return almost segment analytical solution da robust growth end market revenue da totale first quarter year year organic revenue increase year year perkinelmer have be focuse finalize organizational change associate life science business da unit come profit da segment company report first quarter adjust operate income year quarter perkinelmer register high single digit organic revenue growth asia mid single digit organic revenue growth americas europe bric region perkinelmer report solid organic revenue growth drive continue strength brazil india end first quarter management perkinelmer confirm company be now offer product line china da segment perkinelmer inc price consensus perkinelmer inc price consensus perkinelmer inc quote further company be also expect close acquisition china expand elemental analysis product da business solid growth life science apply market boost company business china diagnostic segmentrevenue be compare year reflect year year increase reflect improvement organically diagnostic business perkinelmer infectious disease business exclusively serve emerge market continue show strong growth increase mid digit year year basis reproductive health business diagnostic also grow mid single digit year year however apply genomic business be year year basis due lesser expect micro fluidic sale adjust operate income segment come compare first quarter margin analysisadjust gross profit quarter come year year adjust gross margin percentage revenue be quarter basis point bps year year company expect significant gross margin expansion next year adjust operate income perkinelmer come year year adjust operate margin percentage revenue be quarter basis point bps year year guidance full year perkinelmer expect adjust earning share be significantly higher previously issue guidance notably zack consensus estimate be currently peg share significantly company estimate company expect revenue previously issue range zack consensus estimate be currently peg lower company estimate unfavorable foreign exchange environment put solid pressure quarter review company expect strong adjust operate margin improvement remain quarters management expect bps margin expansion exit first quarter solid note strong performance da segment growth da be bolster strength lifescience end market informatic profile onesource offer company experience healthy growth major geography asia americas europe bric nation solid prospect elemental analysis product line hold promise furthermore positive guidance solid long term outlook boost investor confidence stock flipside have diversify portfolio unfavorable foreign exchange be primary concern softness industrial end market due unfavorable timing instrument order have be major dampener perkinelmer further company continue acquire large number company increase integration risk also high debt level hinder company expansion plan earning medtech major glancea few other top rank stock broader medical space report solid earning season be baxter international inc bax free report varian medical system inc var free report intuitive surgical inc isrg free report intuitive surgical varian sport zack rank strong buy baxter carry zack rank see complete list today zack rank stock here intuitive surgical report adjust earning share surpass zack consensus estimate revenue totale beat zack consensus estimate varian report second quarter fiscal adjust earning share beat zack consensus estimate adjust earning improve year year basis baxter report first quarter adjust earning share cent beat zack consensus estimate improve year quarter figure cent wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
281,BAX,luminex corporation lmnx free report report first quarter earning cent share beating zack consensus estimate cent further earning rise year year basis past month share luminex have gain industry decline luminex carry zack rank buy revenue detailrevenue come beating zack consensus estimate revenue also increase year quarter strength molecular diagnostic franchise notably first quarter luminex report revenue worth molecular diagnostic unit year year be drive sample answer molecular product revenue totale year quarter quarter review company place sample answer molecular system contract compare prior year quarter currently total active sample answer customer be just sample answer utilization customer grow customer verigene ary respectively particularly sale verigene platform grow same ary nearly triple year quarter luminex corporation price consensus ep surprise luminex corporation price consensus ep surprise luminex corporation quote segment analysissystem salesrevenue segment come year quarter consumable segment account revenue year year royalty revenuesroyalty revenue come year year basis assay revenuesthis segment post revenue worth increase year year basis be increase company automate product automate product see rise service revenuesrevenue segment totale nominal year quarter otherother revenue come year marginsgross profit report quarter be year year gross margin be contract basis point bps operate expense totale reflect drop year year basis operate profit be prior year quarter operate margin come bps balance sheet detailsluminex balance sheet remain strong debt free company exit quarter cash cash equivalent guidanceluminex expect second quarter revenue notably second quarter zack consensus estimate revenue be peg be slightly give range company expect revenue zack consensus estimate revenue be pin give range end first quarter solid note beating zack consensus estimate count molecular diagnostic revenue drive result company also ride solid ary verigene platform assay royalty revenue also witness upside new product pipeline be likely expand company portfolio furthermore solid revenue guidance buoy optimism fall operate expense expand operate margin be major positive flip side management first quarter see lowest system placement gross margin contract significantly system consumable service revenue decline year year basis highly competitive life science industry add wo other key pickssome other top rank stock broader medical space have report solid result season be intuitive surgical isrg free report cheme corporation che free report baxter international inc bax free report intuitive surgical sport zack rank strong buy cheme baxter carry zack rank see complete list today zack rank stock here intuitive surgical report first quarter adjust earning share beat zack consensus estimate revenue totale also surpass consensus estimate cheme post first quarter adjust earning share surpass zack consensus estimate revenue come beating zack consensus estimate baxter post first quarter adjust earning share cent beat zack consensus estimate revenue also edge past zack consensus estimate hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
282,BAX,fresenius medical care fms free report post adjust earning cent american depositary share ad first quarter miss zack consensus estimate earning ad decline year year basis quarter review revenue inched year year miss zack consensus estimate constant currency cc revenue decline year year revenue first quarter witness negative impact result foreign currency translation stock have zack rank strong sell fresenius medical have outperformed industry past year company share have return compare favorably industry decline fresenius medical care price consensus ep surprise fresenius medical care price consensus ep surprise fresenius medical care quotesegmental detailshealth care service revenue decline cc year year basis segment witness organic growth year year health care product revenue increase cc organically dialysis treatment increase quarter review courtesy strong contribution same market treatment synergy acquisition geographical growthnorth america revenuesby geography north america revenue decline cc year year basis account total revenue health care product revenue inched cc higher sale renal pharmaceutical peritoneal dialysis product hemodialysis solution concentrate however be partially offset lower sale machine dialyzer end quarter company treat patient clinic north america year year be fuel higher dialysis treatment increase revenue treatment dialysis care business grow cc year year basis region meanwhile care coordination segment decline cc drive shift calcimimetic drug clinical environment unfavorable foreign exchange rate partially offset solid growth region emea revenuesrevenue region increase year year basis cc health care service health care product revenue emea segment increase cc year year basis dialysis product revenue grow cc courtesy higher sale product acute care treatment machine peritoneal dialysis product renal pharmaceutical health care service segment be primarily drive growth same market treatment however same be partially offset decline organic revenue treatment growth dialysis product revenue region be boost higher sale product acute care product peritoneal dialysis machine however be partially offset lower sale dialyzer end quarter company have patient be treat clinic emea region year year dialysis treatment increase year year basis region asia pacific revenuesrevenue asia pacific grow cc year year basis net health care service unit increase cc health care service segment asia pacific region be support acquisition cura group australia meanwhile health care product business increase cc year year basis growth segment be mainly drive higher sale chronic hemodialysis product product acute care treatment dialysis treatment region grow region latin america revenuesrevenue region increase cc year year basis notably health care product increase year year company treat patient clinic latin america year year dialysis treatment increase region solid sale machine well disposable dialysis treatment drive revenue latin america margin profit decline report quarter cc percentage revenue gross margin decline basis point bps revenue quarter fresenius medical estimate revenue growth band cc lower previous guidance cc zack consensus estimate revenue be currently peg reflect rise year year net income attributable shareholder be likely increase medical exit first quarter dull note miss zack consensus estimate count dull performance north america have be major dampener company continue face significant foreign exchange headwind further higher cost related dialysis service peritoneal dialysis product business china be likely put margin pressure fresenius medical face highly regulate environment almost country operate company have fulfill specific legal requirement include tough antitrust regulation company reconfirm mid term outlook growth strategy aim boost revenue corresponding average annual growth rate strong performance health care product segment hold promise wide range dialysis product be major catalyst company earning medtech major glancea few better rank stock broader medical space report solid earning season be baxter international inc bax free report varian medical system inc var free report intuitive surgical inc isrg free report intuitive surgical varian sport zack rank strong buy baxter carry zack rank buy see complete list today zack rank stock here baxter report first quarter adjust earning share cent beat zack consensus estimate improve year quarter figure cent varian report second quarter fiscal adjust earning share beat zack consensus estimate adjust earning improve year year basis intuitive surgical report adjust earning share surpass zack consensus estimate revenue totale beat zack consensus estimate hottest tech mega trend last year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
283,BAX,myriad genetic inc mygn free report report adjust earning share ep cent third quarter fiscal year year moreover adjust ep beat zack consensus estimate cent exceed company guide range cent report earning come cent compare cent year revenuestotal revenue be year year quarter review figure however outpaced zack consensus estimate be company guidance year year decline be however cause price reduction long term contract related hereditary cancer testing further company believe unfavorable weather condition unite state have adverse impact third quarter test volume however decline be partially offset grow new product volume better expect hereditary cancer volume success company elevate program moreover be fifth consecutive quarter company witness year year hereditary cancer volume growth lead encourage response newly launch riskscore test myrisk hereditary cancer testing portfolio myriad genetic inc price consensus ep surprise myriad genetic inc price consensus ep surprise myriad genetic inc quotequarter detailssegment wise molecular diagnostic test total revenue record total revenue year year account decline hereditary cancer testing revenue also hereditary cancer testing revenue decline due price reduction long term contract however volume growth exceed company growth target year year basis endopredict testing revenue remain flat year year report quarter vectra da testing revenue come year year other testing revenue decline further genesight testing revenue rise year year report quarter prolaris test rake revenue quarter year year pharmaceutical clinical service revenue accounting rest quarter totale reflect year year increase margin trendsgross margin quarter review contract basis point bps accord management gross margin performance be affected hereditary cancer test pricing issue partially offset improve efficiency production process result elevate program rise new product reimbursement vectra da prolaris test operate expense contract rise research development expense be offset fall selling general administrative sg expense report quarter financial positionmyriad genetic exit fiscal third quarter cash cash equivalent marketable security compare end precede quarter year date cash flow operation totale compare year year date company register free cash flow compare year period guidancemyriad genetic have raise guidance fiscal revenue zack consensus estimate lie guide range bottom line front company lift adjust ep range current zack consensus estimate be company guide range management have provide guidance fourth quarter fiscal company estimate adjust ep cent total revenue zack consensus estimate adjust ep be cent revenue be consensus estimate earning coincide low end company guide range revenue estimate lie project range viewmyriad genetic perform better expect third quarter fiscal however year year decline revenue be disappointing positive note company observed strong growth genesight vectra da prolaris testing revenue recent fda approval encourage test result buoy optimism flip side unfavorable foreign currency translation continue threat considerable portion revenue come outside unite state company face risk exchange rate fluctuation zack rank other key picksmyriad genetic have zack rank buy other top rank stock broader medical space have report solid result season be intuitive surgical isrg free report cheme corporation che free report baxter international inc bax free report intuitive surgical sport zack rank strong buy cheme baxter carry zack rank see complete list today zack rank stock here intuitive surgical report first quarter adjust ep beat zack consensus estimate revenue totale also surpass consensus estimate cheme post first quarter adjust ep surpass zack consensus estimate revenue come beating zack consensus estimate baxter post first quarter adjust ep cent beat zack consensus estimate revenue edge past zack consensus estimate hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
284,BAX,henry schein inc hsic free report report adjust earning share ep cent first quarter year year adjust ep remain ahead zack consensus estimate year year upside earning be drive strong revenue growth business segment report basis ep come cent first quarter improvement year year revenue detailhenry schein report net sale first quarter year year ahead zack consensus estimate year year improvement come back internal sale growth local currency increase owing foreign currency exchange acquisition growth be quarter henry schein inc price consensus ep surprise henry schein inc price consensus ep surprise henry schein inc quotein first quarter company record sale north american market year year sale totale international market year year segment analysis henry schein derive revenue operate segment dental medical animal health technology value add service first quarter company derive revenue global dental sale year year include growth local currency contribution foreign currency exchange local currency internally generate sale increase acquisition growth be internal growth local currency include growth north america rise internationally company global animal health segment witness rise revenue include growth local currency increase foreign currency exchange local currency internally generate sale increase acquisition growth be internal growth local currency include rise north america improvement internationally worldwide medical revenue rise year year growth local currency be increase owing favorable foreign exchange revenue global technology value add service grow include growth local currency rise related foreign currency exchange acquisition contribute quarter review margin trend gross profit increase report quarter however gross margin contract basis point bps year quarter due rise cost sale rise selling general administrative expense adjust operate income improve year year however adjust operate margin decline bps year year report quarter financial positionhenry schein exit first quarter cash cash equivalent compare end first month net operate cash outflow be compare cash outflow year period result blackout period related spin merger company animal health business quarter review company do not repurchase share common stock close first quarter company have authorize repurchase common stock guidanceexclude cost related restructure spin merger henry schein global animal health business company have reiterate ep guidance company still expect ep range reflect growth adjust ep figure zack consensus estimate adjust ep be remain guide range takehenry schein exit first quarter strong note earning revenue steering past respective zack consensus estimate company operate segment record strong year year growth henry schein strong share gain north american overseas market solid revenue raise optimism better expect revenue performance be disappoint year year deterioration henry schein gross operate margin due higher cost sale expense currently await completion company global animal health business plan spin business contribute nearly company topline spin accordingly be expect bring major change henry schein overall operate result accord company follow spinoff animal health business merge privately hold vet first choice form new public company call vet first corp believe initiative remain part henry schein strategic plan focus more dental medical business zack rank key pickshenry schein have zack rank buy few other top rank stock broader medical space have report solid result season be intuitive surgical isrg free report cheme corp che free report baxter international inc bax free report intuitive surgical sport zack rank strong buy cheme baxter carry zack rank buy see complete list today zack rank stock here intuitive surgical report first quarter adjust ep beat zack consensus estimate revenue totale also surpass consensus estimate cheme post first quarter adjust ep surpass zack consensus estimate revenue come beating zack consensus estimate baxter post first quarter adjust ep cent beat zack consensus estimate revenue also edge past zack consensus estimate look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
285,BAX,hologic inc holx free report be slate report second quarter fiscal financial result close bell last quarter company deliver positive surprise notably hologic earning surpass zack consensus estimate past quarters average beat let see thing be shape prior announcement key catalystwithin diagnostic hologic once again expect stellar performance banking molecular diagnostic unite state company be likely gain increase market share well utilization fully automate panther system market expansion conform testing guideline global growth molecular diagnostic be attribute panther system hologic fully automate molecular diagnostic instrument also owing frequent utilization aptima woman health assay notably aptima assay have gain huge customer base testing chlamydium gonorrhea hpv human papillomavirus trichomona be also hopeful hologic expand market sexually transmit disease testing hologic inc price ep surprise hologic inc price ep surprise hologic inc quote further be upbeat diagnostic business earn regulatory clearance several new product unite state last quarters include first respiratory assay new fusion platform viral load test hiv human virus hepatitis hepatitis steady pace domestic assay innovation strengthen company position consolidate molecular testing panther system january company again announce pma approval aptima hbv quant assay quantitation hepatitis viral load fully automate panther system development be anticipate contribute significantly company topline be report quarter zack consensus estimate molecular diagnostic revenue reflect increase year quarter other few factor likely influence hologic result fiscal second quarter be follow hologic be optimistic sustain solid earning trend courtesy gain breast health segment sale same have improve basis establish clinical superiority segmental product last quarters company have witness consistent rise market share breast health back direct consumer initiativesand insurance coverage additionally company adoption new mammography system dimension performance encourage new product have already start leverage company genius brand also lure customer upgrade exist system company be build broader portfolio breast health product service core genius system so play instrumental role breast health continuum care noteworthy regard be recent pma approval fda clarity hd high resolution imaging intelligent imaging technology product be now available dimension breast tomosynthesis system zack consensus estimate second quarter fiscal remain ahead prior year tally flip side hologic confront challenge related unfavorable foreign currency movement past few quarters escalate operate expense intense competition particularly tomosynthesis market continue raise concern model suggestsper proven zack model company solid zack rank strong buy buy hold have higher chance beating estimate also have positive earning esp hologic have zack rank increase predictive power esp earning esp raise confidence positive surprise together combination suggest company be likely beat earning quarter uncover best stock buy sell re report earning esp filter conversely caution sell rate stock go earning announcement especially company be see negative estimate revision other stock worth lookhere be few other medical stock worth consider right combination element also surpass estimate time baxter international inc bax free report have earning esp zack rank laboratory corporation america holding lh free report have earning esp zack rank stryker corporation syk free report have earning esp be zack rank player see complete list today zack rank stock here today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
286,BAX,baxter international inc bax free report be schedule report first quarter earning apr market open positive tiding regulatory front expand product portfolio strategic collaboration strong presence international market be key positive moment expect company witness steady growth hospital product sale major revenue component be project drive first quarter earning expect improvement revenue other sub segment generate impressive result last quarter baxter post adjust earning share cent beat zack consensus estimate cent improve year quarter figure cent current quarter zack consensus estimate revenue be peg reflect rise year year zack consensus estimate adjust earning share be peg cent indicate increase year year baxter international inc price ep surprise baxter international inc price ep surprise baxter international inc quotelet delve other factor be likely impact baxter first quarter result hospital product drive resultsbaxter have impressive product portfolio improve exist product new product development recently company announce distribution agreement launch arisure close system transfer device last quarter hospital sale be drive solid demand injectable pharmaceutical hospital pharmacy compound service sale segment benefit solid demand company advanced surgery product cytotoxic contract manufacturing service overall zack consensus estimate hospital product revenue be peg reflect increase year quarter here take sneak peek major sub segment hospital product be poise gain be report quarter surgical care surgical care include anesthesia biosurgery sale record year year sale growth last quarter low double digit growth anesthesia critical care product drive grow demand inhaled anesthetic internationally well increase sale brevibloc fast act iv beta blocker mar baxter complete acquisition hemostat sealant product mallinckrodt plc expand exist surgical portfolio hemostat sealant especially intraoperative bleed notably company buy thrombin topical preveleak surgical sealant product line mallinckrodt baxter surgical portfolio include product floseal hemostatic matrix tisseel fibrin sealant coseal surgical sealant vascu guard patch other portfolio be compose hemostasis address bleed tissue sealing hard tissue regeneration well soft tissue repair microsurgery product available nearly country company consistently strive improve advanced surgery business company expect advanced surgery business increase constant currency cc basis baxter announce plan focus launch advanced surgery product japan come day zack consensus estimate segment sale be peg reflect rise year quarter fluid system hospital product sale fluid system be expect be solid robust iv solution sale unite state expect fluid system maintain trend first quarter be evident zack consensus estimate fluid system first quarter reflect rise year quarter integrate pharmacy solution ip global sale ip sub segment hospital product increase formidable margin last quarter partly back increase sale premixed injectable drug however baxter performance last year have lack luster majorly lower sale threat integrate pharmacy solution franchise business baxter expect sale be approximately reflect decline upcoming quarterly result lower sale be expect impact top line low single digit first quarter zack consensus estimate ip be peg show increase year number other factor playguidance baxter expect first quarter adjust earning range cent however net sale first quarter be expect be affected approximately due disruption puerto rico facility baxter estimate sale growth approximately cc adjust earning be expect band regulatory approval baxter have be witness positive tiding regulatory front recently baxter announce approval bivalirudin percent sodium chloride injection bivalirudin management confirm fda have grant new approval temporary importation certain drug facility canada mexico development baxter now have operational site approve address demand market dull projection pharmaceutical unit pharmaceutical business include baxter broad generic injectable portfolio anesthesia critical care product well hospital pharmacy compound service conduct outside unite state be expect be flat year year basis lackluster performance be primarily drive increase competition select product segment further other business segment primarily include baxter contract manufacturing service management expect low single digit decline management sale segment benefit customer order baxter expect lower manufacturing revenue shire acquire year model predictsour quantitative model do not predict earning beat baxter quarter be stock need have positive earning zack rank strong buy buy hold be able beat estimate zack esp earning esp baxter be uncover best stock buy sell re report earning esp filter zack rank baxter carry zack rank stock worth lookhere be few medical stock worth consider have right combination element post earning beat quarter bio rad laboratory bio free report have earning esp zack rank see complete list today zack rank stock here cardinal heath cah free report have earning esp zack rank abbott laboratory free report have earning esp zack rank breaking news cryptocurrency now bigger total market cap cryptos recently surpass more increase previous month re now bigger morgan stanley goldman sachs even visa new asset class expand even more rapidly new investor continue pour wall street become increasingly involved zack have just name company enable investor take advantage explosive growth cryptocurrency stock market click here access stock
287,BAX,maintain streak positive earning surprise athenahealth inc athn free report report adjust earning share first quarter beat zack consensus estimate notably adjust earning report year quarter be cent watertown base maker bill medical practice management software post revenue beating zack consensus estimate revenue increase year year athenahealth carry zack rank hold detailssegment detailsrevenue business service be year quarter however revenue implementation other segment be year year network expansionper management company expand network ambulatory hospital population health platform recently athenahealth surpass patient threshold currently serve more healthcare provider first quarter athenahealth add new hospital company end quarter hospital network company network have collector provider clinical provider communicator provider respectively year year basis athenaone hospital platform number discharge bed increase whopping year year population health platform number cover life increase year year buoy stellar network expansion company be expect fortify foothold revenue cycle management rcm space drive revenue earning long haul athenahealth inc price consensus athenahealth inc price consensus athenahealth inc quote margin analysisa strong client base have be major growth driver company adjust gross margin first quarter be compare year quarter athenahealth operate income increase year year drive top line growth cost save initiative company see operate margin total revenue basis point year year reiterate fiscal financial guidance company expect revenue range meanwhile zack consensus estimate revenue be peg company expect adjust operate income range adjust operate margin be expect band net revenue exit first quarter solid note earning revenue outpace zack consensus estimate believe application athenaclinical athenaclinical streamline athenainsight athenaone athenacollector hospital health system brand promise unbreak healthcare be fortify market position term exclusiveness service provide strong client base have be key catalyst business service revenue witness year year growth same implementation other segment decline major concern athenahealth ehr solution face significant competition like allscript healthcare solution other further athenahealth fall short booking goal quarter review deteriorate client retention rate also add company wo earning medtech major glancea few better rank stock broader medical space report solid earning season be baxter international inc bax free report cheme corporation che free report intuitive surgical inc isrg free report intuitive surgical sport zack rank strong buy baxter cheme carry zack rank see complete list today zack rank stock here intuitive surgical report adjust earning share surpass zack consensus estimate revenue totale beat zack consensus estimate baxter report first quarter adjust earning share cent beat zack consensus estimate improve year quarter figure cent cheme post adjust earning share outpace zack consensus estimate revenue come beating zack consensus estimate hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
288,BAX,baxter international inc bax free report have be healthy growth trajectory late company ride solid first quarter performance raise guidance strategic acquisition have lend company competitive edge medtech space stock zack rank buy be attractive pick moment past month baxter share have rally compare industry current level be also higher index gain stock have market cap company earning growth rate next year be also favorable additionally baxter have deliver positive average earning surprise trail quarters baxter have impressive growth style score growth style score highlight vital metric company financial obtain clearer picture quality sustainability growth research show stock style score combine zack rank strong buy hold offer best investment opportunity let find factor be work favor stock currently solid earningsbaxter end first quarter solid note beating consensus mark earning revenue adjust earning quarter come cent share cent prior year quarter revenue be year year constant currency cc geographically sale inched year year meanwhile international sale increase year year company deliver strong result back solid performance core renal pharmaceutical business renal unit sale increase year year basis pharmaceutical sale rise raise guidancebuoy solid first quarter earning result baxter raise financial outlook second quarter company expect sale growth approximately cc company expect adjust earning continue operation band cent company also expect sale growth cc expect adjust earning share continue operation range full year strategic buyout have be long help baxter international gain market traction recently company complete acquisition thrombin topical preveleak surgical sealant product line mallinckrodt deal be expect widen baxter surgical portfolio hemostat sealant buyout have not be accretive first quarter earning baxter expect be so buyout india base claris injectable limit have provide baxter robust portfolio generic injectable molecule be approve unite state other key picksother top rank stock broader medical space be bio rad laboratory bio free report envision healthcare corporation evhc free report fresenius medical care fms free report bio rad have expect long term earning growth rate stock sport zack rank strong buy see complete list today zack rank stock here envision healthcare have expect long term earning growth rate stock carry zack rank fresenius have expect long term earning growth rate stock carry zack rank hottest tech mega trend last year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend baxter international inc bax free report have be healthy growth trajectory late company ride solid first quarter performance raise guidance strategic acquisition have lend company competitive edge medtech space stock zack rank buy be attractive pick moment past month baxter share have rally compare industry current level be also higher index gain stock have market cap company earning growth rate next year be also favorable additionally baxter have deliver positive average earning surprise trail quarters baxter have impressive growth style score growth style score highlight vital metric company financial obtain clearer picture quality sustainability growth research show stock style score combine zack rank strong buy hold offer best investment opportunity let find factor be work favor stock currently solid earning baxter end first quarter solid note beating consensus mark earning revenue adjust earning quarter come cent share cent prior year quarter revenue be year year constant currency cc geographically sale inched year year meanwhile international sale increase year year company deliver strong result back solid performance core renal pharmaceutical business renal unit sale increase year year basis pharmaceutical sale rise raise guidance buoy solid first quarter earning result baxter raise financial outlook second quarter company expect sale growth approximately cc company expect adjust earning continue operation band cent company also expect sale growth cc expect adjust earning share continue operation range full year strategic acquisition strategic buyout have be long help baxter international gain market traction recently company complete acquisition thrombin topical preveleak surgical sealant product line mallinckrodt deal be expect widen baxter surgical portfolio hemostat sealant buyout have not be accretive first quarter earning baxter expect be so buyout india base claris injectable limit have provide baxter robust portfolio generic injectable molecule be approve unite state other key pick other top rank stock broader medical space be bio rad laboratory bio free report envision healthcare corporation evhc free report fresenius medical care fms free report bio rad have expect long term earning growth rate stock sport zack rank strong buy see complete list today zack rank stock here envision healthcare have expect long term earning growth rate stock carry zack rank fresenius have expect long term earning growth rate stock carry zack rank hottest tech mega trend last year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
289,BAX,baxter international inc bax free report have be healthy growth trajectory late positive tiding regulatory front strategic acquisition have be provide company competitive edge medtech solid prospect zack rank buy stock be attractive pick moment baxter international have outperformed industry past year stock have gain outperform gain broader industry stock have market cap company next year earning growth rate be also favorable compare increase company have positive earning surprise last quarters also have long term expect earning growth rate baxter international have impressive growth style score well growth style score highlight vital metric company financial obtain clearer picture quality sustainability growth research show stock style score combine zack rank strong buy hold offer best investment opportunity let find recent positive trend be sustainable strategic market be upbeat company recent acquisition hemostat sealant product thrombin topical recombinant preveleak surgical sealant mallinckrodt plc solid baxter estimate sale growth approximately constant currency adjust earning full year be expect band share solid estimate revision company estimate revision trend current year have be positive past couple month analyst moved north movement opposite direction earning estimate rise same time frame positive regulatory market be also encourage note baxter international receive fda approval bivalirudin percent sodium chloride injection bivalirudin other key picksother top rank stock broader medical sector be bio rad laboratory bio free report athenahealth inc athn free report varian medical system inc var free report bio rad laboratory sport zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate athenahealth be zack rank player company have long term expect earning growth rate varian medical have long term expect earning growth rate stock carry zack rank today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
290,BAX,follow encourage fourth quarter result share mallinckrodt public limit company mnk free report moved hit challenge mallinckrodt stock have lose year compare industry fall company report adjust earning share report quarter year figure beating zack consensus estimate net sale quarter come year year surpass zack consensus estimate mallinckrodt plc price consensus mallinckrodt plc price consensus mallinckrodt plc quote quarter company report result segment specialty brand specialty generic sale specialty brand segment be year quarter acthar mallinckrodt largest product garner sale due patient withdrawal issue mallinckrodt be reel industry wide challenge increase number written prescription be go unfilled inomax second largest product generate sale ofirmev sale increase year year sale therakos immunology platform be expect weakness specialty generic segment continue due competitive pressure segment record sale adjust selling general administrative expense quarter decrease meanwhile research development expense increase pipeline updateearlier month mallinckrodt acquire erstwhile sucampo pharmaceutical diversify revive beleaguered portfolio sucampo acquisition add approve drug namely amitiza rescula mallinckrodt portfolio last month mallinckrodt enter agreement baxter international bax free report former sell certain hemostasis product latter approximately product include thrombin topical recombinant preveleak surgical sealant baxter assume other expense include contingent liability associate preveleak company have acquire product medicine co mdco free report however mallinckrodt retain raplixa fibrin sealant human topical use be evaluate strategic option product meanwhile fda accept mallinckrodt new drug application nda seek approval recently acquire developmental product stannsoporfin prescription drug user fee act fda set action date respond nda aug agency previously grant fast track status stannsoporfin guidancedue recently announce acquisition divestiture mallinckrodt prospectively classify specialty generic disposal group discontinue operation include specialty generic segment certain promote brand product specialty brand segment company ongoing post divestiture supply agreement net sale be expect grow adjust ep be project be earning sale beat fourth quarter come silver line mallinckrodt have be trouble water quite time now acthar sale continue decline inomax revive bit company be currently streamline business focus better innovative medicine therapy terlipressin stratagraft recently acquire product stannsoporfin xenon gas ocr sucampo buyout diversify company portfolio consider amitiza potential be commendable remain be see be enough bail mallinckrodt current crisis zack rank key carry zack rank hold better rank stock health care space be regeneron pharmaceutical inc regn free report sporting zack rank strong buy see complete list today zack rank stock here regeneron earning share estimate have moved respectively last day company deliver positive earning surprise last quarters average beat wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
291,BAX,nov issue update research report baxter international inc bax free report baxter recently exit third quarter favorable note beating zack consensus estimate count impressive performance hospital product renal segment hold promise stock carry zack rank buy headquarter deerfield il baxter be global medical technology company operate life sustain critical care product category be cushion economic downturn company product be not commodity nature provide strong recur revenue base baxter have be experience burgeon demand dialyzer globe more person be afflict end stage renal disease esrd due grow incidence diabetes blood pressure other kidney related disease come recently report third quarter baxter strong product portfolio plethora regulatory approval completion claris acquisition drive top line buoy solid performance management baxter lift full year guidance baxter estimate sale growth approximately cc adjust earning year be expect band share previous band year have be favorable baxter regulatory front so far third quarter management baxter confirm new fda approval temporary importation certain drug facility canada mexico further fda approval new premixed injectable be key catalyst come product portfolio baxter convenient kidney dialysis solution regenerative tissue product oxiris set continuous renal replacement therapy next generation sigma spectrum infusion pump be latest addition extensive product portfolio notably baxter home solution system be first technology design reduce storage weight handle requirement traditional pd therapy management claim have first patient therapy new system part clinical trial regulatory submission be expect ongoing political conundrum pertain repeal obamacare medtech space devastation cause hurricane marium believe solid foothold global market drive result medtech major large proportion sale come overseas market baxter benefit develop country incremental investment health care system share price movementover past year baxter have outperformed broader industry term price performance company represent solid return higher industry gain roughly current level be also higher return only earning medtech major glancewith most member have report number third quarter earning season be draw close medical broader sector zack sector have put impressive show so far positive revenue momentum favorable revision estimate current period be notable feature season petm express pet free report report earning share cent second quarter fiscal year year basis stock sport zack rank strong buy see complete list today zack rank stock here luminex lmnx free report report adjust earning share cent third quarter year year revenue increase almost year year stock flaunt zack rank intuitive surgical isrg free report post adjust earning share third quarter year year revenue increase year year stock carry zack rank today stock zack hottest strategiesit hard believe even zack market gain top stock pick screen have return respectively outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
292,BAX,baxter international inc bax free report report fourth quarter adjust earning share cent beat zack consensus estimate cent improve year quarter figure cent baxter have zack rank hold figure also come company guidance cent last quarters company deliver positive earning surprise average be baxter post sale marginally beating zack consensus estimate constant currency cc revenue increase year year basis sale be year year international sale increase cc almost baxter international inc price consensus ep surprise baxter international inc price consensus ep surprise baxter international inc quotesegmental detailshospital productssale hospital product segment rise cc year year basis hospital product sale quarter be drive solid sale fluid system select anesthesia critical care product hospital sale be also drive solid demand injectable pharmaceutical hospital pharmacy compound service sale segment benefit solid demand company advanced surgery product cytotoxic contract manufacturing service renal productssale segment increase cc renal product sale be support improve performance major product line therapy globally notably solid performance chronic acute renal therapy drive sale segment consistent effort increase productionper management company puerto rico facility affected hurricane be ramp production additionally baxter have be work closely fda support supply certain product domestic market be caution importation baxter facility ireland australia canada mexico england italy brazil fourth quarter baxter launch oxiris set continuous renal replacement therapy crrt sepsis management protocol select market europe middle east africa oxiris leverage company flagship prismaflex system be expect lend company competitive edge global market recently company upgrade sigma spectrum infusion system launch devicevue advanced asset tracking system baxter be first only smart infusion pump manufacturer offer tagless end end acid tracking application design consultation potential customer drive operational efficiency maximize clinical value pump investment baxter estimate sale growth approximately cc adjust earning full year be expect band share baxter expect first quarter range cent however baxter expect sale first quarter be affected approximately due disruption puerto rico facility glancein baxter register revenue cc year year basis sale hospital product totale net sale baxter renal sale totale more year net sale baxter increase annual dividend rate repurchase worth share also pursue internal external initiative augment growthour takebaxter end fourth quarter encourage note beating zack consensus estimate count company impressive performance hospital product renal segment hold promise recently baxter launch oxiris set continuous renal replacement therapy crrt sepsis management protocol select market europe middle east africa further recent launch devicevue comprehensive asset tracking solution available exclusively hospital boost company product portfolio flip side foreign currency headwind intense competition lackluster sale growth have be dampening baxter performance long generic competition be headwind further recent hurricane be expect dent company result term company report solid earning resultsa few better rank stock report decent result earning season be petm express pet free report perkinelmer pki free report accuray aray free report petm sport zack rank strong buy perkinelmer accuray carry zack rank buy see complete list today zack rank stock here petm recently report third quarter fiscal result adjust earning share be cent prior year quarter revenue rise year year basis perkinelmer report fourth quarter adjust earning share cent adjust revenue be approximately year quarter accuray report loss cent share second quarter fiscal cent narrower year figure total revenue second quarter improve year year wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
293,BAX,headquarter deerfield illinois baxter international inc bax free report be global medical product service company company hospital product business manufacture product used delivery fluid drug patient renal portfolio be mainly patient kidney failure disease healthcare provider currently baxter international have zack rank buy change follow second quarter earning report have just release see complete list today zack rank strong buy stock here have highlighted key detail just release announcement earning baxter adjust earning cent share beat zack consensus estimate cent increase cent year quarter revenue baxter post sale marginally beating zack consensus estimate revenue constant currency cc revenue increase almost year year basis baxter international inc price ep surprise baxter international inc price ep surprise baxter international inc quotekey stat hospital product sale increase cc renal product increase year quarter major factor hospital product sale quarter be drive solid sale fluid system select anesthesia critical care product hospital sale be also favorably impact solid demand parenteral nutrition therapy international bio surgery product renal product sale be drive solid demand center hemodialysis hd product international acute renal care sale global sale peritoneal dialysis pd therapy baxter increase financial outlook full year estimate sale growth approximately cc adjust earning continue operation be forecast band share third quarter adjust earning be expect band cent cent share stock price share have rise roughly past month broader industry have gain same time frame however follow earning release share price do not show movement pre market trading session check back later full baxter international report later hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionary still leave plenty money regular investor make right trade early see zack best stock play trend
294,BAX,baxter international inc bax free report be schedule report second quarter earning jul open bell last report quarter company record positive earning surprise reach quarter average let see thing be shape prior release factor playwe be encourage company guidance second quarter full year second quarter baxter estimate sale growth constant currency adjust earning share be forecast range cent cent versus year figure cent also full year company project earning band share continue operation special item full year earning late baxter have accelerate pace acquisition strategic collaboration enhance product portfolio thereby open significant long term opportunity also several recent fda approval be likely boost growth yet be report second quarter baxter international inc price ep surprise baxter international inc price ep surprise baxter international inc company estimate revision trend be also encourage current year baxter see upward estimate revision movement opposite direction last month however lower sale threat company integrate pharmacy solution franchise second quarter decline sale be expect impact top line low single digit also foray group purchasing organization gpos intensify competition company earning whispersour quantitative model doesn point earning beat quarter be stock need have positive earning esp zack rank strong buy buy hold happen be not case here see zack esp earning esp baxter international be be most accurate estimate zack consensus estimate stand cent uncover best stock buy sell re report earning esp filter zack rank baxter international carry zack rank increase predictive power esp however company esp make surprise prediction difficult caution stock zack rank sell rate go earning announcement especially company be see negative estimate revision stock considerhere be company consider model show have right combination element post earning beat upcoming quarter becton dickinson company bdx free report have earning esp zack rank see complete list today zack rank stock here thermo fisher scientific inc tmo free report have earning esp zack rank stryker corporation syk free report have earning esp zack rank top pick ride hottest tech trendzack just release special report guide space have already begin transform entire economy last year be generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money make right trade early download report top tech stock
295,BAX,ecolab inc ecl free report report first quarter adjust earning cent share beat zack consensus estimate earning also rise year year basis ecolab carry zack rank hold adjust quarterly net sale be year quarter also net sale beat zack consensus estimate segmental analysisglobal industrial sale segment grow year year almost upside be drive major gain water food beverage life science unit europe north america latin america lead global industrial regional growth however acquisition adjust fix currency operate income segment decrease year year basis due higher deliver product cost massive investment business ecolab inc price consensus ecolab inc price consensus ecolab inc quoteglobal increase lead strong growth specialty business line segment witness solid growth north america asia pacific acquisition adjust fix currency operate income rise year year global energy sale rise owing strong growth well stimulation business modest gain downstream business acquisition adjust fix currency operate income remain flat year year other sale decline year year however sale segment witness robust growth north america notably other segment now have ecolab colloidal technology unit unit be previously part global industrial reportable segment acquisition adjust fix currency sale rise year year pest elimination unit segment register solid growth north america europe margin company margin quarter review remain pressure owing higher deliver product cost percentage revenue ecolab register adjust gross margin first quarter basis point bps year year basis adjust operate margin first quarter contract bps net revenue however ecolab remain hopeful latest pricing initiative have undertake management be expect boost margin come quarters view upecolab expect full year adjust earning range share previously issue range notably represent increase band year year notably zack consensus estimate be currently peg share percentage revenue adjust gross margin be expect be net revenue be significantly previously issue range second quarter ecolab expect adjust earning range share current outlook reflect increase year year adjust gross margin second quarter be expect be net revenue end first quarter favorable note beating zack consensus estimate count strength pest elimination business other segment decline year year report basis ecolab operate highly competitive market mar prospect long haul believe volatility foreign currency exchange rate remain significant headwind company ecolab face pricing pressure energy segment be likely hurt profit brighter side strong guidance instill optimism stock further europe north america latin america lead global industrial regional growth quarter strength global institutional segment lead growth specialty healthcare business line be also positive robust product portfolio expand customer base be likely drive organic sale long haul earning medtech major glancea few other top rank stock broader medical space report solid earning season be baxter international inc bax free report varian medical system inc var free report intuitive surgical inc isrg free report intuitive surgical varian sport zack rank strong buy baxter carry zack rank see complete list today zack rank stock here intuitive surgical report adjust earning share surpass zack consensus estimate revenue totale beat zack consensus estimate varian report second quarter fiscal adjust earning share beat zack consensus estimate adjust earning improve year year basis baxter report first quarter adjust earning share cent beat zack consensus estimate improve year quarter figure cent wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
296,BAX,headquarter deerfield illinois baxter international inc bax free report be global medical product service company company hospital product business manufacture product used delivery fluid drug patient renal portfolio be mainly patient kidney failure disease healthcare provider currently baxter international have zack rank hold change follow fourth quarter earning report have just release see complete list today zack rank strong buy stock here have highlighted key detail just release announcement earning baxter adjust earning cent share beat zack consensus estimate cent increase cent year quarter revenue baxter post worldwide sale beating zack consensus estimate revenue constant currency cc revenue increase almost year year basis key stat hospital sale unite state be year year basis renal product deliver revenue worth year quarter unite state major factor sale report quarter be drive solid revenue major segment management increase emphasis innovation portfolio expansion deliver positive result quarter performance segment report quarter be attributable continue strength company fluid system business well favorable demand injectable pharmaceutical full year baxter expect revenue growth be approximately cc adjust earning fiscal be expect band share baxter international inc price ep surprise baxter international inc price ep surprise baxter international inc quotestock price share have rise roughly last year broader industry have gain same time frame follow earning release share price inched pre market trading session check back later full baxter international report later wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
297,BAX,fourth quarter earning season be gain momentum participant have already release financial number jan latest earning preview report cycle be encourage start average proportion company edge past top bottom line expectation total earning member have improve increase revenue result roughly member slate be announce week zack datum estimate period be gradually trend upward board zack sector medical bracket be expect witness earning rise fourth quarter revenue growth projection store medical device industry medical device space broader medical sector somewhat display mixed bag sort part tax overhaul corporate tax rate have be slash previous thus lend huge relief medtech mammoth however ahead industry fourth quarter earning release section analyst expect new tax law negatively impact industry due possible cut overall medicare spending certain criterium be not fulfilled specific date congressional budget office apprehend absence alternative meet fiscal deficit huge tax reduction automatic cut back worth include medicare cut mandatory budget spending be trigger tax reform related concern news congress delay medical device tax year come huge boost industry player investor tax be earlier delay congress couple year deferral once again largely propel activity space let take sneak peek performance major medical device company wait report earning feb boston scientific corporation bsx free report be optimistic company gradually improve performance interventional cardiology lead innovative portfolio robust commercial team globally more specifically watchman platform be expect experience excellent quarter consistent global momentum boston scientific multiple market development effort continue push growth company have positive earning esp zack rank hold favorable zack esp indicate likely positive surprise bullish zack rank strong buy buy increase predictive power esp conversely sell rate stock never be consider go earning announcement especially company be see negative estimate revision read more watchman boost boston scientific earning boston scientific corporation price ep surprise boston scientific corporation price ep surprise boston scientific corporation quotebaxter international inc bax free report fourth quarter baxter international be anticipate gain strong hospital product drive solid sale fluid system business well robust demand injectable pharmaceutical hospital product segment expect fluid system maintain momentum evident zack consensus estimate be report quarter reflect improvement year period banking solid prospect quantitative model also show beat company give combination zack rank earning esp uncover best stock buy sell re report earning esp filter read more baxter beat earning hospital product baxter international inc price ep surprise baxter international inc price ep surprise baxter international inc quotemckesson corporation mck free report major player pharmaceutical medical supply distribution market expect witness solid performance canadian business third quarter fiscal also mckesson specialty health unit be likely drive company top line same time frame unit be likely benefit close intrafusion acquisition recent bdi pharma buyout be unable conclude mckesson be likely beat earning quarter stock carry zack rank increase predictive power esp earning esp however need have positive esp be confident earning surprise see complete list today zack rank stock here read more mckesson report earning beat card mckesson corporation price ep surprise mckesson corporation price ep surprise mckesson corporation quoteedward lifescience corporation ew free report lead cardiovascular product maker be expect grow robust transcatheter heart valve therapy segment fourth quarter back continue therapy adoption geography notable strength unite state company be likely retain bullish run period be report edward lifescience be zack rank player have earning esp positive zack esp denote likely earning surprise favorable zack rank company raise predictive power esp read more edward lifescience thvt likely drive earning edward lifescience corporation price ep surprise edward lifescience corporation price ep surprise edward lifescience corporation quoteidexx laboratory inc idxx free report repeating precede quarter success idexx be estimate gain strong global footprint companion animal group diagnostic recur revenue fourth quarter be also upbeat idexx enhance commercial capability unite state maintain recur revenue growth cag diagnostic company be rank player have earning esp therefore be unable conclude idexx be likely beat earning quarter however idexx trail month average beat be read more idexx post beat earning cag strength idexx laboratory inc price ep surprise idexx laboratory inc price ep surprise idexx laboratory inc hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
298,BAX,company favorable efficiency level be likely be investor radar irrespective market condition be company favorable efficiency level be expect provide impressive return be believe be positively correlated price performance key ratio identify become difficult measure efficiency level company be reason consider popular efficiency ratio select stock efficiency ratio be inventory turnover ratio month cost good sell cog quarter average inventory be consider most popular efficiency ratio indicate company ability maintain suitable inventory position high value indicate company have relatively low level inventory compare cog low value indicate company be face decline sale result excess inventory receivables turnover be ratio month sale quarter average receivables show company potential extend credit collect debt term credit high receivables turnover ratio account receivable turnover ratio debtor turnover ratio be desirable show company be capable collect account receivables have quality customer asset utilization ratio indicate company capability convert asset output be thus widely know measure efficiency level be calculate divide total sale past month last quarter average total asset ratio high asset utilization indicate company be efficient operate margin efficiency measure be ratio operate income past month sale same period measure company ability control operate expense hence high value ratio indicate company manage operate expense more efficiently peer screening parametersin addition mentioned ratio have add favorable zack rank strong buy buy screen objective make strategy more profitable see complete list today zack rank stock here inventory turnover receivables turnover asset utilization operate margin greater industry average value ratio higher industry average indicate efficiency level company be higher peer use few criterium have narrow universe stock only here be stock make screen baxter international inc bax free report provide portfolio renal hospital product company operate segment hospital product renal company have average quarter positive earning surprise stock carry zack rank copart inc cprt free report provide online auction vehicle remarketing service company have average quarter positive earning surprise stock have zack rank apply material inc amat free report provide manufacturing equipment service software semiconductor display related industry worldwide company have average quarter positive earning surprise stock flaunt zack rank steel dynamic inc stld free report engage steel product manufacturing metal recycling business unite state internationally company have average quarter positive earning surprise stock have zack rank get rest stock list signing now week free trial research wizard start used screen own trading further also create own strategy test first take investment plunge research wizard be great place begin easy use everything be plain language very intuitive start research wizard trial today next time read economic report open research wizard plug find see gem come click here sign free trial research wizard today disclosure officer director employee zack investment research own have sell short security hold long short position option be mentioned material affiliated investment advisory firm own have sell short security hold long short position option be mentioned material disclosure performance information zack portfolio strategy be available https www zack com performancezack restaurant recommendation addition dine special place feast stock share zack special report spotlight recent ipos watch stock offer immediate promise boom sector download free
299,BAX,mar issue update research report baxter international inc bax free report company ride high series regulatory approval strategic acquisition however generic competition pricing pressure loom large stock carry zack rank buy baxter have be witness positive tiding regulatory front recently company announce approval bivalirudin sodium chloride injection bivalirudin management baxter have confirm fda have grant new approval temporary importation certain drug canada mexico furthermore fda approval new premixed injectable be key catalyst company new product home pd technology also receive go ahead fda baxter have be enhance product portfolio strategic collaboration lately company take thrombin topical preveleak surgical sealant product line mallinckrodt earlier baxter have close acquisition india base claris injectable limit be expect prove accretive adjust earning baxter have sign agreement india base dorizoe lifescience expansion generic injectable pipeline baxter have solid product portfolio include arisure close system transfer device sigma spectrum infusion system furthermore company launch devicevue advanced asset tracking system first oxiris set acute therapy company also recently launch version ak hemodialysis hd system help dialysis provider however generic competition be concern be part baxter hospital product segment have be post lackluster performance most part last year drop sale pose threat company integrate pharmacy solution franchise business price performance past month baxter share have gain compare industry primary factor back solid share performance be company presence life sustain critical care product category be cushion economic downturn other key pick few other top rank stock broader medical space be athenahealth inc athn free report bio rad laboratory inc bio free report centene corporation cnc free report stock sport zack rank strong buy see complete list today zack rank stock here athenahealth have expect long term growth rate earning share growth rate bio rad have expect long term growth rate earning share growth rate centene have expect long term growth rate earning share growth rate today stock zack hottest strategy hard believe even zack market gain top stock pick screen have return outperformance have not just be recent phenomenon year have be remarkably consistent composite yearly average gain strategy have beaten market more maybe even more remarkable be fact re willing share latest stock cost obligation see free
300,BAX,baxter international inc bax free report be schedule report fourth quarter earning feb market open last quarter company post positive earning surprise baxter international have outperformed zack consensus estimate precede quarters average positive beat be let take look thing be shape prior announcement key last quarter baxter international be expect gain strength hospital product solid sale fluid system business well solid demand injectable pharmaceutical baxter international inc price ep surprise baxter international inc price ep surprise baxter international inc quote hospital product third quarter sale fluid system be significantly robust iv solution sale unite state expect fluid system maintain trend be evident zack consensus estimate fourth quarter reflect rise year quarter global sale integrate pharmacy solution ip sub segment hospital product increase formidable margin third quarter partly back increase sale premixed injectable drug fourth quarter zack consensus estimate ip be peg year report number surgical care include anesthesia biosurgery sale also record year year sale growth third quarter low double digit growth anesthesia critical care product drive grow demand inhaled anesthetic internationally well increase sale brevibloc fast act iv beta blocker fourth quarter zack consensus estimate segment sale stand year quarter also biosurgery sale increase low single digit globally last report quarter company expect growth business continue result continuous effort enhance commercial effectiveness overall zack consensus estimate hospital product net sale reflect increase year quarter notably sep baxter announce launch comprehensive asset tracking solution devicevue solution be used company proprietary pump system sigma spectrum infusion system aid clinician biomedical engineer quickly find unused pump view location status datum pcs ipad iphone be bullish development provide edge sigma spectrum compare other smart pump market here be other factor influence baxter fourth quarter result sale renal business grow significantly third quarter back solid performance line business take stellar third quarter performance consideration expect renal business perform well yet be report quarter well sep baxter announce commercial launch new indication company oxiris set now be used remove excessive level cytokine endotoxin other inflammatory mediator patient blood launch be likely drive top line yet be report quarter company earlier provide guidance sale fourth quarter be expect increase net sale quarter be expect rise constant currency company expect hurricane marium have negative impact fourth quarter revenue company also expect adjust earning range cent cent diluted share include cent negative earning impact hurricane marium be mitigate increase sale projection lower expect tax rate fourth quarter zack consensus estimate fourth quarter revenue be peg same earning be cent reflect increase however pricing pressure continue raise caution here be quantitative model predict baxter have right combination main ingredient positive earning esp zack rank hold higher increase odd earning beat zack esp earning esp baxter international be uncover best stock buy sell re report earning esp filter zack rank baxter international carry zack rank meanwhile zack consensus estimate earning cent reflect improvement year year basis other stock considerhere be few other medical stock worth consider have right combination element post earning beat quarter bio rad laboratory bio free report have earning esp zack rank strong buy see complete list today zack rank stock here myriad genetic mygn free report have earning esp zack rank henry schein hsic free report have earning esp zack rank wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
301,BAX,perkinelmer inc pki free report be expect release fourth quarter result jan market close last quarter company register adjust earning cent share beat zack consensus estimate cent further adjust revenue approximately also beat zack consensus estimate solid performance discovery analytical solution unit well diagnostic segment drive perkinelmer top line fourth quarter fact zack consensus estimate discovery analytical solution revenue be currently peg reflect improvement third quarter further zack consensus estimate diagnostic segment revenue be peg last quarter perkinelmer inc price consensus perkinelmer inc price consensus perkinelmer inc quotenotably perkinelmer have also outperformed industry last year stock have gain surpass industry rally let take look thing be shape prior fourth quarter earning announcement factor considerview upbeat zack consensus estimate perkinelmer fourth quarter earning be cent share reflect year year growth revenue consensus estimate be peg year year earlier management confirm company have be progress favorably original guidance cite begin fiscal expect better expect financial result fourth quarter company revise guidance adjust earning share full year regard perkinelmer now expect full year adjust earning share band compare previous range further post first quarter earning company raise revenue guidance well favorable market trend perkinelmer continue witness favorable market condition first time more year company experience positive organic growth region world end market operate last quarter expect company maintain momentum quarter be report look specifically end market pharma biotech diagnostic be expect see strong sale fourth quarter acquisition drive growth acquisition strategic partnership have prove be key growth catalyst perkinelmer recently company complete previously announce acquisition euroimmun medical laboratory diagnostic ag acquisition euroimmun expand perkinelmer reach autoimmune allergy diagnostic market also fortify company foothold cure new infectious disease management be optimistic acquisition drive growth fiscal solid product portfolio perkinelmer deliver comprehensive suite scientific informatic software solution aggregate datum actionable insight automate scalable way company launch new mass spectrometry platform qsight triple quad lc ms ms clinical market last quarter qsight have already receive very positive response niche space be expect provide perkinelmer competitive edge medtech space fourth quarter company product include industry lead chemdraw software electronic lab notebook include cloud base element saas offer enterprise notebook solution tibco spotfire platform scientific datum analytic perkinelmer expand portfolio be help company market share worldwide thus perkinelmer be confident improve growth trajectory fourth quarter quantitative model conclusively show earning beat perkinelmer quarter be stock need have positive earning esp zack rank strong buy buy hold be able beat estimate zack esp earning esp perkinelmer be most accurate estimate be be line zack consensus estimate uncover best stock buy sell re report earning esp filter zack rank perkinelmer carry zack rank favorable zack rank increase predictive power esp company positive esp make surprise prediction feasible stock worth lookhere be few similar medical stock worth consider have right combination element post earning beat quarter bio rad laboratory inc bio free report have earning esp zack rank see complete list today zack rank stock here bioverativ inc have earning esp zack rank baxter international inc bax free report have earning esp zack rank zack top stock addition stock discuss know finest buy hold ticker entirety last year zack top stock portfolio produce double digit winner include fmc corp vmware rac stellar gain now brand new portfolio have be handpick company cover zack rank don miss chance get long term buy access zack top stock today
302,BAX,bid promote safe handle hazardous drug maintain medication sterility baxter international inc bax free report recently announce distribution agreement launch arisure close system transfer device unite state platform prevent contamination intravenous iv medication delivery system drug preparation management latest development baxter be able ensure safer drug preparation transportation administration disposal system reduce risk accidental exposure contamination patient caregiver arisure close system transfer device include close vial adapter intravenous dry spike close male luer valve arisure close male luer lower exposure risk healthcare professional sharp needle further arisure close male luer be compatible baxter link needle free iv connector clearlink luer activate valve pave way initiate mechanically close system broad product spectrumbaxter have impressive product portfolio convenient kidney dialysis solution regenerative tissue product next generation sigma spectrum infusion pump sigma spectrum infusion system minimize patient risk administer vital fluid medication recently company upgrade sigma spectrum infusion system launch devicevue advanced asset tracking system baxter international inc price baxter international inc price baxter international inc quote baxter be first only smart infusion pump manufacturer offer tagless end end acid tracking application design consultation potential customer drive operational efficiency maximize clinical value pump investment late baxter needle free connector product line have also be focus minimize hospital infection acute therapy baxter launch first oxiris continuous renal replacement therapy sepsis management protocol add baxter multus organ therapy offer utilize prismaflex system stock performance solidover past month baxter have gain compare favorably industry rally baxter be poise gain expand product portfolio increase penetration international market accretive acquisition be also key catalyst long haul company long term expect earning growth rate hold promise regard zack rank key picksbaxter have zack rank hold few better rank stock broader medical sector be integer holding corporation itgr free report bio rad laboratory inc bio free report intuitive surgical inc isrg free report bio rad laboratory flaunt zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate integer holding have long term expect earning growth rate stock carry zack rank buy intuitive surgical have long term expect earning growth rate stock carry zack rank wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
303,BAX,baxter international inc bax free report have complete acquisition hemostat sealant product mallinckrodt plc widen exist surgical portfolio hemostat sealant especially intraoperative bleed notably company buy thrombin topical preveleak surgical sealant product line mallinckrodt baxter expect deal be modestly accretive adjust earning thereafter transaction deal increasingly add capability baxter portfolio drive bottom line turn deal be buy preveleak upfront payment approximately potential contingent payment future deal be announce earlier january baxter now gain major traction only stand alone recombinant thrombin buyout provide more option innovative hemostatic product surgeon deal severity bleed preveleak used vascular reconstruction complement company exist portfolio advanced surgical sealant baxter surgical portfoliobaxter surgical portfolio include product floseal hemostatic matrix tisseel fibrin sealant coseal surgical sealant vascu guard patch other portfolio be compose hemostasis address bleed tissue sealing hard tissue regeneration well soft tissue repair microsurgery product available nearly country company consistently endeavor improve advanced surgery business company expect advanced surgery business increase constant currency basis baxter have also announce plan focus launch advanced surgery product japan come day market potentialper cision report global surgical medical device market be anticipate witness cagr forecast period reach worth consider bullish market sentiment think latest development be timely lead player niche space be abbott free report stock performance estimate revisionshare baxter have outperformed industry past year stock have rally outperform gain broader industry rise company estimate revision trend current year have be positive past couple month analyst moved north revision opposite direction earning estimate rise zack rank other key picksbaxter carry zack rank buy other top rank stock broader medical sector be bio rad laboratory bio free report varian medical system inc var free report bio rad laboratory sport zack rank strong buy see complete list today zack rank stock here company have long term expect earning growth rate varian medical have long term expect earning growth rate stock carry zack rank hacker put money portfolio earlier month credit bureau equifax announce massive datum breach affect american cybersecurity industry be expand quickly response similar event stock be better investment other zack have just release cybersecurity investor guide help zack com reader make most year investment opportunity create hacker other threat reveal stock worth look right away download new report now
304,BAX,headquarter deerfield illinois baxter international inc bax free report be global medical product service company baxter report operate result base reportable geographic segment americas north south america emea europe middle east africa apac asia pacific further renal portfolio be patient kidney failure disease healthcare provider currently baxter international have zack rank buy change follow first quarter earning report have just release see complete list today zack rank strong buy stock here have highlighted key detail just release announcement earning baxter adjust earning cent share beat zack consensus estimate increase year quarter revenue baxter post sale edge past zack consensus estimate revenue increase constant currency cc key stat company core renal care segment record sale worth report quarter year year cc baxter international inc price ep surprise baxter international inc price ep surprise baxter international inc sale register year quarter cc emea sale come increase year quarter cc apac sale come year year basis cc major factor second quarter baxter expect sale growth approximately cc adjust earning share second quarter be expect come cent baxter raise guidance full year company expect sale growth cc baxter expect adjust earning continue operation lie range share stock price share have rise roughly last year industry have gain same time frame follow earning release share price inched pre market trading session check back later full baxter international report later more stock news be bigger iphone become mother technological revolution apple sell mere iphone year new breakthrough be expect generate more device just year create market zack have just release special report spotlight fast emerge phenomenon ticker take advantage don buy now kick click here trade
305,BAX,first quarter earning season be fast unfold member elite index have report financial number apr latest earning preview total earning company have increase year year basis higher revenue further whopping company have surpass earning estimate beat revenue mark however number positive revenue surprise season be lag precede year number end week company be set release result medical zack sector be expect deliver strong result medical product space have lately see slew favorable development change market dynamic artificial intelligence ai big datum application upbeat consumer sentiment abolition taxe increase business investment have be drive growth sector so rather be interesting see major medical product company be place ahead report cycle be major factor shape release medical sectormedical product have be very profitable investment space late favorable consumer behavior grow prevalence minimally invasive surgery demand liquid biopsy test use ensure quick improve patient care shift payment system value base model be suppose growth driver latest tax cut job act be finally sign president trump dec have finally cheer healthcare fraternity act have lower corporate tax rate earlier buoy optimism additionally senate decision postpone medical device tax be put effect jan have instilled confidence investor bill also delay so call cadillac tax tax employer insurance let take look major medical product company be set release result apr zack quantitative model stock advantageous combination solid zack rank strong buy buy hold positive earning esp have higher chance beating estimate uncover best stock buy sell re report earning esp filter baxter international inc bax free report first quarter result be expect show gain hospital product unit solid guidance plethora regulatory approval first quarter zack consensus estimate earning be peg cent indicate year year growth same revenue be fix reflect year year growth further predict earning beat quarter baxter have zack rank earning esp read more hospital product unit aid baxter earning see complete list today zack rank stock here baxter international inc price ep surprise baxter international inc price ep surprise baxter international inc quoteresm inc rmd free report be expect gain strong performance domestic international front third quarter fiscal revenue europe asia other market be likely register solid increase banking strong device mask performance moreover company sleep apnea patient volume have consistently witness steady growth third quarter zack consensus estimate earning be pin cent indicate year year growth same revenue be fix reflect year year growth however model resm be unlikely deliver earning beat season resm have zack rank earning esp make surprise prediction difficult read more resm repeat stable device growth earning resm inc price ep surprise resm inc price ep surprise resm inc quotestryker corporation syk free report first quarter result be expect show strong growth back orthopaedic implant sale major revenue component additionally medsurg help company generate impressive result first quarter zack consensus estimate earning be pin indicate year year growth same revenue be fix reflect year year growth quantitative model predict earning beat stryker be stock have earning esp zack rank read more core segmental growth aid stryker earning stryker corporation price ep surprise stryker corporation price ep surprise stryker corporation quotezimmer biomet holding inc zbh free report first quarter result be expect show strong top line number surgical sport medicine foot ankle extremity trauma arm moreover last november company have receive several fda clearance be particularly excited approval sidus stem free shoulder system first quarter zack consensus estimate earning be pin indicate year year decline same revenue be fix reflect year year growth zimmer biomet have zack rank sell lower predictive power esp have earning esp read more aid zimmer earning supply wo zimmer biomet holding inc price ep surprise zimmer biomet holding inc price ep surprise zimmer biomet holding inc quoteinvestor alert breakthrough pendinga medical advance be now flashpoint theory realization billion dollar research have pour company be already generate substantial revenue even more wondrous product be pipeline cure variety deadly disease be sight so be big potential profit early investor zack name stock buy now click here see
306,BAX,mallinckrodt plc mnk free report enter agreement baxter international inc bax free report former sell certain hemostasis product latter approximately total be paid upfront remain be paid milestone payment future product include thrombin topical recombinant preveleak surgical sealant baxter assume other expense include contingent liability associate preveleak however mallinckrodt retain raplixa fibrin sealant human topical use be evaluate strategic option product company acquire product medicine co mdco free report strengthen grow hospital portfolio move be line mallinckrodt strategy streamline business evolve top perform specialty pharmaceutical company help company focus innovative medicine therapy terlipressin stratagraft recently acquire product stannsoporfin xenon gas ocr divestiture product dilute mallinckrodt bottom line transaction be expect close first half earlier mallinckrodt sell intrathecal therapy business approximately piramal enterprise limit subsidiary piramal critical care uk company also sell global nuclear imaging business iba molecular approximately due linger challenge condition december company announce acquire sucampo pharmaceutical inc revive beleaguered portfolio mallinckrodt stock have tumble year compare industry decline year have be challenge mallinckrodt sale volume lead drug acthar decline weakness generic segment still persist downside be attribute payer environment face specialty drug slump be expect continue fourth quarter well additionally dublin ireland base company be also deal concern related inomax company suffer setback district court invalidate patent cover second largest product inomax company generic segment continue be soft various product category be witness stiff competition turn hurt volume well price further add wo mallinckrodt expect double digit decline revenue segment time also continue sluggishness segment adversely impact company gross profit margin zack carry zack rank hold see complete list today zack rank strong buy stock here zack best private investment ideaswhile be happy share many article best recommendation most depth research be not available public start today next month follow zack private buy sell real time expert cover kind trade value momentum stock etf option move stock corporate insider be buy company be report positive earning surprise even look exclusive portfolio be normally close new investor click here zack private trade
307,BAX,dec issue update research report illumina inc ilmn free report stock carry zack rank hold last month share san diego base company have be trading broader industry stock have rally versus broader industry decline period be encourage note company third quarter performance be quite promising top line be drive solid uptake sequence consumable instrument well microarray portfolio meanwhile company raise guidance indicate bullish trend be here stay management be hopeful recent launch company product portfolio include novaseq flow cell reagent kit novaseq system drive demand novaseq also look forward introduction novaseqxp company launch nextera dna flex buoy optimism moreover have recently partner telegraph hill partner set independent entity be also curious grail prospect illumina venture cancer screening market importantly company have start detailed plan embark large scale clinical trial illumina be currently keep pace goal strengthen foothold multus gene sequence market highly competitive product exist portfolio pipeline market expansion company primary focus be reproductive genetic health space illumina seek widen portfolio provide verifi laboratory develop invasive prenatal test nipt market be rapidly develop global scale allow company witness consistent growth number nipt sample good news be positive nipt reimbursement trend have be observed unite state third quarter incidentally rate nipt adoption be equally high country periphery be particularly upbeat strong uptake veriseq nipt ce ivd solution third quarter positive note country netherlands denmark too have start cover test first quarter follow england france hence company continue see positive reimbursement trend europe well flip side weak margin due novaseq launch higher array service revenue product mix sequence consumable continue raise concern also national institutes health funding issue tough competitive landscape be few more challenge deal key pickssome top rank medical stock be bio rad laboratory bio free report baxter international inc bax free report icu medical inc icui free report notably bio rad laboratory sport zack rank strong buy baxter international inc icu medical inc carry zack rank buy see complete list zack rank stock here bio rad have long term earning growth rate stock have rally roughly year baxter international have earning growth rate next quarter stock have surge roughly year icu medical have long term growth rate stock have soar roughly year wall street next amazonzack evp kevin matra believe familiar stock have only just begin climb become greatest investment time once generation opportunity invest pure genius click detail
308,BAX,share pra health science inc prah free report rally new week high dec close session nominally lower represent strong year date return approximately higher stock sport zack rank strong buy take stable stock performance consideration expect pra health stock scale new high quarters ahead company also have trail quarter average positive earning surprise project long term growth rate outperform broader industry growth rate be encourage estimate revision trend current year look impressive well past couple month estimate have moved north movement opposite direction period earning estimate have improve current fiscal reach share majority last month company share price have considerably outperformed broader industry stock have rally same time frame beating industry gain just pra health science inc price pra health science inc price pra health science inc quotefactor drive stockstellar revenue performance last few quarters consistent revenue performance back strong contribution pharmaceutical biotechnology company contribute company overall health consider favorable foreign exchange scenario strong balanced geographic expansion expect trend continue upcoming period symphony health solution integration positive acquisition symphony health solution pharmaceutical datum healthcare company be close third quarter have already prove be strategic addition pra health overall business third quarter deal deliver significant earning growth revenue growth year year basis constant currency new director appoinment investor have take company management churn positive way regard note company appoint new director dickinson last august competent background analytic informatic be believe have boost firm performance previously dickinson serve executive chairman chroma code private clinical diagnostic company be also senior vice president strategic initiative illumina work national government large institution develop precision medicine program healthcare system key pickssome other top rank medical stock be bio rad laboratory bio free report baxter international inc bax free report icu medical inc icui free report bio rad sport zack rank baxter icu medical carry zack rank buy see complete list zack rank stock here bio rad earning be estimate grow next quarter stock have rally roughly year baxter earning be project increase next quarter stock have rally roughly year icu medical earning be project grow next year stock have rally roughly year zack editor chief go stockfull disclosure kevin matra now have more own money particular stock other believe short term profit potential also prospect more double today reveal explain surprising move new special report download free
309,BAX,dec issue update research report warsaw base zimmer biomet holding inc zbh free report company carry zack rank sell last month lead musculoskeletal healthcare company have be trading broader industry macroeconomic uncertainty pricing pressure unfavorable currency fluctuation stock have lose value versus broader industry gain management zimmer biomet be grapple headwind such supply delay certain product cause inability back lose customer unite state tap new one softened domestic market condition impact consecutive hurricane significant price reduction indian knee market trim guidance issue last quarter result announcement add concern indicate little chance recovery ahead estimate revision trend also remain unfavorable estimate have moved south none opposite direction past couple month stock have see zack consensus estimate current year earning be revise cent downward period share positive note look forward synergy expect be draw recently complete ldr hold acquisition broaden complement company musculoskeletal offer be line strategy grow inorganic mean focuse mega buyout also pin high hope strong tactical financial goal combine entity aim reach now deal have be seal zimmer biomet have be late work fortify foothold emerge market potential provide long term opportunity good news be company plan investment region several quarters view enhance operational sale performance be also yielding result key picksa few better rank medical stock be bio rad laboratory bio free report baxter international inc bax free report icu medical inc icui free report notably bio rad laboratory sport zack rank baxter international inc icu medical inc sport zack rank buy see complete list zack rank stock here bio radha long term growth estimate next quarter stock have rally roughly year baxter international have growth estimate next quarter stock have rally roughly year icu medical have long term growth estimate next year stock have rally roughly year zack editor chief go stockfull disclosure kevin matra now have more own money particular stock other believe short term profit potential also prospect more double today reveal explain surprising move new special report download free
310,BAX,baxter international inc bax free report be currently top perform stock medtech space improvement price performance strong fundamental reflect stock bullish run therefore haven take advantage share price appreciation yet time add stock portfolio company have perform impressively have potential carry momentum upcoming period long term expect earning growth rate be positive attractive pick share price appreciationa glimpse company price trend reveal stock have have impressive run bourse year date baxter return whopping compare favorably index rally current return be also greater industry gain northward estimate revisionsnine estimate current year moved north past day versus southward revision reflect analyst optimism company same period zack consensus estimate adjust earning increase current year positive trend signify analyst bullish sentiment company hold zack rank buy indicate robust fundamental expectation outperformance term strong growth company zack consensus estimate earning reflect year year growth moreover earning be expect register growth zack consensus estimate revenue reflect year year improvement moreover revenue be expect witness growth baxter estimate sale growth approximately compound annual basis notably adjust operate margin full year be expect be approximately revenue previous guidance baxter expect full year adjust diluted earning band share positive earning surprise historybaxter have impressive earning surprise history company outpaced zack consensus estimate trail quarters deliver positive average earning surprise year have be favorable baxter regulatory front recently management confirm fda have grant new approval temporary importation certain drug facility canada mexico development baxter have operational site approve help address demand market further fda approval new premixed injectable be key catalyst baxter launch oxiris set continuous renal replacement therapy crrt sepsis management protocol select market europe middle east africa recently further recent launch devicevue comprehensive asset tracking solution available exclusively hospital bolster company product portfolio company operate life sustain critical care product category be cushion economic downturn baxter product be not commodity nature provide strong recur revenue base baxter have be experience burgeon demand dialyzer globe more person be inflict end stage renal disease esrd due grow incidence diabetes blood pressure other kidney related disease other picksother top rank stock broader medical sector be petm express pet free report luminex corporation lmnx free report idexx laboratory idxx free report petm express flaunt zack rank strong buy company have long term expect earning growth rate see complete list today zack rank stock here luminex have long term expect earning growth rate stock flaunt zack rank idexx laboratory have long term expect earning growth rate stock carry zack rank look stock skyrocket upside zack have just release special report boom investment opportunity legal marijuana ignited new referendum legislation industry be expect blast already robust early investor stand make kill have be ready act know just look see pot trade re target
311,BAX,company favorable efficiency level be expect provide impressive return be believe be positively correlated company price performance efficiency be ability transform input output be potential indicator company financial health however be difficult measure efficiency level company be reason consider popular efficiency ratio select stock build profitable portfolio measure efficiency have consider popular ratio order find efficient company have potential provide impressive return inventory level be key indicator company business health high inventory level indicate company be go rough phase term sale dwindle level indicate company run stock favorable sale condition be inventory turnover come play be ratio month cost good sell cog quarter average inventory thus high value ratio indicate low level inventory relative cog low ratio signal company have excess inventory receivables ratio be used measure company capability extend credit collect debt basis credit receivables turnover ratio account receivable turnover ratio debtor turnover ratio be calculate divide month sale quarter average receivables high ratio indicate company efficiently collect account receivables have quality customer low ratio signal company have inefficient collection procedure have low quality customer inefficient credit policy asset be widely used measure company efficiency asset utilization indicate company potential utilize asset be ratio total sale past month last quarter average total asset so higher ratio greater be chance company be utilize asset efficiently contrary low value ratio signal be fail use asset effectively operate marginanother popular efficiency ratio be operate margin operate profit margin be simply operate income past month divide sale same period indicate well company be control operate expense company have high operate profit margin relation competitor be do better job control operate expense ratio be consider effective measure compare different company particular sector industry be reason have consider only company have higher ratio respective industry average screening parametersin addition mentioned ratio have add favorable zack rank zack rank strong buy buy screen objective make strategy more profitable inventory turnover receivables turnover asset utilization operate margin greater industry average value ratio higher industry average indicate efficiency level company be higher peer zack rank better equal buy only zack rank buy rate stock get use few criterium have narrow universe stock only here be stock pass screen athletic apparel athletica inc lulu together subsidiary design distribute retail athletic apparel accessory woman man female youth company sport zack rank company have average quarter positive earning surprise cheme corporation che free report provide hospice palliative care service unite state company have zack rank have average quarter positive earning surprise see complete list today zack rank stock here baxter international inc bax free report provide portfolio renal hospital product company have zack rank have average quarter positive earning surprise nvr inc nvr free report operate homebuilder unite state company operate segment mid atlantic north east mid east south east company have zack rank have average quarter positive earning surprise copart inc cprt free report provide online auction vehicle remarketing service company have zack rank have average quarter positive earning surprise get rest stock list signing now week free trial research wizard start used screen own trading further also create own strategy test first take investment plunge research wizard be great place begin easy use everything be plain language very intuitive start research wizard trial today next time read economic report open research wizard plug find see gem come click here sign free trial research wizard today disclosure officer director employee zack investment research own have sell short security hold long short position option be mentioned material affiliated investment advisory firm own have sell short security hold long short position option be mentioned material disclosure performance information zack portfolio strategy be available https www zack com performancezack restaurant recommendation addition dine special place feast stock share zack special report spotlight recent ipos watch stock offer immediate promise boom sector download free
312,BAX,jp morgan have launch new fund focuse provide exposure equity space invest company low volatility jpmorgan minimum volatility etf jmin track jp morgan minimum volatility index fund characteristic fund utilize rule base methodology select stock base volatility have aum seek provide exposure low risk equity minimize unsystematic risk charge basis point fee year have top holding nvr inc walmart store inc brownforman corp exposure respectively dec bear less concentration risk just little be allocate top holding sector look fund have high exposure health care consumer good utility exposure respectively dec market impact senate vote favor tax reform be multiple hurdle tax reform become law trump call senate vote major victory republican party unbeatable have somebody don know right now re unbeatable say trump house senate differ radically want establish tax reform multiple compromise be need come conclusion instance house want abolish estate tax senate want raise be significant negotiation make reconcile plan appeal low volatility fund increase be increase uncertainty regard trump deregulation plan increase investor appeal safety turn make shift low volatility fund competition fund face high competition other fund focuse provide exposure same space discuss few etfs seek provide exposure corner see total market etfs here ishare edge msci min vol usa etf usmv free report fund seek provide exposure company be more less immune volatility have aum charge fee basis point year sector look fund have high exposure information technology health care consumer staple allocation respectively dec fund top holding be mcdonald corp mcd free report johnson johnson jnj free report visa inc free report allocation dec fund have return year year date dec have zack etf rank hold medium risk outlook powershare low volatility portfolio splv free report fund seek provide exposure company be more less immune volatility have aum charge fee basis point year sector look fund have high exposure utility financial industrial allocation respectively dec fund top holding be honeywell international inc hon free report coca cola co ko free report pepsico inc pep free report allocation dec fund have return year year date dec have zack etf rank medium risk outlook spdr russell low volatility focus etf onev free report fund seek provide exposure company be more less immune volatility track russell low volatility focuse factor index have aum charge fee basis point year sector look fund have high exposure financial service consumer discretionary producer durable allocation respectively dec fund top holding be equity residential eqr free report sysco corporation syy free report baxter international inc bax free report respective allocation allocation dec fund have return year year date dec have zack etf rank want key etf info deliver straight inbox zack free fund newsletter brief top news analysis well top perform etfs week get free
313,BAX,asia pacific apac be home more half world population so demand healthcare be also exceptionally high region furthermore need cut edge medtech product service be significantly high world apac be exception fact research report mckinsey show apac be expect outpace european union world second largest medtech market pretty soon unite state almost person region be expect enter age group indicate emerge demand healthcare need also apac account third global disease burden further research report statista show medtech market asia pacific region be estimate reach nearly trump focus datum point huge unmet healthcare need apac market investor find president trump recent day long asia trip stop japan south korea china vietnam philippine be positive sign furthermore recent tweet great country be respect again asia see fruit long successful trip many year come be indicative favorable republican stance apac especially respect business trade here take sneak peek major postulate trump recent asia visit bilateral trade agreementtrump promise augment bilateral trade agreement indo pacific nation instill confidence apac policy however trump specifically mentioned agreement be bound follow principle fair reciprocal trade also voiced free open indo pacific trade emphasize increase focus nation japan australia india prospect china pacific be big enough accommodate china unite state say china president xi jinp trump visit china undoubtedly pose serious competitive threat unite state not just healthcare space also electronic semiconductor retail other area jinp statement clearly hint possibility country coexist peacefully political tension also be indicative strategic merger company nation order enhance trade practice medtech company eye apacconsider trump grow focus apac region seem be poise yield accretive return long term fact stakeholder medical universe have be eyee emerge market last couple year company be bullish grow medical awareness economic prosperity age population increase wealth government focus healthcare infrastructure expansion medical insurance coverage apac space meanwhile health policy debacle unite state deteriorate economic condition europe conclude growth emerge market china india japan other bolster global foothold medtech company take look lead medtech player be tap also gain bountiful opportunity apac market baxter international bax free report baxter solid presence asia precisely india be worth mention company have research hub japan china just report third quarter baxter complete acquisition india base claris injectable global generic injectable pharmaceutical company almost december baxter have initiate agreement management acquisition bolster baxter foothold generic pharmaceutical space second quarter baxter sign agreement india base dorizoe lifescience expansion generic injectable pipeline further baxter strong presence peritoneal dialysis nutrition iv fluid anesthesia gase fortify footprint china zack rank buy stock have have impressive run bourse last year stock have return significantly higher broader industry gain corporation bsx free report important part boston scientific growth strategy be continue pursue development opportunity outside unite state just report third quarter business emerge market register organic growth rate remain company target reach sale business china be also remarkable year year company be currently look forward improve performance china banking recent approval synergy boston scientific be also optimistic core cardiology segment be gradually stabilize growth bric nation cardiology capacity china be expect double end india business be project grow more annually zack rank hold stock have yielded stellar return last year way ahead broader industry same time frame see complete list today zack rank stock here intuitive surgical inc isrg free report intuitive surgical grow interest emerge market specifically apac region bode well last couple year company procedure performance asia show continue strength solid growth china japan korea just report third quarter intuitive surgical system placement include japan india new mexico china zack rank hold company have return last year much higher broader industry same period becton dickinson company bdx free report becton dickinson company bd be focuse geographical expansion overseas market particular emerge nation note company be especially focuse broader emerge market india china be see rapid growth economic healthcare sector believe significant emerge market exposure boost company top line turn lead accelerate ep growth bd revenue grow just report fourth quarter fiscal emerge market revenue grow strong year year quarter constant currency drive strong performance greater asia china revenue see double digit growth lead player medtech space be zack rank hold stock have return last year much higher broader industry growth paradoxhowever trump americafirst pitch asia pacific economic cooperation summit apec be hold vietnam november have be serious threat multilateral trade have be clearly portray trump primary focus be be be betterment unite state zack best private investment ideaswhile be happy share many article best recommendation most depth research be not available public start today next month follow zack private buy sell real time expert cover kind trade value momentum stock etf option move stock corporate insider be buy company be report positive earning surprise even look exclusive portfolio be normally close new investor click here zack private trade
314,BAX,astute investor be always lookout plan be likely yield high return regardless market circumstance efficiency level measure company capability transform available input output be often consider important parameter used gauge company potential rake handsome return company promising efficiency level be likely deliver stellar return be assume be positively correlated price performance measure efficiency have consider popular ratio order find efficient company have potential provide impressive return inventory level be key indicator company business health high inventory level indicate company be go rough patch term sale dwindle level indicate company run stock favorable sale condition be inventory turnover come play be ratio month cost good sell cog quarter average inventory thus high value ratio indicate low level inventory relative cog low ratio signal company have excess inventory receivables ratio be used measure company capability extend credit collect debt basis credit receivables turnover ratio account receivable turnover ratio debtor turnover ratio be calculate divide month sale quarter average receivables high ratio indicate company efficiently collect account receivables have quality customer low ratio signal company have inefficient collection procedure have low quality customer inefficient credit policy asset be widely used measure company efficiency asset utilization indicate company potential utilize asset be ratio total sale past month last quarter average total asset so higher ratio greater be chance company be utilize asset efficiently contrary low value ratio signal be fail use asset effectively operate marginanother popular efficiency ratio be operate margin operate profit margin be simply operate income past month divide sale same period indicate well company be control operate expense company have high operate profit margin relation competitor be do better job control operate expense ratio be consider effective measure compare different company particular sector industry be reason have consider only company have higher ratio respective industry average screening parametersin addition mentioned ratio have add favorable zack rank strong buy buy screen objective make strategy more profitable inventory turnover receivables turnover asset utilization operate margin greater industry average value ratio higher industry average indicate efficiency level company be higher peer zack rank better equal buy only zack rank strong buy buy rate stock get use few criterium have narrow universe stock only here be stock pass screen home depot inc hd free report operate home improvement retailer company have zack rank have average quarter positive earning surprise baxter international inc bax free report provide portfolio renal hospital product company operate segment hospital product renal company have zack rank have average quarter positive earning surprise idexx laboratory inc idxx free report develop manufacture distribute product service primarily companion animal veterinary livestock poultry dairy water testing market worldwide company have zack rank have average quarter positive earning surprise see complete list today zack rank stock here nvr inc nvr free report operate homebuilder unite state company have zack rank have average quarter positive earning surprise mam software group inc mam free report provide software information commerce related service business engage automotive aftermarket unite state canada ireland company have zack rank have average quarter positive earning surprise get rest stock list signing now week free trial research wizard start used screen own trading further also create own strategy test first take investment plunge research wizard be great place begin easy use everything be plain language very intuitive start research wizard trial today next time read economic report open research wizard plug find see gem come click here sign free trial research wizard today disclosure officer director employee zack investment research own have sell short security hold long short position option be mentioned material affiliated investment advisory firm own have sell short security hold long short position option be mentioned material disclosure performance information zack portfolio strategy be available https www zack com performancezack restaurant recommendation addition dine special place feast stock share zack special report spotlight recent ipos watch stock offer immediate promise boom sector download free
315,BAX,company favorable efficiency level be likely be investor radar irrespective market condition be company favorable efficiency level be expect provide impressive return be believe be positively correlated price performance key ratio identify become difficult measure efficiency level company be reason consider popular efficiency ratio select stock efficiency ratio be inventory turnover ratio month cost good sell cog quarter average inventory be consider most popular efficiency ratio indicate company ability maintain suitable inventory position high value indicate company have relatively low level inventory compare cog low value indicate company be face decline sale result excess inventory receivables turnover be ratio month sale quarter average receivables show company potential extend credit collect debt term credit high receivables turnover ratio account receivable turnover ratio debtor turnover ratio be desirable show company be capable collect account receivables have quality customer asset utilization ratio indicate company capability convert asset output be thus widely know measure efficiency level be calculate divide total sale past month last quarter average total asset ratio high asset utilization indicate company be efficient operate margin efficiency measure be ratio operate income past month sale same period measure company ability control operate expense hence high value ratio indicate company manage operate expense more efficiently peer screening parametersin addition mentioned ratio have add favorable zack rank buy screen objective make strategy more profitable see complete list today zack rank strong buy stock here inventory turnover receivables turnover asset utilization operate margin greater industry average value ratio higher industry average indicate efficiency level company be higher peer use few criterium have narrow universe stock only here be stock make screen cheme corporation che free report provide hospice palliative care service unite state operate segment vita roto rooter company have average quarter positive earning surprise baxter international inc bax free report provide portfolio renal hospital product company operate segment hospital product renal company have average quarter positive earning surprise idexx laboratory inc idxx free report develop manufacture distribute product service primarily companion animal veterinary livestock poultry dairy water testing market worldwide company have average quarter positive earning surprise advanced energy industry inc aeis free report design manufacture sell support power conversion control product transform power various usable form company have average quarter positive earning surprise pioneer natural resource company pxd free report operate independent oil gas exploration production company unite state company have average quarter positive earning surprise get rest stock list signing now week free trial research wizard start used screen own trading further also create own strategy test first take investment plunge research wizard be great place begin easy use everything be plain language very intuitive start research wizard trial today next time read economic report open research wizard plug find see gem come click here sign free trial research wizard today disclosure officer director employee zack investment research own have sell short security hold long short position option be mentioned material affiliated investment advisory firm own have sell short security hold long short position option be mentioned material disclosure performance information zack portfolio strategy be available https www zack com performancezack restaurant recommendation addition dine special place feast stock share zack special report spotlight recent ipos watch stock offer immediate promise boom sector download free
316,BAX,baxter international inc bax free report have have impressive run bourse late last year company have add outperform broader industry gain current level be also higher return recur revenue stream expand product portfolio strong presence international market be key positive stock have zack rank buy here take sneak peek major factor drive growth baxter moment year have be favorable baxter regulatory front recently management confirm fda have grant new approval temporary importation certain drug facility canada mexico development baxter now have operational site approve meet demand market furthermore fda approval new premixed injectable be key catalyst company new product home peritoneal dialysis pd technology also receive fda nod platform leverage baxter flagship amia automate peritoneal dialysis apd system recent past baxter achieve regulatory milestone advanced dialysis technology company receive approval fda home pd solution system improve patient access home dialysis baxter have strong presence foreign market make international diversification core component strategy bid fortify overseas presence company have launch oxiris set continuous renal replacement therapy crrt sepsis management protocol select market europe middle east africa notably oxiris leverage company flagship prismaflex system be expect lend baxter competitive edge global market large proportion sale come overseas market baxter benefit develop country incremental investment health care system recent acquisition position company well revenue growth rapidly expand asian latin american market other key picksa few other top rank stock broader medical sector be petm express pet free report luminex corporation lmnx free report idexx laboratory idxx free report notably petm express sport zack rank strong buy company have long term expect earning growth rate see complete list today zack rank stock here luminex represent return last year stock have zack rank idexx laboratory have long term expect earning growth rate stock have climb year time have zack rank hottest tech mega trend year generate global revenue predict blast roof fame investor mark cuban say produce world first trillionaire still leave plenty money regular investor make right trade early see zack best stock play trend
